https://stg1.novartis.com/ 2026-03-13T21:58:37+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/ton-buechner 2025-12-19T12:48:46+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/simon-moroney 2026-02-02T09:46:56+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/patrice-bula 2025-12-19T12:48:24+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/nancy-c-andrews 2026-01-21T12:03:09+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/frans-van-houten 2026-01-21T12:02:57+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/karen-hale 2026-01-30T10:43:03+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/lutz-hegemann 2026-01-30T10:40:31+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/elizabeth-liz-doherty 2025-12-19T12:47:18+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/charlotte-pamer-wieser 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/bridgette-heller 2026-01-21T12:03:04+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/vasant-narasimhan 2026-03-05T11:25:35+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/steffen-lang 2026-02-02T09:46:03+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/julie-chauvet 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/vincent-vanwijnsberghe 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/sarah-moundir 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/rob-kowalski 2026-01-30T10:38:10+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/ana-de-pro-gonzalo 2025-12-19T12:45:56+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/victor-bulto 2026-02-02T09:44:29+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/shreeram-aradhye 2026-01-30T10:45:16+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/aharon-ronny-gal-phd 2026-01-30T10:44:05+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/fiona-marshall 2026-01-30T10:40:00+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/john-d-young 2026-02-17T09:44:15+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/michelle-weese 2026-01-30T10:42:35+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/patrick-horber-md 2026-01-30T10:36:56+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/carine-jacquet 2024-12-19T13:46:23+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/giovanni-caforio 2025-12-19T12:47:55+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/elizabeth-mcnally 2025-12-19T12:47:31+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/teresa-jose 2026-01-30T10:42:01+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors/charles-swanton 2026-03-06T14:36:35+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee/mukul-mehta 2026-03-16T06:47:36+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/study/nct04174157 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05562466 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06411626 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06470048 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05274425 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05222529 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04557462 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05335876 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06075758 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06655896 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06517758 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05268289 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04939610 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06133972 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05870579 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05795140 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05634967 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05868629 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06562192 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04657822 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04877522 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05943522 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05703516 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct02445222 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06262919 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05541341 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05803941 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06331312 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06287268 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06462469 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06247995 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05646381 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06517719 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04817618 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06551519 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05217810 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05939414 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct03340506 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06546670 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05293470 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05755386 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05935215 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05948943 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04925479 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05809986 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06517732 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06019637 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04597411 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04094311 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06156683 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04933552 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct03955445 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04985487 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05621733 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06004661 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05750628 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06581198 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04638647 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04480853 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05677451 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05126277 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06439082 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06335979 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06649110 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06606314 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06665256 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06531499 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06733922 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06617793 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06597019 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06659393 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06486779 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06704269 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06799000 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06675864 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06780670 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06006559 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06830720 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06514534 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06597006 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06744920 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06840392 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06501443 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06382051 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06726148 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06868290 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06751238 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05469360 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06952426 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06905288 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06910813 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05827081 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct04104776 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06632600 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06857955 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06865651 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06684964 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06784752 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06711887 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06947993 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06931691 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06514521 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06991556 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07029542 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06401356 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06958315 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06813911 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07029555 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06858332 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06868212 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07047118 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07048197 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06797518 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06855277 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06858319 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06785818 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06846281 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06875973 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07036718 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06797531 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06824103 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07140614 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07206056 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06997588 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07006727 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07094516 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07203001 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07220577 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07217067 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07190300 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07226986 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07235059 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07261631 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06994845 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07102628 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07142265 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06934967 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07093801 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07235046 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07225504 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06930859 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07249463 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06770543 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07288359 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07243002 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07156149 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06838143 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06785779 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07174063 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07039422 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07034690 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07282015 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct06905301 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07358364 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07358780 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07408219 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct05344469 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07243782 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07290270 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07441642 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07431177 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07326709 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07467993 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07375355 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07146906 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07476170 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/clinicaltrials/study/nct07508007 2026-04-03T08:08:34+02:00 0.5 https://stg1.novartis.com/news/media-library/manufacturing-facility-stein-ch 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-production-and-manufacturing-b-roll-video 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/karen-l-hale 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/what-non-alcoholic-steatohepatitis-nash 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/access-fact-sheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/healthy-family-fact-sheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/thalassemia-backgrounder 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/sickle-cell-disease-backgrounder 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chronic-iron-overload-backgrounder 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/myelodysplastic-syndromes-mds-backgrounder 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-interactive-media-guide 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/neuroendocrine-tumors-expert-media-guide 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/leprosy 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/reimagining-management-sickle-cell-disease-africa 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/malaria 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chagas-disease 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-access-fact-sheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chronic-myeloid-leukemia-today-and-tomorrow-visual-fact-sheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/renal-cell-carcinoma-rcc-fact-sheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/early-versus-advanced-breast-cancer-list 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/frontal-view-gehry-building 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/gehry-building-from-distance 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tables-and-chairs-next-green-space 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/steffen-lang-phd 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo 2026-03-11T09:19:28+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/frans-van-houten 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/charlotte-pamer-wieser-phd 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/elizabeth-liz-doherty 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/ton-buechner 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/nancy-c-andrews-md-phd 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/vasant-vas-narasimhan-md 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/trees-casting-shadows-along-fabrikstrasse 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/antimalarial-pills 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/antimalarial-raw-material 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/artemisinin-combination-therapy-act 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/artemisinin-extraction 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/farmer-harvesting-artemisia-annua 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/malaria-diagnostic-test 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/malaria-prevention 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/malaria-researchers-nairobi-kenya 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/mode-action-cgrp-receptor-blocker 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/patients-frozen-t-cells 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/sms-life 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/sms-life-training-session 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/t-cell-arrival-novartis-manufacturing-facility 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-fabrikstrasse-novartis-hq 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/worldwide-distribution-center-novartis-antimalarial-basel-switzerland 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/young-malaria-patient 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/cancer-2030-growing-global-crisis 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/sickle-cell-world-assessment-survey-sway-results 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/new-era-medicine 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/cell-and-gene-key-focus-areas 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/introduction-cell-and-gene-therapy 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-financial-results-q3-2018-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-financial-results-q2-2018-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/impact-migraine 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-financial-results-q1-2018-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/spinal-muscular-atrophy-sma-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/inflammation-and-cardiovascular-risk 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/measuring-inflammation-and-role-hscrp 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chimeric-antigen-receptor-t-cell-car-t-therapy 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chronic-iron-overload-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chronic-myleoid-leukemia-meet-milestones-matter-one-pager 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/facts-about-melanoma-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chronic-iron-overload-complications-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-disease-state-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/about-noncommunicable-diseases-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/access-ncd-treatment-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/understanding-chronic-myeloid-leukemia-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/gastrointestinal-neuroendocrine-tumors-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/pancreatic-neuroendocrine-tumors-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/lung-neuroendocrine-tumors-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tuberous-sclerosis-complex-patient-journey-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/advanced-soft-tissue-sarcoma-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tuberous-sclerosis-complex-common-threads-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/renal-cell-carcinoma-infographic 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/embarking-young-adulthood-tsc-monitoring-manifestations-over-time 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/psychological-social-impact-advanced-breast-cancer 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-us-report-2020 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-esg-report-2020 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2020 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2019 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-us-report-2019 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/malaria-futures-central-africa 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-esg-report-2019 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/malaria-futures-asia 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-social-business-report-2018 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-us-report-2018 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-report-2018 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/malaria-futures-africa 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2018 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2017 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/healthy-family-10-year-report 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-access-two-year-report 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/corporate-responsibility-report-2017 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-access-one-year-report 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/building-trust-society-our-priorities 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/strengthening-our-global-health-corporate-responsibility-function 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/spinal-muscular-atrophy-sma-factsheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/heart-failure-hospitalization-why-moment-matters 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/about-migraine 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/diffuse-large-b-cell-lymphoma-dlbcl 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/acute-lymphoblastic-leukemia-all 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/acute-lymphoblastic-leukemia-fact-sheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/advancing-global-health 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/chronic-myeloid-leukemia-background-fact-sheet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/science-behind-car-t-cell-therapy 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/manufacturing-car-t-cell-therapies-novartis-approach 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/lutz-hegemann-md-phd 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/bridgette-heller 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/simon-moroney-dphil 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/bad-sackingen-novartis-stein-switzerland 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/operator-culture-medium-bag 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-site-stein-switzerland 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/operators-clean-room 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/operator-labels-culture-plates 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/operator-prepares-connecting-hose 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/patrice-bula 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/people-park 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/break-park 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/operator-performs-process-operation-biosafety-cabinet 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/grocery-shop-staircase 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/staircase-fabrikstrasse-6-peter-markli 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/avenue-trees-along-fabrikstrasse 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-fabrikstrasse-6-peter-markli-trees 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-staircase-gehry-building 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/first-results-from-global-net-survey-part-1-time-diagnosis 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tackling-chronic-disease-novartis-access 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/results-from-first-global-net-survey-part-2-net-patient-experience 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/what-polycythemia-vera 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/how-polycythemia-vera-diagnosed 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/what-are-symptoms-and-complications-polycythemia-vera 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tsc-common-threads-future-outlook-tsc 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tsc-common-threads-grandia-family-story 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tsc-talk-did-you-know 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tsc-common-threads-tsc-affects-each-person-differently 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tsc-common-threads-moss-family 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/tsc-common-threads-life-tsc 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/acute-myeloid-leukemia-unique-needs-patients-and-caregivers 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/alk-non-small-cell-lung-cancer-patient-video-anne-marie 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/alk-non-small-cell-lung-cancer-patient-video-miriam-joel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-access-how-well-expand-access-healthcare 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/experts-gather-explore-response-chronic-illness-poor-countries 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-and-international-red-cross-partner-provide-medicines-syrian-refugees 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/museum-ms 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/what-do-you-know-about-noncommunicable-diseases 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/about-erenumab-amg-334 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/erenumab-amg-334-key-clinical-trials-numbers 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/how-does-acz885-work 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/juliet-clinical-trial 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/kymriah-tisagenlecleucel-children-and-young-adults-b-cell-all-refractory-or-relapsed-least-twice 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/rth258-brolucizumab-clinical-trials 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/kymriah-tisagenlecleucel-suspension-intravenous-infusion 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/interleukin-17-il-17a-inflammatory-joint-disease 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/interleukin-17-il-17a-psoriasis 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/rob-kowalski 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/managing-tsc-transition-adult-care 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/nibr-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/nibr-cambridge-united-states 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-forum-1-and-fabrikstrasse-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-fabrikstrasse-15-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/outside-meeting-space-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-asklepios-8-along-rhine-riverbank-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-towards-asklepios-8-and-dreirosenbruckebasel-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-banting-1-and-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-banting-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-novartis-campus-and-banting-1-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-6-passing-cyclist-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-6-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2021 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/ana-de-pro-gonzalo 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-novartis-campus-forum-1-banting-1-and-fabrikstrasse 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-pavillon-banting-1-background 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-pavillon-novartis-campus-and-banting-1-background 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-from-novartis-campus-towards-novartis-pavillon-and-basel-alongside-rhine-river 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-from-novartis-campus-towards-novartis-pavillon-and-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-pavillon-located-park-south-novartis-campus 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-artwork-semiconductor-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-artwork-semiconductor 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/organic-solar-cell-led-core-which-builds-illuminating-skin-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/schoolhub-ground-floor-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/interior-view-ground-floor-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/welcome-wall-and-staircase-exhibition-wonders-medicine-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/welcome-wall-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/content-area-fragility-life-wonders-medicine-exhibition-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/victor-bulto 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/shreeram-aradhye-md 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/crizanlizumab-clinical-setting-from-international-managed-access-program-map 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/aharon-ronny-gal-phd 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/about-gene-therapy 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/gene-therapy-manufacturing-north-carolina 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/about-novartis-gene-therapies 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-gene-therapies-manufacturing-process 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-aav-platform 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/spinal-muscular-atrophy 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/scientist-laboratory-banting-1-office-space-background 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/scientists-fermentation-hub-banting-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/fermentation-hub-banting-1-where-natural-products-and-biomolecules-can-be-produced 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/scientists-one-state-art-laboratories-banting-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/scientists-laboratory-banting-1-where-global-discovery-chemistry-group-based 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-asklepios-building-oscillation-bench-front 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-pavillon-located-park-south-novartis-campus-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/park-south-novartis-campus-view-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/laboratory-building-virchow-6-novartis-campus 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/architects-map-novartis-campus-english-version 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-gehry-building-green-and-fabrikstrasse-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/fiona-h-marshall-phd 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/how-novartis-contributing-fight-against-malaria 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2022 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-integrated-report-2022 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/52-week-results-cosentyx-hidradenitis-suppurativa-summary 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/production-process-rna-therapies-schweizerhalle-switzerland 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-rna-production-schweizerhalle-switzerland 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/manufacturing-rna-therapies-schweizerhalle-switzerland 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-integrierter-geschaftsbericht-2022 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/john-d-young 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/main-entrance-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/birds-eye-view-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-from-kleinbasel-towards-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-novartis-pavillon-towards-dreirosenbrucke-and-city-center 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/view-from-hohlweg-passing-under-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/wonders-medicine-exhibition-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/wonders-medicine-exhibition-from-lab-patient-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/wonders-medicine-exhibition-from-lab-patient-novartis-pavillon-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/wonders-medicine-exhibition-steps-through-time-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/wonders-medicine-exhibition-future-healthcare-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/schoolhub-novartis-pavillon 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/pedestrian-path-trees-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/fabrikstrasse-4-sanaa-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/fabrikstrasse-28-tadao-ando-and-artwork-richard-serra-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/fabrikstrasse-12-vittorio-magnago-lampugnani-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/banting-1-and-artwork-structure-life-claudia-comte-novartis-campus-basel 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-campus-basel-switzerland 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/michelle-weese 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/cardiovascular-disease-victorion-media-summary 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/cardiovascular-disease-numbers 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/cardiovascular-disease-orion-8-media-summary 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo-banting-1-building-from-main-gate-novartis-campus-basel-vertical 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo-banting-1-building-from-park-south-novartis-campus-basel-vertical 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-horizontal 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-logo-through-colorful-facade-forum-3-novartis-campus-basel-vertical 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/access-medicines-eu-member-states 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/intellectual-property-including-regulatory-data-protection-rdp 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/regulatory-framework 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/orphan-medicinal-products-pediatrics 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/security-supply 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/fiona-h-marshall-phd-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/fiona-h-marshall-phd-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/aharon-ronny-gal-phd-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/aharon-ronny-gal-phd-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/rob-kowalski-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/rob-kowalski-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/shreeram-aradhye-md-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/victor-bulto-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/victor-bulto-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/steffen-lang-phd-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/steffen-lang-phd-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/lutz-hegemann-md-phd-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/lutz-hegemann-md-phd-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/karen-l-hale-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/karen-l-hale-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/karen-l-hale-2 2025-12-08T12:51:41+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/michelle-weese-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/patrick-horber-md 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/patrick-horber-md-0 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/patrick-horber-md-1 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/patrick-horber-md-2 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-integrated-report-2023 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2023 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-radioligand-therapy-rlt-manufacturing 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-integrierter-geschaftsbericht-2023 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/quality-control-environmental-monitoring-radioligand-therapy-rlt-manufacturing 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/specialized-equipment-manufacture-radioligand-therapy-rlt 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/refrigeration-room-novartis-radioligand-therapy-rlt-manufacturing-facility 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/radioligand-therapy-rlt-production-line 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-radioligand-therapy-rlt-manufacturing-facility 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/research-and-innovation 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-integrated-report-2024 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2024 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-society-integrierter-geschaftsbericht-2024 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/giovanni-caforio-md 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/elizabeth-mcnally-md-phd 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/teresa-jose 2025-11-11T07:12:48+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/durham-north-carolina-united-states-groundbreaking-ceremony 2026-01-21T15:21:49+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/groundbreaking-durham-north-carolina-united-states 2026-01-21T15:22:20+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-executives-and-dignitaries-groundbreaking-durham-north-carolina-united-states 2026-01-21T15:22:58+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-manufacturing-facility-carlsbad-california-united-states 2026-01-21T15:23:31+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-executives-and-dignitaries-attend-rlt-facility-ribbon-cutting-carlsbad-california-united-states 2026-01-21T15:24:04+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-executives-and-dignitaries-cut-ribbon-rlt-facility-carlsbad-california-united-states 2026-01-21T15:25:04+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/vasant-vas-narasimhan-md-2 2026-01-30T11:31:26+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/novartis-annual-report-2025 2026-02-03T22:19:34+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/report-nonfinancial-matters-2025 2026-02-03T21:24:45+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/charles-swanton-mbphd 2026-03-06T14:35:47+01:00 daily 1.0 https://stg1.novartis.com/news/media-library/mukul-mehta 2026-03-16T06:48:06+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2022 2024-10-25T15:12:20+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2022 2024-10-25T15:13:01+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2021 2024-11-06T11:03:37+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2021 2025-05-20T10:20:03+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2021 2025-05-20T10:11:46+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2021-financial-results 2024-10-25T15:13:36+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-asco-and-eha-2022 2025-05-20T10:05:58+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-ash 2025-05-20T09:59:24+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-asco 2024-10-25T12:00:39+02:00 daily 1.0 https://stg1.novartis.com/events/asco-2023 2024-10-25T12:00:39+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2024 2024-10-27T09:49:55+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-2023-financial-results 2024-10-27T09:48:44+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2024 2024-10-27T09:49:23+01:00 daily 1.0 https://stg1.novartis.com/events/jp-morgan-healthcare-conference-2024 2024-10-25T15:04:59+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2023 2024-11-20T10:44:34+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2023 2024-10-25T15:06:53+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2023 2024-10-25T15:09:04+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2022-financial-results 2024-10-25T15:09:36+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2022 2025-10-29T10:47:37+01:00 daily 1.0 https://stg1.novartis.com/events/world-economic-forum-2023 2024-10-25T15:11:21+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2020-financial-results 2025-05-20T07:18:34+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2016-financial-results 2024-10-25T15:25:25+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2017-financial-results 2024-10-25T15:24:25+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2020 2025-05-20T07:14:40+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2018 2024-10-25T15:22:24+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2020 2025-05-20T07:09:49+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2020 2025-05-20T07:06:00+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2019-financial-results 2025-05-20T07:01:17+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2018-financial-results 2025-05-20T06:54:34+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2019 2025-05-20T06:49:37+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2019 2025-05-20T06:44:34+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2019 2025-05-20T06:33:25+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2024 2025-10-24T09:32:53+02:00 daily 1.0 https://stg1.novartis.com/events/world-economic-forum-annual-meeting-2025 2025-01-23T11:49:14+01:00 daily 1.0 https://stg1.novartis.com/events/jp-morgan-healthcare-conference-2025 2025-01-15T11:38:29+01:00 daily 1.0 https://stg1.novartis.com/events/annual-general-meeting-2025 2026-02-04T09:00:23+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-2024-financial-results 2025-01-31T13:48:52+01:00 daily 1.0 https://stg1.novartis.com/events/eurovision-song-contest-2025 2025-02-03T17:04:39+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2025 2025-10-23T15:09:48+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2025 2026-02-03T16:51:24+01:00 daily 1.0 https://stg1.novartis.com/events/early-career-expo 2025-04-14T12:28:51+02:00 daily 1.0 https://stg1.novartis.com/events/empowering-kids-through-music 2025-04-28T11:23:32+02:00 daily 1.0 https://stg1.novartis.com/events/feel-beat-inclusive-eurovision-song-contest-disco 2025-04-28T11:26:15+02:00 daily 1.0 https://stg1.novartis.com/events/arena-plus-experience-eurovision-song-contest-grand-final-together 2025-04-28T11:28:21+02:00 daily 1.0 https://stg1.novartis.com/events/all-aboard-eurovision-tram 2025-04-28T11:29:57+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-pavillon-campus-unique-destination-during-eurovision-and-beyond 2025-04-28T11:33:43+02:00 daily 1.0 https://stg1.novartis.com/events/basel-bench-place-pause-reflect-and-reimagine 2025-04-28T11:24:46+02:00 daily 1.0 https://stg1.novartis.com/events/eurovision-village-place-experiment-celebrate-and-have-fun 2025-07-17T10:04:09+02:00 daily 1.0 https://stg1.novartis.com/events/asco-2025 2025-05-27T17:03:21+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2025 2025-10-23T15:16:32+02:00 daily 1.0 https://stg1.novartis.com/events/european-society-cardiology-esc-congress-2025 2025-08-30T17:12:17+02:00 daily 1.0 https://stg1.novartis.com/events/european-committee-treatment-and-research-multiple-sclerosis-ectrims-congress-2025 2025-09-25T14:09:56+02:00 daily 1.0 https://stg1.novartis.com/events/european-academy-dermatology-and-venereology-eadv-congress-2025 2025-09-01T15:07:00+02:00 daily 1.0 https://stg1.novartis.com/events/european-society-medical-oncology-esmo-congress-2025 2025-10-20T08:21:22+02:00 daily 1.0 https://stg1.novartis.com/events/us-early-career-expo 2025-10-13T10:01:32+02:00 daily 1.0 https://stg1.novartis.com/events/novartis-2025-financial-results 2026-02-04T13:52:17+01:00 daily 1.0 https://stg1.novartis.com/events/jp-morgan-healthcare-conference-2026 2026-02-03T16:54:08+01:00 daily 1.0 https://stg1.novartis.com/events/world-economic-forum-annual-meeting-2026 2026-01-23T13:43:33+01:00 daily 1.0 https://stg1.novartis.com/events/annual-general-meeting-2026 2026-02-04T08:59:35+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q1-2026 2026-02-04T09:05:28+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q2-2026 2026-02-04T09:09:55+01:00 daily 1.0 https://stg1.novartis.com/events/novartis-financial-results-q3-2026 2026-02-04T09:12:22+01:00 daily 1.0 https://stg1.novartis.com/events/annual-general-meeting-2027 2026-03-11T09:59:41+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/pandemic-has-been-reset-pharmas-reputation 2021-09-10T11:48:12+02:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/moving-towards-next-normal 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/enabling-stable-supply-medicines-during-covid-19 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/overcoming-manufacturing-challenges 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/proactive-scenario-planning-and-supply-risk-management 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/supply-chain-organization-during-covid-19-pandemic 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/coronavirus-giving-health-and-pharma-companies-chance-woo-tech-talent 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/pharmas-pandemic-response-could-help-attract-tech-talent 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/new-era-healthcare-innovation 2021-09-21T07:06:57+02:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/developing-drugs-during-pandemic 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/breaking-through-glass-ceiling-spring-women-artificial-intelligence 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/curious-advantage-curiosity-ceo-and-chief-people-and-organization-officer-perspective 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-pharmaceuticals-head-chief-marie-france-tschudin-rethinking-drug-launch-formula 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-ceo-vasant-narasimhan-building-trust-society 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/how-be-boss-unbossed-company 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/medicines-and-transformative-effect 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/its-time-pivot-towards-transformational-innovation 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-flipping-pyramid-explains-steven-baert 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/fortunes-most-admired-pharmaceutical-companies-2019 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/science-and-business-innovative-medicines 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/how-long-till-final-world-malaria-day 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-and-government-cameroon-sign-agreement-fight-chronic-diseases 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/changing-world 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/increasing-access-ncd-treatments-uganda 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-and-government-pakistan-sign-memorandum-understanding 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspective-key-fighting-chronic-disease-south-east-asia-young-people 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspective-how-smart-partnerships-can-help-us-fight-chronic-disease-africa 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/what-really-driving-malaria-control-personal-accountability-and-passion-community-health-workers 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/juncture-malaria-eradication 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/world-malaria-report-2016-keeping-momentum 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspectives-pharma-partners-african-countries-chronic-diseases 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/confronting-next-global-health-challenge 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/new-strategies-improving-access-lower-income-countries 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/tackling-chronic-disease-novartis-access 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/price-drugs-should-reflect-value-they-deliver 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspectives-making-medicines-affordable-worlds-poorest-people 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/reigniting-passion-science 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspectives-how-new-business-models-can-help-fight-chronic-diseases 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspectives-kenyas-new-health-care-battle 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/perfecting-access-through-embedded-sustainability-pooling-resources-and-consolidating-expertise 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/expanding-access-healthcare-what-will-it-really-take 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/malarias-deadly-comeback 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspectives-expanding-access-healthcare-what-will-it-really-take 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-hosts-second-stakeholder-dialogue 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspectives-fighting-africas-future-epidemics 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/beautiful-medicine-rediscover-power-natures-exquisite-complexity 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/crispr-genome-editing-fuels-cancer-drug-discovery 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-perspectives-tailoring-tactics-tackle-chronic-disease-low-income-countries 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/joe-jimenez-how-improve-healthcare 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-access-one-year-report 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/in-the-news/novartis-ceo-outlines-how-improve-pandemic-preparedness-warns-another-one-bound-happen 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/terms-use 2026-03-06T07:54:26+01:00 daily 1.0 https://stg1.novartis.com/privacy 2025-10-10T13:12:22+02:00 daily 1.0 https://stg1.novartis.com/home 2026-03-13T21:58:37+01:00 daily 1.0 https://stg1.novartis.com/page-not-found 2025-09-16T10:23:06+02:00 daily 1.0 https://stg1.novartis.com/careers 2026-03-19T15:05:14+01:00 daily 1.0 https://stg1.novartis.com/news/newsroom 2025-05-21T15:16:22+02:00 daily 1.0 https://stg1.novartis.com/investors/event-calendar 2026-03-26T08:01:28+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data 2026-03-16T17:11:16+01:00 daily 1.0 https://stg1.novartis.com/investors/shareholder-information 2026-01-13T16:26:30+01:00 daily 1.0 https://stg1.novartis.com/about/board-directors 2026-03-06T14:36:43+01:00 daily 1.0 https://stg1.novartis.com/about/executive-committee 2026-03-16T06:48:35+01:00 daily 1.0 https://stg1.novartis.com/contacts 2025-03-26T05:15:15+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/about-clinical-trials 2025-05-21T08:00:40+02:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/glossary-clinical-trial-terms 2025-03-26T05:15:15+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/medical-congresses-and-events 2025-09-01T18:09:56+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas 2025-09-19T09:06:24+02:00 daily 1.0 https://stg1.novartis.com/careers/early-careers/us-biomedical-research-internship-programs 2026-01-21T15:57:15+01:00 daily 1.0 https://stg1.novartis.com/about/awards-and-recognition 2025-07-23T19:29:57+02:00 daily 1.0 https://stg1.novartis.com/investors/company-overview/corporate-governance 2025-03-27T14:08:24+01:00 daily 1.0 https://stg1.novartis.com/investors/share-data-and-analysis/share-overview 2026-02-03T15:55:07+01:00 daily 1.0 https://stg1.novartis.com/investors/share-data-and-analysis/share-ownership 2026-02-02T10:53:14+01:00 daily 1.0 https://stg1.novartis.com/investors/share-data-and-analysis/return-investment-calculator 2024-02-09T10:18:39+01:00 daily 1.0 https://stg1.novartis.com/investors/share-data-and-analysis/dividend-information 2026-03-27T10:07:22+01:00 daily 1.0 https://stg1.novartis.com/investors/shareholder-information/american-depositary-receipts-adr/adr-voting-center 2026-02-03T21:29:16+01:00 daily 1.0 https://stg1.novartis.com/investors/shareholder-information/share-buy-back 2026-03-16T08:21:11+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/annual-results 2026-02-16T09:28:48+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results 2026-02-25T15:33:47+01:00 daily 1.0 https://stg1.novartis.com/investors/share-data-and-analysis/share-monitor 2024-02-09T10:16:21+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/sec-filings 2024-04-11T10:12:45+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/product-sales 2026-01-27T18:20:56+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/expected-currency-impact 2026-03-16T17:10:24+01:00 daily 1.0 https://stg1.novartis.com/investors/shareholder-information/american-depositary-receipts-adr 2026-02-03T15:09:43+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-and-european-union-eu/eucancerplan 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/investigator-initiated-trials-studies-clinical-and-investigator-initiated-research-non-clinical 2025-08-18T12:03:37+02:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/novartis-external-funding 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/chemical-biology-biomedical-research 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/healthcare-professional-resources-country 2026-02-26T15:31:36+01:00 daily 1.0 https://stg1.novartis.com/patients-and-caregivers/novartis-commitment-patients-and-caregivers 2026-02-12T08:16:27+01:00 daily 1.0 https://stg1.novartis.com/esg/environmental-sustainability/climate 2026-02-19T16:16:06+01:00 daily 1.0 https://stg1.novartis.com/esg/environmental-sustainability/climate/case-study-breezhaler-carbon-footprint 2022-05-13T08:50:15+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/science-car-t-cell-therapy 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/process-car-t-cell-therapy 2025-05-27T07:10:17+02:00 daily 1.0 https://stg1.novartis.com/diseases/malaria 2026-02-03T21:45:36+01:00 daily 1.0 https://stg1.novartis.com/diseases/sickle-cell-disease 2024-02-08T17:59:20+01:00 daily 1.0 https://stg1.novartis.com/news/stay-up-to-date/subscribed 2021-11-03T15:55:34+01:00 daily 1.0 https://stg1.novartis.com/news/stay-date/subscription-cancelled 2021-09-15T13:46:29+02:00 daily 1.0 https://stg1.novartis.com/diseases/chagas-disease 2025-01-28T15:41:49+01:00 daily 1.0 https://stg1.novartis.com/diseases/leprosy 2026-03-12T08:33:57+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/translational-medicine-research-novartis 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding 2025-06-26T11:59:33+02:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/payments-healthcare-professionals 2026-03-19T10:42:33+01:00 daily 1.0 https://stg1.novartis.com/investors/reporting-and-transparency-hub/public-policy 2025-12-10T09:58:36+01:00 daily 1.0 https://stg1.novartis.com/investors/reporting-and-transparency-hub/animal-research 2026-03-09T11:44:37+01:00 daily 1.0 https://stg1.novartis.com/diseases/coronavirus/patients-and-caregivers-covid-19-information 2025-03-26T06:17:47+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-collaborations/novartis-global-scholars-program 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/about/inclusion/promoting-inclusion 2026-01-13T16:41:18+01:00 daily 1.0 https://stg1.novartis.com/diseases/coronavirus/can-covid-clinical-trial 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/about/inclusion/promoting-inclusion/our-equal-pay-international-coalition-epic-commitments 2026-01-13T16:39:47+01:00 daily 1.0 https://stg1.novartis.com/about/inclusion/promoting-inclusion/lgbtqi-inclusion 2025-06-02T11:27:32+02:00 daily 1.0 https://stg1.novartis.com/about/inclusion/building-belonging 2025-11-13T14:49:12+01:00 daily 1.0 https://stg1.novartis.com/about/inclusion/parental-leave 2025-06-06T19:58:52+02:00 daily 1.0 https://stg1.novartis.com/esg/access/novartis-access-principles 2026-04-02T07:31:55+02:00 daily 1.0 https://stg1.novartis.com/esg/access/novartis-access-principles/research-development 2026-03-05T10:14:18+01:00 daily 1.0 https://stg1.novartis.com/esg/access/novartis-access-principles/affordability 2026-04-02T07:32:21+02:00 daily 1.0 https://stg1.novartis.com/esg/access/novartis-access-principles/strengthening-healthcare-systems 2026-04-02T07:32:48+02:00 daily 1.0 https://stg1.novartis.com/esg/access/patents-and-licensing 2025-01-28T15:39:16+01:00 daily 1.0 https://stg1.novartis.com/esg/access/donations 2026-03-02T13:18:28+01:00 daily 1.0 https://stg1.novartis.com/privacy/privacy-policy 2025-10-10T13:16:22+02:00 daily 1.0 https://stg1.novartis.com/partnering/partnering-opportunities 2026-01-09T11:33:17+01:00 daily 1.0 https://stg1.novartis.com/privacy/novartis-binding-corporate-rules-bcr 2025-10-10T13:14:53+02:00 daily 1.0 https://stg1.novartis.com/investors/shareholder-information/frequently-asked-questions 2026-02-18T18:13:57+01:00 daily 1.0 https://stg1.novartis.com/privacy/general-privacy-notice-external-stakeholders 2025-10-10T13:25:19+02:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/managed-access-programs 2026-02-17T09:48:40+01:00 daily 1.0 https://stg1.novartis.com/investors/shareholder-information/general-meetings 2026-04-02T08:16:27+02:00 daily 1.0 https://stg1.novartis.com/novartis-directory 2023-10-04T10:13:19+02:00 daily 1.0 https://stg1.novartis.com/partnering/our-approach-partnering 2026-03-16T07:46:15+01:00 daily 1.0 https://stg1.novartis.com/partnering/partnering-leadership-team 2026-03-16T07:47:50+01:00 daily 1.0 https://stg1.novartis.com/esg/access/creating-sustainable-business-models 2025-05-20T14:21:31+02:00 daily 1.0 https://stg1.novartis.com/esg/access/creating-sustainable-business-models/novartis-access 2025-01-28T15:35:50+01:00 daily 1.0 https://stg1.novartis.com/esg/access/creating-sustainable-business-models/healthy-family-programs 2025-05-20T14:06:57+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/fixed-income-securities 2026-03-18T15:12:05+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/clinical-trials-faqs 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/patients-and-caregivers 2025-05-20T13:48:13+02:00 daily 1.0 https://stg1.novartis.com/about/novartis-gene-therapies/what-cell-and-gene-therapy 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-gene-therapies/cell-and-gene-therapy-explained-vox-creative 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/transparency 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/ethics-clinical-trials 2025-03-26T06:17:47+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/fixed-income-securities/disclaimer 2021-09-28T10:59:10+02:00 daily 1.0 https://stg1.novartis.com/esg/access/novartis-oncology-access 2024-02-08T17:54:48+01:00 daily 1.0 https://stg1.novartis.com/investors/reporting-and-transparency-hub/reporting-archive 2026-01-26T13:53:24+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas/global-health-disease-area-research-novartis 2026-02-23T15:23:58+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/collaborations 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/contacts/media-contacts 2025-01-01T11:54:43+01:00 daily 1.0 https://stg1.novartis.com/contacts/investor-contacts 2025-08-07T10:07:38+02:00 daily 1.0 https://stg1.novartis.com/careers/early-careers/community-exploration-and-learning-lab-cell 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/ethical-behavior/code-ethics 2025-10-08T07:00:58+02:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/ethical-behavior/speakup 2025-07-03T10:13:54+02:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/ethical-behavior 2024-06-12T14:15:02+02:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/compliance 2026-03-05T10:44:21+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/compliance/anti-bribery-report 2024-01-30T15:46:33+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/compliance/doing-business-ethically 2023-10-31T15:48:09+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/integrated-risk-assurance 2024-11-05T11:01:43+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/bing-wang-phd 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/immunology-postdoc-mentors/daniela-cipolletta-phd 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/immunology-postdoc-mentors/frederic-bornancin-phd 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/carlotta-costa-phd 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/david-kodack-phd 2025-03-26T06:17:47+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/giorgio-g-galli-phd 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/tobias-schmelzle-phd 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/xiaomo-jiang-phd 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/tony-dalessio-phd 2025-03-26T06:17:47+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/immunology-postdoc-mentors/martin-alexander-schneider-phd 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/about/people-and-culture/giving-matching-volunteering 2025-06-13T15:31:48+02:00 daily 1.0 https://stg1.novartis.com/about/novartis-gene-therapies/about-novartis-gene-therapies 2023-10-04T06:35:20+02:00 daily 1.0 https://stg1.novartis.com/about/novartis-gene-therapies/gene-therapy-manufacturing 2023-10-04T06:37:34+02:00 daily 1.0 https://stg1.novartis.com/about/novartis-gene-therapies/resources-rare-disorders-patient-community 2023-10-04T06:38:03+02:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/human-rights 2026-03-05T17:50:49+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/learning-and-engagement 2026-02-17T08:10:39+01:00 daily 1.0 https://stg1.novartis.com/diseases/heart-failure 2021-10-11T11:04:22+02:00 daily 1.0 https://stg1.novartis.com/diseases/acute-myeloid-leukemia-aml 2025-05-27T06:49:03+02:00 daily 1.0 https://stg1.novartis.com/diseases/chronic-myeloid-leukemia 2025-05-20T13:00:49+02:00 daily 1.0 https://stg1.novartis.com/diseases/multiple-myeloma 2025-05-20T12:54:36+02:00 daily 1.0 https://stg1.novartis.com/diseases/advanced-melanoma 2025-05-20T11:50:20+02:00 daily 1.0 https://stg1.novartis.com/esg/access/value-based-pricing 2024-02-08T17:54:05+01:00 daily 1.0 https://stg1.novartis.com/investors/reporting-and-transparency-hub/esg-rating-performance 2026-03-25T15:32:04+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/integrated-risk-assurance/external-partner-risk-management-eprm 2025-07-01T16:46:13+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas/oncology-research-novartis 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas/immunology-disease-research-novartis 2025-04-08T11:14:44+02:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/integrated-risk-assurance/enterprise-risk-management 2026-03-05T07:19:08+01:00 daily 1.0 https://stg1.novartis.com/about/quality/novartis-quality-management-system-qms 2025-03-24T10:37:49+01:00 daily 1.0 https://stg1.novartis.com/about/quality/product-and-patient-safety-training 2026-02-03T12:32:12+01:00 daily 1.0 https://stg1.novartis.com/about/quality/product-recalls 2026-02-04T06:26:25+01:00 daily 1.0 https://stg1.novartis.com/about/quality/third-party-suppliers 2025-07-01T16:52:57+02:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/managed-access-programs/zolgensma-global-managed-access-program-gmap 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/collaborations/academic-partnerships-and-external-innovation 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-gene-therapies/novartis-gene-therapies-request-funding 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas/neuroscience-research-novartis 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/diseases/spinal-muscular-atrophy-sma 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular 2022-03-10T14:21:41+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-program-leadership/darrin-stuart-phd 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-cell-therapy-pioneering-cancer-therapy 2025-05-19T15:47:09+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/treatment-landscape-haematologic-malignancies 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance/compliance/our-commitment-ethical-and-responsible-use-artificial-intelligence 2026-02-14T15:19:41+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr 2021-10-07T07:54:38+02:00 daily 1.0 https://stg1.novartis.com/diseases/spinal-muscular-atrophy-sma/newborn-screening-spinal-muscular-atrophy-sma 2025-05-20T11:36:01+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/collaborations/biomedical-research-business-development-licensing 2023-10-04T14:12:25+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas/dax-exploratory-disease-research-novartis 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/pioneers-car-t-cell-and-gene-therapy 2025-05-19T13:46:35+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/open-source-science 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/cara-brocklehurst-phd 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/folkert-reck-phd 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/frederic-berst-phd 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/jay-larrow-phd 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/tejas-pathak-phd 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/computational-sciences-postdoc-mentors/florian-nigsch-phd 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/computational-sciences-postdoc-mentors/hanneke-jansen-phd 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/computational-sciences-postdoc-mentors/nicole-renaud-phd 2025-03-26T06:13:10+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/musculoskeletal-postdoc-mentors/mara-fornaro-phd 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/musculoskeletal-postdoc-mentors/olivier-leupin-phd 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/musculoskeletal-postdoc-mentors/valerie-salazar-phd 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/david-rowlands-phd 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/feng-cong-phd 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/john-koschwanez-phd 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/robert-esterberg-phd 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/careers/early-careers 2026-03-05T18:40:40+01:00 daily 1.0 https://stg1.novartis.com/esg/access/sub-saharan-africa 2023-01-27T09:22:57+01:00 daily 1.0 https://stg1.novartis.com/careers/career-search/notice-all-applicants-us-job-openings 2025-02-14T10:44:56+01:00 daily 1.0 https://stg1.novartis.com/open-source 2025-10-13T18:18:45+02:00 daily 1.0 https://stg1.novartis.com/art-collection 2023-09-05T14:45:56+02:00 daily 1.0 https://stg1.novartis.com/diseases/prostate-cancer 2025-05-20T11:29:17+02:00 daily 1.0 https://stg1.novartis.com/diseases/multiplesclerosis 2026-02-04T08:47:39+01:00 daily 1.0 https://stg1.novartis.com/diseases/multiplesclerosis/types-ms-and-ms-progression 2021-12-16T08:30:07+01:00 daily 1.0 https://stg1.novartis.com/diseases/multiplesclerosis/ms-tools 2025-06-26T16:45:51+02:00 daily 1.0 https://stg1.novartis.com/diseases/multiplesclerosis/ms-treatment-options 2021-12-16T08:33:26+01:00 daily 1.0 https://stg1.novartis.com/diseases/migraine 2021-12-16T08:24:30+01:00 daily 1.0 https://stg1.novartis.com/diseases/migraine/types-migraine 2021-12-16T10:58:41+01:00 daily 1.0 https://stg1.novartis.com/diseases/migraine/migraine-treatment-options 2021-12-16T08:18:35+01:00 daily 1.0 https://stg1.novartis.com/diseases/migraine/migraine-tools 2023-06-29T16:09:50+02:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/joanne-wong-phd 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/careers/career-programs/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/anke-bill-phd 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/diseases/rare-kidney-diseases 2024-05-02T10:38:23+02:00 daily 1.0 https://stg1.novartis.com/diseases/rare-kidney-diseases/complement-mediated-kidney-diseases-and-their-impact 2022-03-09T07:17:19+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/novartis-medical-information 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/diseases/dry-eye-disease 2022-03-28T14:59:19+02:00 daily 1.0 https://stg1.novartis.com/privacy/privacy-notice-pharmacovigilance 2025-10-10T13:27:01+02:00 daily 1.0 https://stg1.novartis.com/privacy/general-privacy-notice-business-partners 2025-10-10T13:19:00+02:00 daily 1.0 https://stg1.novartis.com/privacy/general-privacy-notice-third-parties 2025-10-10T13:24:43+02:00 daily 1.0 https://stg1.novartis.com/diseases/elevated-lipoproteina 2025-03-27T15:59:12+01:00 daily 1.0 https://stg1.novartis.com/esg/global-health/pandemic-preparedness 2024-02-08T17:58:12+01:00 daily 1.0 https://stg1.novartis.com/privacy/scc-c2p 2025-10-10T13:29:00+02:00 daily 1.0 https://stg1.novartis.com/privacy/scc-c2c 2025-10-10T13:30:37+02:00 daily 1.0 https://stg1.novartis.com/esg/index 2026-02-03T21:31:00+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-collaborations 2024-12-03T09:45:40+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/sourcing-and-procurement 2025-07-01T16:37:30+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/supplier-onboarding 2025-07-10T18:04:07+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/invoicing-novartis 2024-06-27T10:09:40+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/simple-invoice-checking 2023-10-04T13:55:08+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/documentation 2025-09-15T08:56:32+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/tr/sourcing-and-procurement 2023-01-16T14:20:20+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/tr/supplier-onboarding 2024-06-06T14:01:49+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/tr/invoicing-novartis 2022-09-16T15:08:56+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/fr/sourcing-and-procurement 2023-01-16T14:12:59+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/fr/supplier-onboarding 2024-06-06T13:59:58+02:00 daily 1.0 https://stg1.novartis.com/diseases/lung-cancer 2023-06-12T09:16:49+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/es/sourcing-and-procurement 2023-01-16T14:15:34+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/es/supplier-onboarding 2024-06-06T13:57:23+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/es/invoicing-novartis 2022-12-16T16:42:21+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/fr/simple-invoice-checking 2023-10-04T13:56:40+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/es/simple-invoice-checking 2023-10-04T13:57:31+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/tr/simple-invoice-checking 2023-10-04T13:57:05+02:00 daily 1.0 https://stg1.novartis.com/diseases/lung-cancer/sound-up 2025-05-20T11:19:03+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/fr/invoicing-novartis 2022-12-16T16:43:35+01:00 daily 1.0 https://stg1.novartis.com/news/sandoz-spinoff 2025-05-20T11:09:36+02:00 daily 1.0 https://stg1.novartis.com/privacy/general-privacy-notice-clinical-trial-site-personnel 2025-10-10T13:32:04+02:00 daily 1.0 https://stg1.novartis.com/about/therapeutic-areas/oncology/hematology 2025-05-20T10:59:12+02:00 daily 1.0 https://stg1.novartis.com/diseases/breast-cancer 2025-05-20T10:51:02+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/de/sourcing-and-procurement 2025-07-03T09:48:26+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/de/supplier-onboarding 2024-06-06T13:56:43+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/de/invoicing-novartis 2023-03-24T22:22:53+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/cn/sourcing-and-procurement 2025-07-03T10:16:23+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/cn/supplier-onboarding 2024-06-06T14:02:34+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/cn/invoicing-novartis 2023-03-24T22:24:37+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/jp/sourcing-and-procurement 2023-04-11T16:15:31+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/it/sourcing-and-procurement 2025-07-03T09:56:43+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/jp/supplier-onboarding 2024-06-06T14:03:22+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/jp/invoicing-novartis 2023-03-24T22:25:10+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/it/supplier-onboarding 2024-06-06T14:00:30+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/it/invoicing-novartis 2023-03-24T22:23:31+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/pt/sourcing-and-procurement 2023-03-24T22:23:54+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/pt/supplier-onboarding 2024-06-06T14:01:05+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/pt/invoicing-novartis 2023-03-24T22:24:09+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/cn/simple-invoice-checking 2023-10-04T13:58:54+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/de/simple-invoice-checking 2023-10-04T13:59:11+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/it/simple-invoice-checking 2023-10-04T13:59:35+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/jp/simple-invoice-checking 2023-10-04T13:59:55+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/pt/simple-invoice-checking 2023-10-04T14:00:14+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/ru/sourcing-and-procurement 2025-07-03T09:53:57+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/ru/supplier-onboarding 2024-06-06T13:55:59+02:00 daily 1.0 https://stg1.novartis.com/supplier-portal/ru/invoicing-novartis 2023-03-24T22:25:39+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal/ru/simple-invoice-checking 2023-03-24T22:25:43+01:00 daily 1.0 https://stg1.novartis.com/news/world-economic-forum-2023/health-systems-building-through-disruption 2023-01-18T17:37:17+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2022-q4-and-full-year-results-transcript 2024-07-24T12:13:28+02:00 daily 1.0 https://stg1.novartis.com/diseases/neuroendocrine-tumors-nets 2023-02-28T11:19:27+01:00 daily 1.0 https://stg1.novartis.com/careers/our-business-functions/careers-operations 2026-03-05T18:31:42+01:00 daily 1.0 https://stg1.novartis.com/careers/our-business-functions/careers-global-functions 2026-03-05T18:35:09+01:00 daily 1.0 https://stg1.novartis.com/careers/benefits-rewards 2025-05-28T10:39:33+02:00 daily 1.0 https://stg1.novartis.com/careers/our-business-functions/careers-research-and-development 2026-03-05T18:30:02+01:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2023-q1-transcript 2024-07-24T12:10:14+02:00 daily 1.0 https://stg1.novartis.com/partnering/partnering-event-calendar 2026-03-16T13:26:09+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting/asco-2023 2026-02-25T13:16:26+01:00 daily 1.0 https://stg1.novartis.com/about/therapeutic-areas/neuroscience 2026-03-05T08:25:11+01:00 daily 1.0 https://stg1.novartis.com/about/therapeutic-areas/immunology 2026-03-05T08:26:41+01:00 daily 1.0 https://stg1.novartis.com/diseases/chronic-myeloid-leukemia/innovation-cml-novartis 2025-05-20T10:32:32+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2023-q2-transcript 2024-07-24T12:19:47+02:00 daily 1.0 https://stg1.novartis.com/careers/early-careers/students 2026-03-05T18:43:58+01:00 daily 1.0 https://stg1.novartis.com/careers/early-careers/graduates 2026-03-05T18:42:20+01:00 daily 1.0 https://stg1.novartis.com/diseases/paroxysmal-nocturnal-hemoglobinuria-pnh 2023-11-27T16:47:53+01:00 daily 1.0 https://stg1.novartis.com/about/people-and-culture/giving-volunteering/non-profit-partnering-positive-sustainable-social-change 2025-06-13T15:35:38+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/radioligand-therapy/radioligand-therapy-delivering-now-building-future 2024-01-08T09:21:29+01:00 daily 1.0 https://stg1.novartis.com/about/therapeutic-areas/cardiovascular-renal-and-metabolic 2026-03-06T10:20:50+01:00 daily 1.0 https://stg1.novartis.com/about/therapeutic-areas/oncology 2026-03-05T08:28:15+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/transparency/leadership 2026-02-03T09:07:04+01:00 daily 1.0 https://stg1.novartis.com/investors/morphosys-acquisition 2024-06-20T08:57:39+02:00 daily 1.0 https://stg1.novartis.com/privacy/scc-p2c 2025-10-10T13:33:28+02:00 daily 1.0 https://stg1.novartis.com/privacy/scc-p2p 2025-10-10T13:51:30+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2023-q4-and-full-year-results-transcript 2024-07-24T12:18:42+02:00 daily 1.0 https://stg1.novartis.com/about/manufacturing/contract-manufacturing/derisk-your-mrna-program-ebook 2024-12-13T08:27:42+01:00 daily 1.0 https://stg1.novartis.com/events 2025-11-12T15:40:01+01:00 daily 1.0 https://stg1.novartis.com/diseases/iga-nephropathy 2024-04-09T16:42:16+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2024-q1-transcript 2024-05-07T11:34:00+02:00 daily 1.0 https://stg1.novartis.com/diseases/c3-glomerulopathy 2024-10-28T09:31:07+01:00 daily 1.0 https://stg1.novartis.com/report 2025-12-22T08:22:57+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting/asco-2024 2024-06-04T20:42:56+02:00 daily 1.0 https://stg1.novartis.com/partnering/biome 2024-12-13T08:32:35+01:00 daily 1.0 https://stg1.novartis.com/investors/morphosys-acquisition/voluntary-public-takeover-offer 2024-08-14T17:10:50+02:00 daily 1.0 https://stg1.novartis.com/investors/morphosys-acquisition/delisting-purchase-offer 2024-08-14T17:08:43+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2024-q2-transcript 2024-07-24T11:39:49+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2024-q3-transcript 2024-12-23T13:42:05+01:00 daily 1.0 https://stg1.novartis.com/careers/early-careers/early-career-professionals 2026-03-19T10:04:45+01:00 daily 1.0 https://stg1.novartis.com/eurovision 2025-05-09T21:37:50+02:00 daily 1.0 https://stg1.novartis.com/investors/financial-data/quarterly-results/2024-q4-and-full-year-results-transcript 2025-02-27T15:38:24+01:00 daily 1.0 https://stg1.novartis.com/corporate-social-media-community-management-guidelines 2025-11-19T16:54:58+01:00 daily 1.0 https://stg1.novartis.com/news/newsroom/featured-news 2025-05-20T09:52:19+02:00 daily 1.0 https://stg1.novartis.com/news/newsroom/pulse-updates 2025-05-20T10:49:47+02:00 daily 1.0 https://stg1.novartis.com/about/inclusion/caring-mental-health-and-wellbeing-our-people 2025-10-20T08:40:48+02:00 daily 1.0 https://stg1.novartis.com/about/people-and-culture/giving-volunteering/novartis-refugee-program 2025-06-16T10:54:19+02:00 daily 1.0 https://stg1.novartis.com/about/manufacturing/contract-manufacturing/novartis-cdmo-brochure 2025-06-23T15:58:20+02:00 daily 1.0 https://stg1.novartis.com/diseases/chronic-spontaneous-urticaria 2025-09-16T15:50:28+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/research-disease-areas/diseases-aging-and-regenerative-medicine-dare-research-novartis 2025-09-19T09:04:20+02:00 daily 1.0 https://stg1.novartis.com/diseases/sjogrens-disease 2025-10-15T17:00:23+02:00 daily 1.0 https://stg1.novartis.com/about/quality/audit-program-and-regulatory-inspections 2026-02-04T06:31:06+01:00 daily 1.0 https://stg1.novartis.com/esg/environmental-sustainability/nature 2026-02-19T16:19:25+01:00 daily 1.0 https://stg1.novartis.com/investors 2026-03-26T08:05:28+01:00 daily 1.0 https://stg1.novartis.com/investors/share-data-and-analysis 2025-08-05T11:23:08+02:00 daily 1.0 https://stg1.novartis.com/about 2026-03-06T10:56:15+01:00 daily 1.0 https://stg1.novartis.com/patients-and-caregivers 2026-03-05T16:35:28+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials 2025-03-26T05:15:15+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals 2026-03-05T16:36:59+01:00 daily 1.0 https://stg1.novartis.com/research-and-development 2026-03-05T16:38:37+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms 2025-03-26T05:15:15+01:00 daily 1.0 https://stg1.novartis.com/diseases/coronavirus 2025-03-26T05:15:15+01:00 daily 1.0 https://stg1.novartis.com/esg 2026-03-05T16:39:43+01:00 daily 1.0 https://stg1.novartis.com/news 2026-03-05T17:03:19+01:00 daily 1.0 https://stg1.novartis.com/investors/company-overview 2025-07-03T11:44:48+02:00 daily 1.0 https://stg1.novartis.com/esg/environmental-sustainability 2026-03-05T17:34:12+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-and-european-union 2026-03-05T08:31:11+01:00 daily 1.0 https://stg1.novartis.com/esg/global-health 2026-03-05T17:43:06+01:00 daily 1.0 https://stg1.novartis.com/partnering 2026-03-16T13:25:39+01:00 daily 1.0 https://stg1.novartis.com/esg/access 2026-04-02T07:31:24+02:00 daily 1.0 https://stg1.novartis.com/about/inclusion 2026-03-05T08:42:09+01:00 daily 1.0 https://stg1.novartis.com/about/people-and-culture 2026-03-05T17:12:52+01:00 daily 1.0 https://stg1.novartis.com/about/novartis-gene-therapies 2026-01-21T15:55:16+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/about/quality 2026-01-27T16:34:38+01:00 daily 1.0 https://stg1.novartis.com/esg/ethics-risk-and-compliance 2025-08-12T13:47:42+02:00 daily 1.0 https://stg1.novartis.com/diseases 2025-11-04T13:52:35+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/radioligand-therapy 2026-03-06T16:23:41+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/gene-therapy 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/supplier-portal 2024-06-25T15:55:51+02:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/cell-therapy 2024-12-13T08:33:12+01:00 daily 1.0 https://stg1.novartis.com/about/manufacturing/contract-manufacturing 2026-03-05T18:11:05+01:00 daily 1.0 https://stg1.novartis.com/microbial-manufacturing 2023-10-31T11:36:39+01:00 daily 1.0 https://stg1.novartis.com/quality-regulatory 2023-10-31T11:42:52+01:00 daily 1.0 https://stg1.novartis.com/about/manufacturing 2026-03-05T08:46:54+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/healthcare-professionals-researchers 2024-12-13T10:58:31+01:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/patients 2025-08-12T14:18:18+02:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/novartis-trials 2025-08-12T15:08:57+02:00 daily 1.0 https://stg1.novartis.com/clinicaltrials/NCT05089656 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/about/therapeutic-areas 2026-03-05T18:21:04+01:00 daily 1.0 https://stg1.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting 2025-05-21T09:20:04+02:00 daily 1.0 https://stg1.novartis.com/careers/why-novartis 2026-03-05T18:37:17+01:00 daily 1.0 https://stg1.novartis.com/careers/our-business-functions/careers-commercial-and-sales 2026-03-05T18:33:15+01:00 daily 1.0 https://stg1.novartis.com/careers/our-business-functions 2026-03-05T18:27:47+01:00 daily 1.0 https://stg1.novartis.com/careers/career-hub 2026-03-30T13:51:38+02:00 daily 1.0 https://stg1.novartis.com/about/therapeutic-areas/oncology/my-cancer-my-words 2024-10-28T09:28:47+01:00 daily 1.0 https://stg1.novartis.com/investors/reporting-and-transparency-hub 2026-03-12T11:39:09+01:00 daily 1.0 https://stg1.novartis.com/research-and-development/technology-platforms/radioligand-therapy/supporting-healthcare-system-readiness-rlt 2024-09-12T13:50:45+02:00 daily 1.0 https://stg1.novartis.com/careers/why-novartis/shared-purpose-feels-personal 2026-02-26T07:03:07+01:00 daily 1.0 https://stg1.novartis.com/news/media-releases/novartis-drug-afinitor-significantly-improves-progression-free-survival-advanced-nonfunctional-gastrointestinal-and-lung-net 2021-10-05T11:51:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-entrestotm-recommended-chmp-eu-approval 2021-10-05T11:51:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-james-e-bradner-md-president-novartis-institutes-biomedical-research-mark-fishman-retires 2022-04-08T11:39:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-nomme-le-dr-james-e-bradner-president-des-instituts-novartis-pour-la-recherche-biomedicale-suite-au-prochain-depart-la-retraite-de-mark-fishman 2021-10-05T11:51:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ernennt-dr-james-e-bradner-zum-prasidenten-der-novartis-institutes-biomedical-research-da-mark-fishman-den-ruhestand-tritt 2021-10-05T11:51:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-launches-novartis-access-portfolio-affordable-medicines-treat-chronic-diseases-lower-income-countries 2021-10-05T11:51:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lance-novartis-access-une-gamme-de-medicaments-prix-abordables-pour-lutter-contre-les-maladies-chroniques-dans-les-pays-faible-revenu 2021-10-05T11:51:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lanciert-novartis-access-ein-portfolio-von-erschwinglichen-medikamenten-zur-behandlung-von-chronischen-erkrankungen-landern-mit-niedrigen-einkommen 2021-10-05T11:51:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/swissmedic-approves-novartis-new-heart-failure-medicine-entrestotm 2021-10-05T11:51:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-foundation-healthcare-models-and-disease-elimination-programs-showcased-ectmih 2021-10-05T11:51:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-farydak-first-its-class-anticancer-agents-approved-patients-multiple-myeloma 2021-10-05T11:51:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-launches-zarxiotm-filgrastim-sndz-first-biosimilar-united-states 2021-10-05T11:51:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-new-revolade-use-first-class-therapy-patients-severe-aplastic-anemia 2021-10-05T11:51:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-global-partnership-amgen-develop-and-commercialize-pioneering-neuroscience-treatments 2021-10-05T11:51:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-setzt-sich-weiter-fur-die-endgultige-ausrottung-von-lepra-ein 2021-10-05T11:51:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-lapproche-de-la-derniere-ligne-droite-dans-la-lutte-visant-eradiquer-la-lepre 2021-10-05T11:51:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-tafinlar-and-mekinist-first-combination-approved-patients-aggressive-form-melanoma 2021-10-05T11:51:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-commitment-go-last-mile-effort-eliminate-leprosy 2021-10-05T11:51:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/das-novartis-international-biocamp-zeigt-wie-zusammenarbeit-und-vielfalt-innovationen-fordern-und-inspiriert-kunftige-wissenschaftliche-fuhrungskrafte 2021-10-05T11:51:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/le-novartis-international-biocamp-souligne-le-role-de-la-collaboration-et-de-la-diversite-pour-stimuler-linnovation-et-inspirer-les-futurs-leaders-scientifiques 2021-10-05T11:51:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-international-biocamp-highlights-how-collaboration-and-diversity-drive-innovation-and-inspires-future-science-leaders 2021-10-05T11:51:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-expands-use-novartis-drug-promacta-include-treatment-children-ages-1-and-older-chronic-immune-thrombocytopenia 2021-10-05T11:51:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquires-all-remaining-rights-gsks-ofatumumab-develop-treatments-ms-and-other-autoimmune-indications 2021-10-05T11:51:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-odomzo-gains-eu-approval-locally-advanced-basal-cell-carcinoma-providing-new-non-invasive-therapy-patients 2021-10-05T11:51:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-divestiture-influenza-vaccines-business-csl-limited-usd-275-million 2021-10-05T11:51:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-partners-phase-4-partners-and-institutional-investors-help-create-mereo-biopharma-group-ltd 2021-10-05T11:51:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-foundation-confirms-new-members-its-board-trustees-including-new-chairman-dr-joerg-reinhardt 2021-10-05T11:51:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer 2021-10-05T11:51:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-and-mekinist-achieves-important-eu-and-us-regulatory-milestones 2021-10-05T11:51:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-revolade-recommended-chmp-eu-approval-treat-patients-severe-aplastic-anemia-serious-blood-disorder 2021-10-05T11:51:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-solid-performance-second-quarter-strong-innovation-and-progress-new-launches 2021-10-05T11:51:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-solide-performance-au-deuxieme-trimestre-grace-la-force-de-linnovation-et-aux-progres-des-nouveaux-lancements 2021-10-05T11:51:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-eine-solide-performance-mit-starken-innovationen-und-fortschritten-bei-neueinfuhrungen 2021-10-05T11:51:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-malaria-treatment-coartem-80480mg-receives-who-prequalification-enabling-greater-access-patients 2021-10-05T11:51:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization 2021-10-05T11:52:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-receives-european-approval-pre-loaded-intraocular-lens-delivery-system-treat-patients-undergoing-cataract-surgery 2021-10-05T11:52:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pharmaceuticals-launches-first-app-visually-impaired-people-use-apple-watch-and-other-smart-watches 2021-10-05T11:52:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-deepens-its-industry-leading-pipeline-acquisition-spinifex-pharmaceuticals-inc 2021-10-05T11:52:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-publication-lancet-showing-sustained-efficacy-secukinumab-over-one-year-psoriatic-arthritis-patients 2021-10-05T11:52:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-farydak-recommended-chmp-eu-approval-treat-multiple-myeloma-providing-patients-new-mechanism-action 2021-10-05T11:52:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxone-20mg 2021-10-05T11:52:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-strong-innovation-momentum-its-second-meet-novartis-management-investor-day 2021-10-05T11:52:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-receives-european-approval-new-trifocal-presbyopia-correcting-intraocular-lens-patients-undergoing-cataract-surgery 2021-10-05T11:52:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-from-large-european-study-reinforcing-benefit-first-line-tasigna-newly-diagnosed-patients-cml 2021-10-05T11:52:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-data-show-majority-patients-polycythemia-vera-treated-jakavi-achieved-long-term-disease-control 2021-10-05T11:52:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-eha-show-increased-pfs-benefit-farydak-new-subgroup-patients-previously-treated-multiple-myeloma 2021-10-05T11:52:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-arzerra-improved-median-progression-free-survival-54-patients-relapsed-chronic-lymphocytic-leukemia 2021-10-05T11:52:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-new-analysis-showing-xolair-improving-quality-life-78-chronic-spontaneous-urticaria-patients 2021-10-05T11:52:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-gains-fda-approval-promacta-providing-new-option-children-ages-6-and-older-chronic-itp-rare-blood-disorder 2021-10-05T11:52:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-wcd-demonstrating-significant-efficacy-cosentyx-patients-psoriasis-nails-palms-and-soles 2021-10-05T11:52:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-one-year-results-demonstrating-sustained-secukinumab-efficacy-ankylosing-spondylitis-patients 2021-10-05T11:52:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-ctl019-data-showing-its-potential-treatment-specific-types-hard-treat-non-hodgkin-lymphoma 2021-10-05T11:52:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-asco-zykadia-and-combination-tafinlar-and-mekinist-certain-nsclc-patients-unmet-needs 2021-10-05T11:52:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/combination-novartis-drugs-tafinlar-and-mekinist-shows-significant-survival-benefit-patients-metastatic-melanoma 2021-10-05T11:52:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-21-medicines-and-11-investigational-compounds-asco-and-eha 2021-10-05T11:52:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-afinitor-extended-progression-free-survival-phase-iii-trial-advanced-gastrointestinal-or-lung-neuroendocrine-tumors 2021-10-05T11:52:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-two-positive-us-phase-iii-programs-copd-qva149-and-nva237 2021-10-05T11:52:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia-gains-eu-approval-providing-new-therapy-certain-patients-alk-nsclc 2021-10-05T11:52:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-phase-iii-study-arzerra-met-primary-endpoint-improved-progression-free-survival-patients-relapsed-cll 2021-10-05T11:52:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-sales-growth-cc-significant-margin-expansion-cc-and-strong-innovation-q11-now-more-focused-portfolio 2021-10-05T11:52:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-affiche-au-t11-une-forte-progression-de-ses-ventes-tcc-une-hausse-importante-de-sa-marge-tcc-et-une-innovation-tres-dynamique-avec-un-portefeuille-desormais-mieux-cible 2021-10-05T11:52:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal1-umsatzsteigerungen-kwk-deutlich-hohere-margen-kwk-und-beachtliche-innovationen-jetzt-mit-einem-starker-fokussierten-portfolio 2021-10-05T11:52:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-celebrates-19th-annual-community-partnership-day-more-27000-associates-volunteering-their-local-communities 2021-10-05T11:52:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/data-aan-showed-gilenya-high-efficacy-achieving-no-evidence-disease-activity-previously-treated-highly-active-ms-patients 2021-10-05T11:52:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-fda-approval-glatopatm-first-generic-competitor-ms-therapy-copaxone-20mg 2021-10-05T11:52:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-receives-fda-approval-new-multifocal-intraocular-lens-treat-cataract-patients-united-states 2021-10-05T11:52:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/data-lancet-show-novartis-drug-arzerra-plus-chlorambucil-improved-median-progression-free-survival-71-cll-patients 2021-10-05T11:52:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/gilenya-data-aan-highlight-novartis-leadership-innovation-new-ms-assessment-methods-benefit-patients-and-physicians 2021-10-05T11:52:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-approval-jadenutm-simplify-treatment-administration-patients-chronic-iron-overload 2021-10-05T11:52:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-accelerates-cancer-immunotherapy-efforts-aduro-biotech-alliance-and-launch-new-immuno-oncology-research-group 2021-10-05T11:52:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyxtm-two-year-data-shows-sustained-effect-and-favorable-safety-profile-psoriasis-patients 2021-10-05T11:52:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-shows-cosentyxtm-significantly-superior-stelara-and-clears-skin-pasi-90-nearly-80-psoriasis-patients 2021-10-05T11:52:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-jakavi-polycythemia-vera-first-targeted-therapy-approved-patients-rare-blood-cancer 2021-10-05T11:52:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-new-late-breaking-cosentyxtm-data-aad-2015-showing-significant-patient-benefit-achieving-clear-skin 2021-10-05T11:52:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-first-biosimilar-zarxiotm-filgrastim-sndz-from-sandoz 2021-10-05T11:52:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-completion-transactions-gsk 2021-10-05T11:52:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-gibt-abschluss-von-transaktionen-mit-gsk-bekannt 2021-10-05T11:52:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-annonce-la-conclusion-des-transactions-avec-gsk 2021-10-05T11:52:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/positive-phase-ii-data-highlights-benefits-alcons-rth258-patients-neovascular-wet-age-related-macular-degeneration 2021-10-05T11:52:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-novartis-board-directors 2021-10-05T11:52:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration 2021-10-05T11:52:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/aktionare-genehmigen-alle-antrage-des-verwaltungsrats-von-novartis 2021-10-05T11:52:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia-recommended-eu-approval-patients-alk-nsclc-previously-treated-crizotinib 2021-10-05T11:52:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-farydak-first-hdac-inhibitor-patients-multiple-myeloma 2021-10-05T11:52:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-heart-failure-medicine-lcz696-granted-fda-priority-review 2021-10-05T11:52:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-receives-fda-approval-pazeotm-solution-ocular-allergy-itch-relief 2021-10-05T11:52:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-study-nejm-showing-jakavi-was-superior-standard-therapy-rare-blood-cancer-polycythemia-vera 2021-10-05T11:52:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-solid-sales-growth-margin-expansion-and-pipeline-progress-2014-portfolio-transformation-will-focus-company-leading-businesses 2021-10-05T11:52:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enregistre-en-2014-une-forte-augmentation-de-ses-ventes-sa-marge-et-progres-de-son-pipeline-la-transformation-du-portefeuille-concentrera-lentreprise-sur-ses-principales-activites 2021-10-05T11:53:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-2014-solide-umsatzsteigerungen-hohere-margen-und-fortschritte-der-pipeline-mit-der-umgestaltung-des-portfolios-fokussiert-sich-das-unternehmen-auf-fuhrende-geschaftsbereiche 2021-10-05T11:53:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-bexsero-vaccine-approved-fda-prevention-meningitis-b-leading-cause-bacterial-meningitis-us 2021-10-05T11:53:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-jakavi-recommended-chmp-eu-approval-treat-adults-rare-blood-cancer-polycythemia-vera 2021-10-05T11:53:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab-moderate-severe-plaque-psoriasis-patients 2021-10-05T11:53:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyxtm-first-il-17-inhibitor-receive-eu-approval-first-line-treatment-moderate-severe-psoriasis-patients 2021-10-05T11:53:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pharmaceuticals-announces-joint-investment-company-qualcomm-leading-innovation-digital-medicines-physicians-and-patients 2021-10-05T11:53:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-robust-phase-iii-results-qva149-and-nva237-and-submits-regulatory-applications-us-fda 2021-10-05T11:53:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-biosimilar-filgrastim-recommended-approval-fda-oncologic-drugs-advisory-committee 2021-10-05T11:53:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-collaborates-intellia-therapeutics-and-caribou-biosciences-explore-making-medicines-and-drug-discovery-tools-crispr-genome-editing-technology 2021-10-05T11:53:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-sandoz-erelzitm-treat-multiple-inflammatory-diseases 2021-10-05T12:04:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-convenes-experts-discuss-new-technologies-healthcare-novartis-international-biocamp 2021-10-05T12:04:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/experten-diskutieren-am-novartis-international-biocamp-neue-technologien-im-gesundheitsbereich 2021-10-05T12:04:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-convie-plusieurs-experts-au-novartis-international-biocamp-afin-de-discuter-des-nouvelles-technologies-en-matiere-de-sante 2021-10-05T12:04:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients-secondary-progressive-ms 2021-10-05T12:04:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/six-leading-scientists-receive-prestigious-novartis-prizes-immunology-16th-international-congress-immunology 2021-10-05T12:04:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cdk46-inhibitor-lee011-ribociclib-receives-fda-breakthrough-therapy-designation-first-line-treatment-hrher2-advanced-breast-cancer 2021-10-05T12:04:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-achieves-us-approval-cypass-micro-stent-micro-invasive-surgical-device-treat-glaucoma 2021-10-05T12:04:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-solid-q2-despite-full-quarter-us-gleevec-generic-impact-significant-positive-innovation-news-strengthens-future-growth-prospects 2021-10-05T12:04:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-un-2eme-trimestre-solide-malgre-limpact-sur-le-trimestre-du-generique-de-gleevec-aux-us-nouvelles-positives-importantes-de-linnovation-renforcent-les-perspectives-de-croissance 2021-10-05T12:04:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-2-quartal-solide-ergebnisse-trotz-us-generikakonkurrenz-fur-gleevec-im-gesamten-quartal-wichtige-positive-neuigkeiten-zu-innovationen-starken-zukunftige-wachstumsperspektiven 2021-10-05T12:04:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-launches-dailies-total1-multifocal-contact-lenses-first-and-only-water-gradient-lenses-designed-people-presbyopia 2021-10-05T12:04:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-biosimilar-etanercept-recommended-fda-advisory-committee-approval-treat-multiple-inflammatory-diseases 2021-10-05T12:04:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-shows-sandoz-biosimilar-etanercept-candidate-has-equivalent-efficacy-originator-product 2021-10-05T12:04:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pkc412-midostaurin-pivotal-data-published-nejm-show-60-response-rate-advanced-systemic-mastocytosis-sm 2021-10-05T12:04:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/largest-global-psoriasis-survey-shows-84-people-face-discrimination-and-humiliation-because-their-skin 2021-10-05T12:04:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-adds-bispecific-antibodies-its-growing-immuno-oncology-portfolio-through-collaboration-and-licensing-agreement-xencor 2021-10-05T12:04:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/timely-use-novartis-entresto-could-prevent-or-postpone-over-28000-us-deaths-year-among-hfref-patients-according-expert-analysis-jama-cardiology 2021-10-05T12:04:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-partnership-medicines-malaria-venture-develop-next-generation-antimalarial-treatment 2021-10-05T12:04:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erweitert-partnerschaft-mit-medicines-malaria-venture-zur-entwicklung-von-malariamedikamenten-der-nachsten-generation 2021-10-05T12:04:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-etend-son-partenariat-avec-medicines-malaria-venture-pour-developper-la-prochaine-generation-de-traitement-antipaludeen 2021-10-05T12:04:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-long-term-safety-data-revolade-adults-chronic-immune-thrombocytopenia-rare-blood-disorder 2021-10-05T12:04:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-data-showing-jakavi-superior-best-available-therapy-patients-less-advanced-polycythemia-vera-pv 2021-10-05T12:04:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-demonstrates-sandoz-etanercept-and-rituximab-biosimilar-candidates-bioequivalent-originator-products 2021-10-05T12:04:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-patients-monthly-migraine-days-phase-ii-study-chronic-migraine-prevention 2021-10-05T12:04:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-scientific-evidence-cosentyx-ankylosing-spondylitis-and-psoriatic-arthritis-patients-eular-2016 2021-10-05T12:04:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-demonstrates-overall-survival-benefit-three-year-follow-patients-advanced-melanoma 2021-10-05T12:04:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pivotal-data-tafinlar-mekinist-demonstrated-63-percent-overall-response-rate-treating-rare-form-lung-cancer 2021-10-05T12:04:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-more-50-percent-eligible-ph-cml-patients-maintain-treatment-free-remission-tfr-after-stopping-tasigna 2021-10-05T12:04:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-afinitor-receives-eu-approval-treat-certain-types-advanced-gastrointestinal-gi-and-lung-neuroendocrine-tumors-net 2021-10-05T12:04:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-its-strong-foundation-long-term-sustainable-growth-third-meet-novartis-management-event 2021-10-05T12:04:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicines-agency 2021-10-05T12:04:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-entresto-given-strong-class-i-recommendation-both-us-and-eu-heart-failure-guidelines-less-year-after-regulatory-approvals 2021-10-05T12:04:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-investment-fortihfy-clinical-program-entresto-and-heart-failure 2021-10-05T12:04:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-pivotal-data-hematologic-and-solid-tumor-cancers-2016-asco-annual-meeting 2021-10-05T12:04:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/monaleesa-2-trial-novartis-lee011-ribociclib-stopped-due-positive-efficacy-results-interim-analysis-hrher2-advanced-breast-cancer 2021-10-05T12:05:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-focuses-pharmaceuticals-division-creating-two-business-units-novartis-pharmaceuticals-and-novartis-oncology-appoints-leaders-executive-committee-novartis 2021-10-05T12:05:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-renforce-la-division-pharmaceuticals-par-la-creation-de-deux-unites-daffaires-novartis-pharmaceuticals-et-novartis-oncology-et-nomme-de-nouveaux-dirigeants-son-comite-de-direction 2021-10-05T12:05:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-fokussiert-ihre-division-pharmaceuticals-durch-schaffung-der-geschaftseinheiten-novartis-pharmaceuticals-und-novartis-oncology-und-beruft-deren-leiter-die-geschaftsleitung-von-novartis 2021-10-05T12:05:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-innovative-hypertension-program-vietnam 2021-10-05T12:05:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/major-study-published-nejm-confirms-novartis-ultibro-breezhaler-superiority-over-seretide-preventing-copd-exacerbations 2021-10-05T12:05:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-afinitor-recommended-chmp-european-union-approval-treat-select-gi-and-lung-neuroendocrine-tumors 2021-10-05T12:05:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-three-fda-breakthrough-therapy-designations-ilaris-treat-rare-types-periodic-fever-syndromes 2021-10-05T12:05:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-solid-q1-despite-gleevec-loss-exclusivity-investing-behind-new-launches-long-term-growth 2021-10-05T12:05:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-trotz-verlust-der-exklusivrechte-gleevec-solide-ergebnisse-und-investiert-neueinfuhrungen-zugunsten-langfristigen-wachstums 2021-10-05T12:05:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enregistre-un-premier-trimestre-solide-malgre-la-perte-dexclusivite-de-gleevec-et-investi-dans-de-nouveaux-lancements-pour-soutenir-la-croissance-long-terme 2021-10-05T12:05:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-afinitor-significantly-reduces-seizures-phase-iii-study-patients-tuberous-sclerosis-complex 2021-10-05T12:05:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-ec-approval-subcutaneous-route-administration-biosimilar-binocrits-nephrology-indication 2021-10-05T12:05:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-revolade-first-class-therapy-children-aged-1-year-and-above-chronic-itp 2021-10-05T12:05:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-analyses-show-novartis-entrestotm-reduced-cardiovascular-death-or-hospitalization-heart-failure-consistently-benefitting-patients-reduced-ejection-fraction-regardless 2021-10-05T12:05:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-publishes-updated-2015-segment-financials-reflecting-new-division-structure 2021-10-05T12:05:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-superior-stelara-delivering-long-lasting-skin-clearance-pasi-90-psoriasis-patients-52-weeks 2021-10-05T12:05:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-new-indication-novartis-drug-afinitor-progressive-nonfunctional-gi-and-lung-neuroendocrine-tumors-net 2021-10-05T12:05:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors 2021-10-05T12:05:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-0 2021-10-05T12:05:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-aktionare-genehmigen-alle-antrage-des-verwaltungsrats 2021-10-05T12:05:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-receives-breakthrough-therapy-designation-from-fda-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml 2021-10-05T12:05:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-expands-leadership-position-treating-glaucoma-through-acquisition-transcend-medical-inc 2021-10-05T12:05:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-strengthens-its-biosimilars-portfolio-acquisition-pfizers-biosimilar-infliximab-eea 2021-10-05T12:05:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-advances-its-biosimilars-program-ema-acceptance-regulatory-submission-biosimilar-pegfilgrastim 2021-10-05T12:05:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-foundation-commemorates-world-leprosy-day-its-continued-efforts-go-last-mile-toward-elimination 2021-10-05T12:05:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-and-core-margin-expansion-cc1-2015-announces-plans-accelerate-growth-alcon-streamline-group-operations 2021-10-05T12:05:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enregistre-en-2015-une-forte-croissance-des-ventes-et-une-hausse-de-sa-marge-core-tcc1-et-annonce-des-plans-pour-accelerer-la-croissance-dalcon-et-rationaliser-les-operations-du-groupe 2021-10-05T12:05:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-2015-eine-kraftige-steigerung-des-umsatzes-und-der-kern-gewinnmarge-kwk1-plane-zur-wachstumsbeschleunigung-bei-alcon-und-zur-straffung-der-konzernaktivitaten-bekannt-gegeben 2021-10-05T12:05:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis-us 2021-10-05T12:05:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-grow-immuno-oncology-pipeline-through-collaboration-and-licensing-agreement-surface-oncology 2021-10-05T12:05:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pharmaceuticals-collaborates-qualcomm-digital-innovation-breezhalertm-inhaler-device-treat-copd 2021-10-05T12:05:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-two-major-trials-showing-significant-efficacy-cosentyx-ankylosing-spondylitis-patients 2021-10-05T12:05:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/300-million-child-friendly-antimalarial-treatments-supplied-without-profit-novartis 2021-10-05T12:05:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-advances-its-biosimilars-program-european-medicines-agency-ema-acceptance-regulatory-submission-biosimilar-etanercept 2021-10-05T12:05:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-new-ctl019-phase-ii-data-demonstrating-93-complete-remission-pediatric-patients-rr-all 2021-10-05T12:05:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/phase-iii-data-shows-sandoz-proposed-biosimilar-pegfilgrastim-has-similar-safety-and-efficacy-reference-product 2021-10-05T12:05:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-improves-overall-survival-23-global-phase-iii-study-aml-patients-flt3-mutations 2021-10-05T12:05:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-ctl019-study-data-demonstrating-overall-response-adult-patients-certain-types-lymphoma 2021-10-05T12:05:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-phase-iii-studies-jakavi-show-disease-improvement-patients-myelofibrosis-and-polycythemia-vera 2021-10-05T12:05:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-targeted-combination-therapy-sabcs-reinforcing-commitment-breast-cancer-patients 2021-10-05T12:05:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-clinical-advances-ash-2015-underscoring-leadership-hematology-research 2021-10-05T12:05:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval 2021-10-05T12:05:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-two-landmark-european-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis 2021-10-05T12:05:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pharmaceuticals-corporation-finalizes-settlement-agreement-resolving-civil-suit-filed-us-attorneys-office-southern-district-new-york 2021-10-05T12:05:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/regulatory-submission-sandoz-proposed-biosimilar-pegfilgrastim-accepted-fda 2021-10-05T12:05:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/flame-study-shows-superiority-novartis-ultibro-breezhaler-over-seretide-reducing-copd-exacerbations 2021-10-05T12:05:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-introduces-contoura-vision-first-personalized-lasik-procedure-american-academy-ophthalmology-annual-meeting 2021-10-05T12:05:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-two-year-data-cosentyx-showing-no-progression-joint-damage-84-psoriatic-arthritis-patients 2021-10-05T12:05:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-two-year-data-novartis-cosentyx-show-sustained-response-and-no-progression-spinal-damage-shown-x-ray-80-patients-ankylosing-spondylitis 2021-10-05T12:05:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-nominating-elizabeth-doherty-and-ton-buechner-board-directors 2021-10-05T12:05:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-new-hypertension-program-ghana 2021-10-05T12:05:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-core-margin-expansion-cc-and-continued-strengthen-pipeline-q3-track-full-year-guidance 2021-10-05T12:06:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-au-troisieme-trimestre-une-forte-hausse-de-sa-marge-core-tcc-et-continue-de-renforcer-son-pipeline-confirmant-ainsi-ses-previsions-pour-lexercice 2021-10-05T12:06:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-steigert-die-kerngewinnmarge-kwk-im-dritten-quartal-kraftig-starkt-erneut-die-pipeline-und-ist-auf-kurs-fur-die-jahresprognose 2021-10-05T12:06:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-il-17a-inhibitor-cosentyxtm-treat-ankylosing-spondylitis-and-psoriatic-arthritis 2021-10-05T12:06:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-broadens-immuno-oncology-pipeline-acquisition-admune-therapeutics-and-licensing-agreements-xoma-and-palobiofarma 2021-10-05T12:06:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment-options-against-chronic-diseases 2021-10-05T12:06:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-showing-majority-patients-are-able-maintain-clear-or-almost-clear-skin-cosentyx-across-3-years 2021-10-05T12:06:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/long-term-efficacy-gilenya-reinforced-new-no-evidence-disease-activity-neda-4-analysis-ms-patients-over-seven-years 2021-10-05T12:06:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-receives-fda-approval-pre-loaded-intraocular-lens-delivery-system-treat-patients-undergoing-cataract-surgery 2021-10-05T12:06:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-proposed-biosimilar-etanercept 2021-10-05T12:06:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-secukinumab-phase-iii-data-confirming-significant-efficacy-patients-psoriatic-arthritis 2021-10-05T12:06:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/patients-aggressive-form-melanoma-lived-more-two-years-average-when-taking-novartis-therapies-tafinlar-mekinist 2021-10-05T12:06:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-next-generation-car-t-cell-therapy-ctl119-combined-ibrutinib-shows-high-rate-responses-cll-patients 2021-10-05T12:08:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-expanded-use-zykadia-first-line-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc 2021-10-05T12:08:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-analyses-reinforce-potential-ultibro-breezhaler-copd-patients-historically-treated-steroids 2021-10-05T12:08:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-line-use-zykadia-alk-positive-advanced-non-small-cell-lung-cancer-nsclc 2021-10-05T12:08:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-asco-icml-and-eha-meetings-demonstrate-meaningful-advancements-cancer-care 2021-10-05T12:08:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-initiative-tackle-hypertension-and-its-root-causes-low-income-urban-communities 2021-10-05T12:08:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-celebrates-21st-annual-community-partnership-day-over-24500-associates-volunteering-their-local-communities 2021-10-05T12:08:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-exercises-exclusive-option-agreement-conatus-treatment-nash 2021-10-05T12:08:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-rydapt-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-systemic-mastocytosis-sm 2021-10-05T12:08:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-announces-eu-launch-cypass-micro-stent-micro-invasive-glaucoma-surgical-device-lower-intraocular-pressure-iop-patients-primary-open-angle-glaucoma 2021-10-05T12:08:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-sales-growth-across-all-divisions-cc1-growth-drivers-including-cosentyx-and-entresto-more-offset-generic-erosion-innovation-momentum-continued 2021-10-05T12:08:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ventes-en-progression-tcc1-dans-toutes-ses-divisions-les-moteurs-de-croissance-cosentyx-et-entresto-inclus-compensent-lerosion-due-aux-generiques-linnovation-toujours-en-plein-essor 2021-10-05T12:08:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-umsatzsteigerungen-allen-divisionen-kwk1-wobei-wachstumstreiber-wie-cosentyx-und-entresto-die-einbussen-durch-generika-mehr-als-wettmachen-innovationsdynamik-setzt-sich-fort 2021-10-05T12:08:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-global-collaboration-amgen-commercialize-first-class-amg-334-erenumab-program-migraine-prevention-us-and-canada 2021-10-05T12:08:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-real-world-data-aan-confirms-benefit-gilenya-four-key-measures-disease-activity-relapsing-ms 2021-10-05T12:08:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-proposed-biosimilars-rituximab-and-etanercept-recommended-approval-europe 2021-10-05T12:08:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/nih-study-nejm-shows-novartis-drug-eltrombopag-first-line-therapy-standard-treatment-improves-responses-severe-aplastic-anemia 2021-10-05T12:08:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-development-programs-nash-through-clinical-collaboration-allergan 2021-10-05T12:08:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation-treatment-adult-patients-rr-dlbcl 2021-10-05T12:08:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-strengthen-rd-pipeline-licensing-ecf843-ophthalmic-indications 2021-10-05T12:08:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-combination-tafinlar-mekinist-receives-eu-approval-braf-v600-positive-advanced-non-small-cell-lung-cancer-nsclc 2021-10-05T12:08:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-first-car-t-cell-therapy-bla-pediatric-and-young-adult-patients-rr-b-cell-all-granted-fda-priority-review 2021-10-05T12:08:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-receives-us-fda-approval-new-acrysof-iq-restor-25-multifocal-toric-iol-activefocustm-design-uncompromised-distance-vision-and-presbyopia-correction 2021-10-05T12:08:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart-failure 2021-10-05T12:08:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-first-and-only-il-17a-inhibitor-potentially-modify-course-psoriasis 2021-10-05T12:08:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-analysis-shows-novartis-entresto-improves-glycemic-control-reduced-ejection-fraction-heart-failure-patients-diabetes 2021-10-05T12:08:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-ribociclib-lee011-receives-fda-approval-first-line-treatment-hrher2-metastatic-breast-cancer-combination-any-aromatase-inhibitor 2021-10-05T12:08:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-winners-inaugural-healthcare-access-challenge-sandoz-hack 2021-10-05T12:08:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-shows-almost-all-psoriasis-patients-rapidly-regain-skin-clearance-following-treatment-pause 2021-10-05T12:08:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-demonstrate-sandoz-proposed-biosimilar-adalimumab-has-equivalent-efficacy-reference-medicine 2021-10-05T12:08:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats 2021-10-05T12:08:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting 2021-10-05T12:08:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle 2021-10-05T12:08:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tafinlar-mekinist-braf-positive-non-small-cell-lung-cancer-nsclc-patients 2021-10-05T12:08:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-zykadia-receives-fda-priority-review-first-line-use-patients-alk-metastatic-nsclc 2021-10-05T12:08:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-recu-la-certification-top-employer-suisse-2017 2021-10-05T12:08:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-als-top-arbeitgeber-schweiz-2017-ausgezeichnet 2021-10-05T12:08:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-votubia-receives-eu-approval-treat-refractory-partial-onset-seizures-patients-tsc 2021-10-05T12:08:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-progress-towards-access-and-environmental-goals-2016-corporate-responsibility-performance-report 2021-10-05T12:08:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-launches-new-trifocal-toric-intraocular-lens-patients-astigmatism-undergoing-cataract-surgery 2021-10-05T12:08:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-solid-2016-performance-growth-products1-absorbing-gleevec-us-loe-innovation-momentum-continued-announces-share-buyback 2021-10-05T12:08:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-solide-performance-en-2016-les-produits-de-croissance1-absorbant-la-perte-dexclusivite-de-gleevec-aux-usa-dynamique-continue-dinnovation-rachat-dactions-annonce 2021-10-05T12:08:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-2016-solide-ergebnisse-wobei-die-wachstumsprodukte1-den-verlust-der-exklusivrechte-fur-gleevec-den-usa-wettmachen-innovationsdynamik-halt-aktienruckkauf-angekundigt 2021-10-05T12:08:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-invests-next-generation-therapies-reduce-cardiovascular-risk-patients-underlying-lipid-disorders 2021-10-05T12:08:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-bolsters-ophthalmology-pipeline-through-acquisition-encore-vision-inc 2021-10-05T12:08:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-exclusive-option-collaboration-and-license-agreement-conatus-develop-new-oral-treatments-chronic-liver-diseases 2021-10-05T12:08:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-recommendation-ilaris-treat-rare-diseases-adults-and-children-called-periodic-fever-syndromes 2021-10-05T12:08:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-votubia-recommended-chmp-eu-approval-treat-refractory-partial-onset-seizures-patients-tsc 2021-10-05T12:08:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-bolsters-innovative-dermatology-portfolio-through-acquisition-ziarco-group-limited 2021-10-05T12:08:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-launches-sms-life-20-nigeria-help-improve-access-essential-medicines 2021-10-05T12:08:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lance-sms-life-20-au-nigeria-pour-aider-ameliorer-lacces-aux-medicaments-essentiels 2021-10-05T12:08:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-fuhrt-sms-life-20-nigeria-ein-um-den-zugang-zu-unentbehrlichen-arzneimitteln-zu-verbessern 2021-10-05T12:08:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-pegpleranib-phase-iii-clinical-trial-program-patients-neovascular-age-related-macular-degeneration-namd-or-wet-amd 2021-10-05T12:08:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lee011-ribociclib-plus-letrozole-analyses-show-superior-pfs-across-broad-spectrum-patients-first-line-hrher2-advanced-breast-cancer-versus-letrozole 2021-10-05T12:08:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ultibro-breezhaler-improved-lung-function-and-copd-symptoms-after-direct-switch-from-previous-treatment 2021-10-05T12:08:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lucentis-received-eu-approval-new-indication-lucentis-only-treatment-available-wide-range-cnv-conditions 2021-10-05T12:08:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-zykadia-first-line-study-results-showing-166-month-progression-free-survival-patients-alk-advanced-nsclc 2021-10-05T12:08:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-shows-treatment-free-remission-rates-are-consistently-above-50-regardless-reason-switch-tasigna-from-glivec 2021-10-05T12:09:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-burden-myeloproliferative-neoplasms-rare-blood-cancers-daily-activity-and-ability-work 2021-10-05T12:09:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-interim-data-demonstrate-sandoz-proposed-biosimilar-rituximab-has-equivalent-efficacy-reference-product 2021-10-05T12:09:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-results-from-first-global-registration-trial-ctl019-pediatric-and-young-adult-patients-rr-b-all 2021-10-05T12:09:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-seg101-crizanlizumab-formerly-selg1-significantly-reduces-frequency-sickle-cell-pain-crises-phase-ii-study 2021-10-05T12:09:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-access-communique-son-bilan-un-et-annonce-la-signature-dun-protocole-daccord-avec-le-rwanda 2021-10-05T12:09:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-access-shares-one-year-learnings-and-announces-memorandum-understanding-rwanda 2021-10-05T12:09:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-access-informiert-uber-erfahrungen-im-ersten-jahr-und-gibt-memorandum-understanding-mit-ruanda-bekannt 2021-10-05T12:09:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquires-selexys-pharmaceuticals-corporation-and-selg1-antibody-reduction-pain-crises-sickle-cell-disease-scd 2021-10-05T12:09:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-commends-publication-major-report-which-recommends-broad-use-dual-bronchodilators-treat-copd 2021-10-05T12:09:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/innovative-study-three-treatment-switches-confirms-sandoz-biosimilar-etanercept-has-equivalent-efficacy-originator 2021-10-05T12:09:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-monthly-migraine-days-second-pivotal-phase-iii-episodic-migraine-study 2021-10-05T12:09:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-showcase-latest-innovations-development-patients-blood-disorders-and-breast-cancer 2021-10-05T12:09:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-analysis-novartis-entresto-data-shows-long-term-benefits-heart-failure-readmissions-and-total-cardiovascular-deaths 2021-10-05T12:09:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-newly-diagnosed-flt3-mutated-aml-and-advanced-systemic-mastocytosis 2021-10-05T12:09:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-cosentyx-data-showing-long-lasting-efficacy-psoriatic-arthritis-over-3-years-including-patient-reported-pain 2021-10-05T12:09:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-improves-ranking-2016-access-medicine-index 2021-10-05T12:09:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lee011-ribociclib-granted-fda-priority-review-first-line-treatment-hrher2-advanced-breast-cancer 2021-10-05T12:09:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-wins-two-prestigious-prix-galien-foundation-awards-gleevec-recognized-discovery-decade-best-pharmaceutical-product-cosentyx-best-biotechnology-product 2021-10-05T12:09:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-solid-third-quarter-growth-products1-offsetting-gleevec-patent-expiration-several-positive-readouts-potential-blockbusters 2021-10-05T12:09:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-solide-ergebnisse-wobei-die-wachstumsprodukte1-den-verlust-des-patents-fur-gleevec-wettmachen-mehrere-positive-daten-fur-potenzielle-blockbuster 2021-10-05T12:09:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-un-troisieme-trimestre-solide-les-produits-de-croissance1-ayant-compense-lexpiration-du-brevet-de-glivec-plusieurs-resultats-positifs-concernant-des-blockbusters-potentiels 2021-10-05T12:09:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-launches-cypass-micro-stent-american-academy-ophthalmology-aao-2016-annual-meeting 2021-10-05T12:09:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-alk-metastatic-nsclc-therapy-zykadia-extends-progression-free-survival-beyond-18-months-phase-ii-study 2021-10-05T12:09:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tafinlar-dabrafenib-mekinist-trametinib-demonstrate-superior-overall-survival-benefit-advanced-melanoma-patients-three-year-follow 2021-10-05T12:09:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-breakthrough-therapy-lee011-plus-letrozole-demonstrates-superior-progression-free-survival-first-line-treatment-hrher2-advanced-breast-cancer-compared-standard-care 2021-10-05T12:09:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-over-half-psoriasis-patients-do-not-reach-achievable-treatment-goal-clear-skin-largest-global-survey 2021-10-05T12:09:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-late-breaking-data-show-cosentyx-delivers-high-and-long-lasting-skin-clearance-over-4-years-psoriasis-patients 2021-10-05T12:09:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-phase-iii-study-shows-amg-334-significantly-reduces-monthly-migraine-days-people-episodic-migraine 2021-10-05T12:09:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-invites-young-entrepreneurs-enter-sandoz-hack-global-competition-help-solve-healthcare-access-challenges 2021-10-05T12:10:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-three-new-fda-approvals-expanded-use-ilaris-treating-rare-periodic-fever-syndrome-conditions 2021-10-05T12:10:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-top-line-results-from-ascend-4-phase-iii-trial-zykadia-untreated-adult-alk-nsclc-patients 2021-10-05T12:10:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novel-novartis-malaria-compound-shows-potential-be-effective-against-infections-resistant-all-currently-available-antimalarial-drugs 2021-10-05T12:10:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/important-new-analysis-shows-novartis-entresto-associated-higher-relative-health-related-quality-life-scores-among-hfref-patients 2021-10-05T12:10:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients 2021-10-05T12:10:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-presented-ectrims-show-benefit-gilenya-patient-disability-progression-10-years 2021-10-05T12:10:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-positive-data-ehmtic-showing-amg-334-significantly-reduces-monthly-migraine-days-chronic-migraine 2021-10-05T12:10:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-foundation-showcases-progress-leprosy-elimination-programs-19th-international-leprosy-congress 2021-10-05T12:10:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-point-care-nijitm-system-may-provide-earlier-diagnosis-severe-allergic-asthma-and-faster-treatment-decisions 2021-10-05T12:10:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-launches-ngenuity-3d-visualization-system-designed-further-enhance-retinal-surgeon-experience 2021-10-05T12:10:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ultibro-breezhaler-consistently-more-effective-seretide-reducing-copd-flare-ups-across-different-patient-groups 2021-10-05T12:10:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/airflusal-forspiro-showed-superiority-12-months-over-seretide-diskus1-persistence-treatment 2021-10-05T12:10:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-data-reinforces-superiority-cosentyx-versus-stelara-achieving-skin-clearance-psoriasis-patients 2021-10-05T12:36:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-regulatory-submission-proposed-biosimilar-adalimumab-accepted-fda 2021-10-05T12:36:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-elizabeth-barrett-oncology-head 2021-10-05T12:36:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ernennt-elizabeth-barrett-zur-chefin-onkologie 2021-10-05T12:36:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-advances-head-head-superiority-trials-cosentyx-versus-humira-and-proposed-biosimilar-adalimumab 2021-10-05T12:36:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa 2021-10-05T12:36:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-received-fda-breakthrough-therapy-designation-initial-endocrine-based-treatment-premenopausal-women-hrher2-advanced-breast-cancer 2021-10-05T12:36:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-tasigna-approved-fda-first-and-only-cml-therapy-treatment-free-remission-data-its-label 2021-10-05T12:36:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-granted-fda-priority-review-adjuvant-treatment-stage-iii-braf-v600-mutation-positive-melanoma 2021-10-05T12:36:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-oncology-head-retire 2021-10-05T12:36:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-gibt-rucktritt-des-onkologie-chefs-bekannt 2021-10-05T12:36:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-crizanlizumab-shown-prolong-time-patients-first-sickle-cell-pain-crisis-subgroup-analysis-sustain-study 2021-10-05T12:36:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult-treat-cancer 2021-10-05T12:36:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-new-phase-i-data-showing-proposed-biosimilar-pegfilgrastim-matches-reference-medicine 2021-10-05T12:36:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tender-offer-advanced-accelerator-applications-commences 2021-10-05T12:36:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/kisqali-first-and-only-cdk46-inhibitor-show-superior-efficacy-vs-oral-endocrine-therapy-1l-treatment-randomized-phase-iii-trial-premenopausal-women-hrher2-advanced-breast-cancer 2021-10-05T12:36:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-first-biologic-show-long-term-efficacy-nail-and-palmoplantar-psoriasis-which-can-impact-90-psoriasis-patients 2021-10-05T12:36:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-phase-iii-strive-data-published-nejm-demonstrating-significant-and-sustained-efficacy-erenumab-amg334-migraine-prevention 2021-10-05T12:36:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ultibro-breezhaler-significantly-improved-copd-patients-lung-function-after-direct-switch-from-seretide 2021-10-05T12:36:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-tasigna-nilotinib-secures-eu-approval-first-and-second-line-treatment-ph-cml-cp-children 2021-10-05T12:36:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ascp-and-acs-join-forces-fight-cancer-ethiopia-uganda-and-tanzania 2021-10-05T12:36:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-sabcs-across-broad-range-breast-cancer-patient-populations-combination-treatments-and-lines-therapy 2021-10-05T12:36:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-reinforces-clinical-basis-switching-sandoz-biosimilar-medicines 2021-10-05T12:36:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-canakinumab-acz885-reduced-cardiovascular-risk-25-subgroup-cantos-phase-iii-trial-participants 2021-10-05T12:36:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-its-differentiated-late-stage-pipeline-rd-update-and-investor-event 2021-10-05T12:36:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-entresto-real-world-evidence-data-shows-beneficial-impact-quality-life-people-living-heart-failure 2021-10-05T12:36:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/punjab-province-pakistan-signs-agreement-novartis-access-against-chronic-diseases 2021-10-05T12:36:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key-secondary-endpoint-measures-disease-activity-namd-leading-cause-blindness 2021-10-05T12:36:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-positive-results-from-phase-iii-trial-kisqali-ribociclib-combination-therapy-premenopausal-women-hrher2-advanced-or-metastatic-breast-cancer 2021-10-05T12:36:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-study-data-demonstrating-cosentyx-reduced-signs-and-symptoms-psoriatic-arthritis-while-inhibiting-progression-joint-structural-damage 2021-10-05T12:36:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-seeks-leadership-cosentyx-showing-no-radiographic-progression-ankylosing-spondylitis-4-years 2021-10-05T12:36:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reaches-another-regulatory-milestone-ctl019-tisagenlecleucel-submission-its-maa-ema-children-young-adults-rr-b-cell-all-and-adult-patients-rr-dlbcl 2021-10-05T12:36:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-amgen-announce-expanded-collaboration-banner-alzheimers-institute-pioneering-prevention-program 2021-10-05T12:36:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-data-ash-patients-serious-blood-disorders-lymphoma-leukemia-and-sickle-cell-disease 2021-10-05T12:37:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-submits-application-fda-kymriahtm-tisagenlecleucel-adult-patients-rr-dlbcl-seeking-second-indication-first-ever-fda-approved-car-t-therapy 2021-10-05T12:37:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-first-its-kind-evidence-cosentyx-potential-maintain-mobility-patients-and-psa 2021-10-05T12:37:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications-strengthen-oncology-portfolio 2021-10-05T12:37:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-paradigms-data-show-children-and-adolescents-ms-had-82-lower-relapse-rate-gilenya-vs-interferon-beta-1a 2021-10-05T12:37:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-proposed-biosimilar-pegfilgrastim-accepted-ema-regulatory-review 2021-10-05T12:37:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-confirms-leadership-multiple-sclerosis-ms-scientific-advancements-and-new-data-presented-ectrims 2021-10-05T12:37:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-growth-top-and-bottom-line-all-divisions-q3 2021-10-05T12:37:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-au-troisieme-trimestre-croissance-du-chiffre-daffaires-et-du-resultat-dans-toutes-les-divisions 2021-10-05T12:37:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-steigert-im-dritten-quartal-umsatz-und-gewinn-allen-divisionen 2021-10-05T12:37:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-combination-adjuvant-therapy-tafinlar-mekinist-receives-fda-breakthrough-therapy-designation-stage-iii-braf-v600-mutation-positive-melanoma-patients 2021-10-05T12:37:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-revolade-shows-long-term-disease-control-chronicpersistent-immune-thrombocytopenia-itp 2021-10-05T12:37:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-receives-ce-mark-first-its-kind-autonometm-preloaded-intraocular-lens-iol-delivery-system-clareon-iol 2021-10-05T12:37:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-introduces-new-innovations-cataract-surgery-european-society-cataract-refractive-surgeons-2017-annual-congress 2021-10-05T12:37:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-uc-berkeley-collaborate-tackle-undruggable-disease-targets 2021-10-05T12:37:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-max-foundation-transform-pioneering-cancer-access-program-people-lower-income-countries 2021-10-05T12:37:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-rydapt-midostaurin-receives-eu-approval-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-advanced-systemic-mastocytosis-sm 2021-10-05T12:37:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-xolair-confirms-re-treatment-efficacy-chronic-spontaneous-urticaria-patients-after-treatment-interruption 2021-10-05T12:37:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-proposed-biosimilar-adalimumab-matches-reference-biologic-terms-efficacy-and-safety-long-term-study 2021-10-05T12:37:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-sets-new-benchmark-psoriasis-robust-5-year-sustained-phase-iii-efficacy-and-safety-data 2021-10-05T12:37:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-proposed-biosimilar-rituximab-accepted-review-fda 2021-10-05T12:37:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-study-demonstrates-adjuvant-tafinlar-mekinist-reduced-risk-disease-recurrence-53-patients-resected-braf-v600-mutation-positive-melanoma 2021-10-05T12:37:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-analysis-demonstrating-amg-334-erenumab-significantly-reduced-monthly-migraine-days-patients-who-failed-previous-preventive-therapies 2021-10-05T12:37:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-landmark-phase-iii-trial-shows-fingolimod-significantly-reduces-relapses-children-and-adolescents-ms 2021-10-05T12:37:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-ceo-joseph-jimenez-retire-from-novartis-2018-vasant-narasimhan-appointed-ceo-effective-february-1-2018 2021-10-05T12:37:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice 2021-10-05T12:37:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-analysis-published-lancet-showing-acz885-reduced-lung-cancer-mortality-77-cantos-study-further-studies-planned 2021-10-05T12:37:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz885-reduces-cardiovascular-risk 2021-10-05T12:37:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-bertrand-bodson-chief-digital-officer 2021-10-05T12:37:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-ribociclib-receives-eu-approval-first-line-treatment-hrher2-locally-advanced-or-metastatic-breast-cancer-combination-any-aromatase-inhibitor 2021-10-05T12:37:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-et-medicines-malaria-venture-lancent-une-etude-clinique-en-afrique-pour-kaf156-un-candidat-medicament-novateur-contre-le-paludisme-multiresistant 2021-10-05T12:37:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-launch-patient-trial-africa-kaf156-novel-compound-against-multidrug-resistant-malaria 2021-10-05T12:37:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-und-medicines-malaria-venture-starten-afrika-eine-patientenstudie-mit-kaf156-einem-neuartigen-wirkstoff-gegen-multiresistente-malaria 2021-10-05T12:37:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-expands-partnership-world-child-cancer-help-children-access-treatment-four-developing-countries 2021-10-05T12:37:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-rydapt-midostaurin-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-advanced-systemic-mastocytosis-sm 2021-10-05T12:37:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/die-ergebnisse-im-zweiten-quartal-bestatigen-die-jahresprognosen-starke-forschungs-und-entwicklungsresultate-untermauern-das-potenzial-einiger-hoch-innovativer-produkte 2021-10-05T12:37:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-resultats-du-t2-confirment-les-previsions-de-lexercice-2017-les-tres-bons-resultats-du-pipeline-etayent-le-potentiel-de-plusieurs-produits-hautement-novateurs 2021-10-05T12:37:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/q2-results-confirm-full-year-guidance-strong-pipeline-results-underpin-potential-several-highly-innovative-products 2021-10-05T12:37:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-confirms-5-year-data-first-and-only-fully-human-il-17a-inhibitor-cosentyx-reinforcing-sustained-efficacy-and-safety-profile-psoriasis 2021-10-05T12:37:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-unanimously-10-0-recommended-approval-fda-advisory-committee-treat-pediatric-young-adult-rr-b-cell-all 2021-10-05T12:38:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-approval-eu-cosentyx-label-update-includes-long-term-superiority-data-versus-stelara-psoriasis 2021-10-05T12:38:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-first-line-use-zykadia-alk-positive-advanced-non-small-cell-lung-cancer-nsclc 2021-10-05T12:38:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-approval-europe-erelzi-biosimilar-etanercept-treat-multiple-inflammatory-diseases 2021-10-05T12:38:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/nejm-publishes-full-analysis-rydapt-midostaurin-phase-iii-ratify-trial-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml 2021-10-05T12:38:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-ribociclib-receives-positive-chmp-opinion-first-line-treatment-hrher2-locally-advanced-or-metastatic-breast-cancer-combination-any-aromatase-inhibitor 2021-10-05T12:38:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-shows-half-eligible-ph-cml-cp-patients-remain-treatment-free-remission-nearly-two-years-after-stopping-tasigna 2021-10-05T12:38:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pivotal-ctl019-6-month-follow-data-show-durable-remission-rates-children-young-adults-rr-b-cell-all 2021-10-05T12:38:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-combination-targeted-therapy-tafinlar-mekinist-receives-fda-approval-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer-nsclc 2021-10-05T12:38:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-study-shows-acz885-canakinumab-reduces-cardiovascular-risk-people-who-survived-heart-attack 2021-10-05T12:38:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-achieves-important-regulatory-milestone-amg-334-erenumab-migraine-prevention-ema-filing-acceptance 2021-10-05T12:38:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients-majority-12-week-injection-interval 2021-10-05T12:38:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-real-world-study-shows-almost-half-chronic-urticaria-patients-are-not-receiving-any-treatment-despite-significant-disease-burden 2021-10-05T12:38:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathon-biosimilar-rituximab-treat-blood-cancers-and-immunological-diseases 2021-10-05T12:38:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-international-ag-new-patient-survey-highlights-need-more-action-help-severe-asthma-patients-gain-control-their-disease 2021-10-05T12:38:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-generic-version-advair-diskus 2021-10-05T12:38:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-shows-sustained-improvements-signs-and-symptoms-both-and-psa-80-patients-3-years 2021-10-05T12:38:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraine-prevention-american-headache-society-annual-meeting 2021-10-05T12:38:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-interim-results-from-global-pivotal-ctl019-trial-show-durable-complete-responses-adults-rr-dlbcl 2021-10-05T12:38:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-tasigna-receives-eu-approval-inclusion-treatment-free-remission-tfr-data-product-label 2021-10-05T12:38:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-bristol-myers-squibb-evaluate-potential-treatments-metastatic-colorectal-cancer 2021-10-05T12:38:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-ground-breaking-collaboration-ibm-watson-health-outcomes-based-care-advanced-breast-cancer 2021-10-05T12:38:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-landmark-study-tafinlar-mekinist-demonstrates-durable-survival-benefit-five-years-patients-braf-mutation-positive-metastatic-melanoma 2021-10-05T12:38:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-updated-data-reinforce-efficacy-and-safety-kisqali-ribociclib-plus-letrozole-first-line-option-hrher2-advanced-or-metastatic-breast-cancer 2021-10-05T12:38:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/progress-reported-global-fight-against-diarrheal-disease-cryptosporidiosis 2021-10-05T12:38:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-regulatory-review-european-medicines-agency 2021-10-05T12:38:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-focus-innovation-and-productivity-expects-next-growth-phase-begin-2018 2021-10-05T12:38:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ernennt-dr-klaus-moosmayer-zum-chief-ethics-risk-and-compliance-officer 2021-10-05T12:39:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-marks-new-era-migraine-patients-eu-approval-aimovig-first-its-kind-treatment-specifically-designed-migraine-prevention 2021-10-05T12:39:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-biosimilar-hyrimoz-adalimumab 2021-10-05T12:39:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-combination-tafinlar-mekinist-receives-positive-chmp-opinion-adjuvant-treatment-braf-v600-mutation-positive-melanoma 2021-10-05T12:39:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-renews-drug-donation-egaten-triclabendazole-until-2022-reaffirming-its-commitment-fight-against-liver-fluke 2021-10-05T12:39:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-demonstrates-commitment-lead-immuno-dermatology-licensing-il-17c-compound-atopic-dermatitis 2021-10-05T12:39:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-now-first-and-only-cdk46-inhibitor-indicated-us-first-line-therapy-specifically-premenopausal-women-and-initial-therapy-fulvestrant-postmenopausal-women 2021-10-05T12:39:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-solid-growth-second-quarter-and-continues-transformation-focused-medicines-company 2021-10-05T12:39:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-une-solide-croissance-au-deuxieme-trimestre-et-poursuit-sa-transformation-en-une-entreprise-axee-sur-les-medicaments 2021-10-05T12:39:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-ein-solides-wachstum-und-setzt-die-transformation-zu-einem-fokussierten-arzneimittelunternehmen-fort 2021-10-05T12:39:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kymriah-treating-two-aggressive-blood-cancers-marking-important-medical-advance-patients-europe 2021-10-05T12:39:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erhalt-positive-chmp-stellungnahme-fur-kymriah-zur-behandlung-zweier-aggressiver-blutkrebsarten-ein-wichtiger-medizinischer-fortschritt-fur-patientinnen-und-patienten-europa 2021-10-05T12:39:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-intention-seek-shareholder-approval-100-spinoff-alcon-eye-care-devices-business-initiates-share-buyback-usd-5-bn 2021-10-05T12:39:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-gibt-absicht-bekannt-die-genehmigung-der-aktionare-fur-einen-100igen-spin-des-geschafts-mit-ophthalmologischen-produkten-von-alcon-einzuholen-und-leitet-gleichzeitig-einen-aktienruck 2021-10-05T12:39:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-annonce-son-intention-de-solliciter-lapprobation-des-actionnaires-pour-la-scission-100-dalcon-sa-division-de-produits-ophtalmologiques-et-initie-un-rachat-dactions-hauteur-dusd 2021-10-05T12:39:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovig-erenumab-patients-chronic-and-episodic-migraine 2021-10-05T12:39:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-international-ag-global-study-novartis-and-european-migraine-and-headache-alliance-reveals-60-employed-people-severe-migraine-miss-average-week-work-month 2021-10-05T12:39:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-clear-about-psoriasis-survey-data-highlights-challenges-psoriasis-patients-face-achieve-goal-clear-skin 2021-10-05T12:39:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-international-ag-alcon-acrysof-iq-panoptix-trifocal-intraocular-lens-shows-superior-visual-performance-head-head-trial-post-cataract-surgery 2021-10-05T12:39:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-juliet-trial-kymriah-demonstrates-more-one-year-durability-responses-adults-relapsed-or-refractory-dlbcl 2021-10-05T12:39:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-impact-immune-thrombocytopenia-or-itp-rare-blood-disease-patients-quality-life 2021-10-05T12:39:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-study-real-world-data-concludes-jakavi-associated-reduction-risk-death-and-dangerous-blood-clots-patients-rare-blood-cancer 2021-10-05T12:39:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-presents-new-long-term-and-switching-data-biosimilars-zessly-infliximab-and-erelzi-etanercept-rheumatoid-arthritis 2021-10-05T12:39:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-data-advance-understanding-role-il-17a-and-reinforce-cosentyx-leadership-spondyloarthritis 2021-10-05T12:39:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-jco-publication-lutathera-netter-1-data-showing-significantly-longer-time-deterioration-key-quality-life-measures-patients-progressive-midgut-nets 2021-10-05T12:39:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-schullabor-empfangt-hunderttausendsten-besucher 2021-10-05T12:39:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/third-novartis-phase-iii-trial-shows-kisqali-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancer 2021-10-05T12:39:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-presented-asco-find-nearly-half-cml-patients-treated-tasigna-remain-remission-almost-three-years-after-stopping-therapy 2021-10-05T12:39:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-sale-stake-consumer-healthcare-joint-venture-gsk-usd130-billion 2021-10-05T12:40:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-adalimumab 2021-10-05T12:40:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovig-erenumab-prevention-migraine 2021-10-05T12:40:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saa 2021-10-05T12:40:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-international-ag-patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entresto 2021-10-05T12:40:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-zessly-infliximab-gastroenterological-rheumatological-and-dermatological-diseases 2021-10-05T12:40:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention 2021-10-05T12:40:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-asco-and-eha-reinforce-companys-commitment-reimagining-cancer 2021-10-05T12:40:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung 2021-10-05T12:40:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-strategy-focus-company-and-drive-sustainable-growth 2021-10-05T12:40:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-changes-executive-committee 2021-10-05T12:40:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avexis-inc 2021-10-05T12:40:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-arrow-trial-assess-mechanistic-superiority-direct-il-17a-inhibition-cosentyx-over-il-23-inhibition-tremfya 2021-10-05T12:40:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-avexis-inc 2021-10-05T12:40:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-approval-gilenya-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis 2021-10-05T12:40:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-cares-project-100-commits-reducing-cataract-blindness-globally 2021-10-05T12:40:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-complete-response-letter-from-us-fda-proposed-biosimilar-rituximab 2021-10-05T12:40:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma 2021-10-05T12:40:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-proposed-acquisition-avexis 2021-10-05T12:40:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutant-melanoma 2021-10-05T12:40:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-phase-iii-data-brolucizumab-demonstrate-reliability-12-week-treatment-interval 2021-10-05T12:40:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-launches-focalview-app-providing-opportunity-patients-participate-ophthalmology-clinical-trials-from-home 2021-10-05T12:40:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-analyses-aan-show-siponimods-efficacy-disability-and-cognition-secondary-progressive-ms-patients 2021-10-05T12:40:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-john-tsai-head-global-drug-development-and-chief-medical-officer 2021-10-05T12:40:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-first-quarter-and-acted-become-more-focused-medicines-company 2021-10-05T12:40:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-une-bonne-performance-au-premier-trimestre-et-agi-pour-devenir-une-entreprise-plus-centree-sur-les-medicaments 2021-10-05T12:40:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-verzeichnet-ein-starkes-erstes-quartal-und-ergreift-schritte-um-ein-starker-fokussiertes-arzneimittelunternehmen-zu-werden 2021-10-05T12:40:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-signs-agreement-pear-therapeutics-develop-and-commercialize-prescription-digital-therapeutics-patients-substance-use-disorder-and-opioid-use-disorders 2021-10-05T12:40:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-first-its-kind-evidence-aan-reinforcing-robust-and-consistent-efficacy-aimovigtm-erenumab-migraine-patients-multiple-treatment-failures 2021-10-05T12:40:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-renews-commitment-malaria-elimination-investing-usd-100-million-research-and-develop-next-generation-antimalarials 2021-10-05T12:40:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-bekraftigt-engagement-zur-eliminierung-von-malaria-und-investiert-usd-100-millionen-die-erforschung-und-entwicklung-der-nachsten-generation-von-malariamedikamenten 2021-10-05T12:40:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-afin-deliminer-le-paludisme-en-investissant-100-millions-de-dollars-dans-la-recherche-et-le-developpement-dantipaludiques-de-nouvelle-generation 2021-10-05T12:40:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tender-offer-avexis-commences 2021-10-05T12:40:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-analysis-demonstrating-entresto-helped-preserve-kidney-function-patients-chronic-heart-failure-especially-those-diabetes 2021-10-05T12:40:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enters-agreement-acquire-avexis-inc-usd-87-bn-transform-care-sma-and-expand-position-gene-therapy-and-neuroscience-leader 2021-10-05T12:40:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-schliesst-vereinbarung-zum-erwerb-von-avexis-inc-fur-usd-87-mrd-ab-um-therapie-der-sma-zu-transformieren-und-position-als-fuhrendes-gentherapie-und-neuroscience-unternehmen-auszubauen 2021-10-05T12:40:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-outlines-plans-next-healthcare-access-challenge-hack-support-local-digital-innovation 2021-10-05T12:40:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-jama-cardiology-publication-data-showing-entresto-improves-physical-and-social-activity-hfref-patients-versus-enalapril 2021-10-05T12:40:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-predictability-data-brolucizumab-namd-from-pivotal-hawk-and-harrier-trials-arvo 2021-10-05T12:40:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-sell-stake-consumer-healthcare-joint-venture-gsk-usd130-billion-focus-strategic-priorities 2021-10-05T12:40:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-verkauft-beteiligung-consumer-healthcare-joint-venture-fur-usd-13-milliarden-gsk-um-sich-auf-strategische-prioritaten-zu-konzentrieren 2021-10-05T12:40:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-infliximab 2021-10-05T12:40:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improves-outcomes-patients-secondary-progressive-ms 2021-10-05T12:40:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-drug-tasigna-approved-fda-treat-children-rare-form-leukemia 2021-10-05T12:40:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-teams-harvard-develop-next-generation-biomaterial-systems-deliver-immunotherapies 2021-10-05T12:40:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-changes-executive-committee-support-strategic-priorities 2021-10-05T12:40:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung-zur-unterstutzung-strategischer-prioritaten 2021-10-05T12:40:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-annonce-des-changements-au-sein-de-son-comite-de-direction-afin-de-soutenir-ses-priorites-strategiques 2021-10-05T12:41:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-alliance-science-37-advance-virtual-clinical-trials-program 2021-10-05T12:41:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-xolair-recommended-new-global-chronic-urticaria-guideline 2021-10-05T12:41:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-0 2021-10-05T12:41:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale 2021-10-05T12:41:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-0 2021-10-05T12:41:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosis 2021-10-05T12:41:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/treatment-novartis-ultibro-breezhaler-improved-cardiac-function-copd-patients-lung-hyperinflation 2021-10-05T12:41:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-data-show-cosentyx-improved-quality-life-over-5-years-two-thirds-patients-moderate-severe-plaque-psoriasis 2021-10-05T12:41:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-cosentyx-data-confirms-robust-efficacy-and-quality-life-improvements-scalp-psoriasis 2021-10-05T12:41:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-forms-alliance-develop-medicines-treating-infectious-diarrheal-disease 2021-10-05T12:41:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopa-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis 2021-10-05T12:41:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-cosentyx-label-update-include-moderate-severe-scalp-psoriasis 2021-10-05T12:41:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-subsequent-offering-period-tender-offer-advanced-accelerator-applications-sa 2021-10-05T12:41:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-kymriahtm-children-young-adults-rr-all 2021-10-05T12:41:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumors 2021-10-05T12:41:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-exclusively-licenses-first-ophthalmology-gene-therapy-all-markets-outside-us-milestone-patients-rare-inherited-vision-loss 2021-10-05T12:41:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-good-operational-performance-and-landmark-innovation-2017-entering-our-next-growth-phase 2021-10-05T12:41:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enregistre-en-2017-une-belle-performance-operationnelle-et-des-innovations-majeures-entrant-ainsi-dans-une-nouvelle-phase-de-croissance 2021-10-05T12:41:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-2017-eine-gute-operative-performance-sowie-wegweisende-innovationen-und-ist-gut-gerustet-fur-die-nachste-wachstumsphase 2021-10-05T12:41:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-erenumab-met-all-primary-and-secondary-endpoints-unique-phase-iiib-study-episodic-migraine-patients-who-have-failed-multiple-prior-preventive-treatments 2021-10-05T12:41:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-tender-offer-advanced-accelerator-applications-sa-and-announces-commencement-subsequent-offering-period 2021-10-05T12:41:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation-biosimilars 2021-10-05T12:41:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-granted-us-fda-priority-review-kymriahtm-tisagenlecleucel-formerly-ctl019-adults-rr-dlbcl 2021-10-05T12:41:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/europe-africa-partnership-spearheads-development-next-generation-antimalarial-drug 2023-07-03T16:44:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-drives-differentiated-portfolio-deal-commercialize-new-treatment-opioid-induced-constipation-key-european-countries 2021-10-05T12:42:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-transformation-leading-medicines-company-completion-alcon-spin 2021-10-05T12:42:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-updates-migraine-collaboration-amgen 2021-10-05T12:42:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-resubmits-biosimilar-pegfilgrastim-application-us-fda 2021-10-05T12:42:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-first-class-cosentyx-approved-china-psoriasis-patients 2021-10-05T12:42:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-expands-world-leading-gene-therapy-manufacturing-capacity-purchase-advanced-biologics-therapy-manufacturing-campus-longmont-colorado 2021-10-05T12:42:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-adds-clinical-and-preclinical-anti-inflammatory-programs-portfolio-acquisition-ifm-tre 2021-10-05T12:42:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease 2021-10-05T12:42:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-plans-alcon-spin-april-9-2019 2021-10-05T12:43:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-announces-acquisition-powervision-inc 2021-10-05T12:43:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-joins-global-chagas-disease-coalition-and-also-announces-first-multinational-prospective-randomized-study-people-chronic-chagas-cardiomyopathy 2021-10-05T12:43:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-change-sandoz-leadership 2021-10-05T12:43:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/three-winners-2019-sandoz-healthcare-access-challenge-hack-are-announced-sxsw 2021-10-05T12:43:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-shows-superior-improvements-psoriasis-patients-quality-life-versus-janssens-il-23-stelara 2021-10-05T12:43:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-confirm-rapid-response-and-high-efficacy-cosentyx-psoriasis-patients-first-time-china 2021-10-05T12:43:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-1 2021-10-05T12:43:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/die-aktionare-von-novartis-heissen-der-generalversammlung-alle-antrage-des-verwaltungsrates-gut 2021-10-05T12:43:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-0 2021-10-05T12:43:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-issues-summary-financial-information-alcon-eye-care-business-ahead-shareholder-vote-proposed-spin 2021-10-05T12:43:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pursue-transformational-therapy-reduce-risk-cardiovascular-disease-people-living-elevated-levels-inherited-lipoproteina 2021-10-05T12:43:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-egaten-treatment-fascioliasis-neglected-tropical-disease 2021-10-05T12:43:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-core-margin-expansion-built-leading-advanced-therapy-platforms-and-focused-company-2018 2021-10-05T12:43:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/en-2018-novartis-enregistre-une-forte-croissance-de-ses-ventes-avec-une-expansion-de-sa-marge-core-developpe-des-plates-formes-leaders-de-traitements-de-pointe-et-recentre-lentreprise 2021-10-05T12:43:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-2018-ein-kraftiges-umsatzwachstum-bei-gleichzeitiger-steigerung-der-kerngewinnmarge-baut-wegweisende-therapieplattformen-auf-und-fokussiert-das-unternehmen 2021-10-05T12:43:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-prevention-vaso-occlusive-crises-sickle-cell-disease 2021-10-05T12:43:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-us-launch-reset-otm-help-treat-opioid-use-disorder 2021-10-05T12:43:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-endocyte 2021-10-05T12:43:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-european-commission-ec-approval-expanded-indication-kisqali-ribociclib 2021-10-05T12:43:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-offer-acquire-cellforcure-expand-manufacturing-capacity-innovative-cell-and-gene-therapies 2021-10-05T12:43:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-ceo-oncology-business-unit 2021-10-05T12:43:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-enters-commercialization-and-supply-agreement-insulin-biosimilars-anticipating-growing-demand-diabetes-burden-rises 2021-10-05T12:43:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-announces-acquisition-tear-film-innovations-inc 2021-10-05T12:43:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-european-commission-approval-self-administration-xolair-across-all-indications 2021-10-05T12:43:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-inc-and-pear-therapeutics-obtain-fda-clearance-reset-otm-treat-opioid-use-disorder 2021-10-05T12:43:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-demonstrates-consistent-efficacy-and-tolerability-kisqali-combination-therapy-hrher2-advanced-breast-cancer-patients-difficult-treat-visceral-disease 2021-10-05T12:43:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-consistently-improved-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-new-solar-1-analyses 2021-10-05T12:43:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-advances-ligelizumab-qge031-urticaria-phase-iii-basis-strong-phase-ii-head-head-data 2021-10-05T12:43:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-avxs-101-one-time-treatment-designed-address-genetic-root-cause-sma-type-1 2021-10-05T12:44:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/real-world-data-show-novartis-drug-revolade-improves-outcomes-itp-patients-compared-other-second-line-therapies 2021-10-05T12:44:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-longer-term-analyses-from-pivotal-kymriah-trials-showed-durable-responses-are-maintained-patients-advanced-blood-cancers 2021-10-05T12:44:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-crizanlizumab-seg101-data-analysis-sickle-cell-disease-and-investment-sentry-clinical-program 2021-10-05T12:44:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-eu-approval-gilenya-children-and-adolescents-ms-making-it-first-and-only-oral-disease-modifying-treatment-these-patients-europe 2021-10-05T12:44:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-eighth-european-commission-approval-biosimilar-ziextenzo-pegfilgrastim 2021-10-05T12:44:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits-standalone-company-investors-and-analysts-new-york-and-london 2021-10-05T12:44:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease 2021-10-05T12:44:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-rises-second-place-2018-access-medicine-index 2021-10-05T12:44:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-launch-reset-treatment-patients-substance-use-disorder 2021-10-05T12:44:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-drug-promacta-first-line-saa-and-grants-breakthrough-therapy-designation-additional-new-indication 2021-10-05T12:44:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-expand-kisqali-combination-therapy-all-women-hrher2-locally-advanced-or-metastatic-breast-cancer 2021-10-05T12:44:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-files-initial-form-20-f-registration-statement-sec-proposed-spinoff-plans-investor-days-new-york-and-london 2021-10-05T12:44:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-study-supports-entresto-foundational-hfref-therapy-and-hospital-initiation-appropriate-stabilized-heart-failure-patients 2021-10-05T12:44:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading-development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms 2021-10-05T12:44:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-decides-not-pursue-us-biosimilar-rituximab-will-focus-robust-biosimilar-portfolio-unmet-access-and-sustainability-needs 2021-10-05T12:44:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-show-strength-pipeline-and-portfolio-hematology-and-oncology 2021-10-05T12:44:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoztm-adalimumab-adaz 2021-10-05T12:44:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-pfizer-advance-treatment-nash 2021-10-05T12:44:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd 2021-10-05T12:44:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-approval-cosentyx-label-update-europe-include-dosing-flexibility-psoriatic-arthritis 2021-10-05T12:44:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-develop-smart-suite-digital-health-platform-cataract-surgery 2021-10-05T12:44:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-lancet-publication-pioneering-study-migraine-prevention-showing-efficacy-aimovig-where-other-treatments-have-failed 2021-10-05T12:44:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-combi-ad-study-tafinlar-mekinist-continues-demonstrate-relapse-free-survival-benefit-patients-braf-v600-mutant-stage-iii-melanoma 2021-10-05T12:44:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-nearly-doubles-median-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-compared-fulvestrant-alone 2021-10-05T12:44:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-ii-geometry-mono-1-trial-investigational-medicine-capmatinib-inc280-shows-positive-results-patients-met-mutated-advanced-nsclc 2021-10-05T12:44:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-presentation-new-lutathera-netter-1-data-esmo-demonstrating-significant-improvement-pfs-regardless-baseline-liver-tumor-burden 2021-10-05T12:44:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms 2021-10-05T12:44:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-growth-and-innovation-during-third-quarter-including-progressing-advanced-therapy-platforms-drive-future-growth 2021-10-05T12:44:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enregistre-au-troisieme-trimestre-une-forte-croissance-et-fait-preuve-dune-innovation-dynamique-incluant-des-plateformes-therapeutiques-avancees-pour-soutenir-la-croissance-future 2021-10-05T12:44:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-starkes-wachstum-und-treibt-innovationen-wie-fortschrittliche-therapieplattformen-voran-um-das-zukunftige-wachstum-zu-beschleunigen 2021-10-05T12:44:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-5-year-data-psoriatic-arthritis-and-ankylosing-spondylitis-reinforces-cosentyx-leadership-spondyloarthritis 2021-10-05T12:44:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-global-resolution-biosimilar-adalimumab-patent-disputes-securing-patient-access 2021-10-05T12:44:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-data-from-first-direct-head-head-trial-demonstrate-superior-efficacy-gilenya-over-copaxone-patients-relapsing-remitting-multiple-sclerosis 2021-10-05T12:44:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/breadth-data-ectrims-underpins-novartis-relentless-commitment-decoding-science-multiple-sclerosis-ms-and-decreasing-patient-burden 2021-10-05T12:44:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-analysis-shows-crizanlizumab-seg101-increased-number-patients-free-sickle-cell-pain-crises-vs-placebo-during-sustain-study 2021-10-05T12:44:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-siponimod-first-and-only-drug-shown-meaningfully-delay-disability-progression-typical-spms-patients 2021-10-05T12:44:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-healthcare-access-challenge-hack-returns-seeking-digital-solutions-local-healthcare-access-challenges 2021-10-05T12:44:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-licenses-three-novel-anti-infective-programs-boston-pharmaceuticals 2021-10-05T12:44:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-five-grant-recipients-excellence-ophthalmology-vision-award-xova-nonprofit-sustainable-eye-health-initiatives 2021-10-05T12:45:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-file-new-lucentis-ranibizumab-indication-retinopathy-prematurity-rop-rare-disease-premature-infants-often-leads-blindness 2021-10-05T12:45:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-analysis-novartis-phase-iii-brolucizumab-rth258-data-reinforces-superior-reduction-retinal-fluid-key-marker-disease-activity-namd 2021-10-05T12:45:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-pegfilgrastim 2021-10-05T12:45:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-gilenya-treatment-children-and-adolescents-ms-marking-major-medical-advance-young-ms-patients-europe 2021-10-05T12:45:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-chmp-opinion-one-time-gene-therapy-luxturna-treat-children-and-adults-rare-inherited-retinal-disease 2021-10-05T12:45:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/worlds-largest-alzheimers-survey-reveals-most-adults-believe-cure-will-be-developed-their-lifetime 2021-10-05T12:45:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/launch-alcon-experience-academy-reinforces-commitment-training-and-education-eye-care-professionals 2021-10-05T12:45:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-real-world-evidence-confirms-efficacy-and-safety-benefits-cosentyx-daily-life-psoriasis-patients 2021-10-05T12:45:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-landmark-paradigms-study-demonstrating-significant-benefit-gilenya-children-and-adolescents-ms 2021-10-05T12:45:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-survey-shows-psoriasis-patients-want-treatment-effect-beyond-clear-skin 2021-10-05T12:45:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-confirms-commitment-switzerland-ahead-proposed-spinoff-from-novartis 2021-10-05T12:45:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-bestatigt-vor-dem-vorgeschlagenen-spin-von-novartis-das-engagement-der-schweiz 2021-10-05T12:45:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-confirme-son-engagement-envers-la-suisse-en-perspective-de-la-scission-proposee-avec-novartis 2021-10-05T12:45:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-divest-sandoz-us-dermatology-business-and-generic-us-oral-solids-portfolio-aurobindo 2021-10-05T12:45:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/european-commission-approves-novartis-combination-therapy-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutation-positive-melanoma 2021-10-05T12:45:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/alcon-announces-voluntary-global-market-withdrawal-cypass-micro-stent-surgical-glaucoma 2021-10-05T12:45:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel 2021-10-05T12:45:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erhalt-die-zulassung-fur-seine-car-t-zell-therapie-kymriah-tisagenlecleucel-von-der-europaischen-kommission 2021-10-05T12:45:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-data-show-entresto-sacubitrilvalsartan-can-be-initiated-early-safely-hospitalized-patients-after-acute-heart-failure-episode 2021-10-05T12:45:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/solar-1-trial-novartis-investigational-alpha-specific-pi3k-inhibitor-byl719-alpelisib-meets-primary-endpoint-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T12:45:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-dr-klaus-moosmayer-chief-ethics-risk-and-compliance-officer 2021-10-05T12:45:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-breadth-data-2019-ash-demonstrates-commitment-reimagining-medicine-hematology-through-innovative-therapeutic-platforms 2021-10-05T12:50:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global-cause-death 2021-10-05T12:50:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-launches-innovation-prize-assistive-tech-encourage-new-technologies-address-unmet-needs-multiple-sclerosis-community 2021-10-05T12:50:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref 2021-10-05T12:50:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-approved-fda-reduce-frequency-pain-crises-individuals-living-sickle-cell-disease 2021-10-05T12:50:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-mayzent-siponimod-treatment-adult-patients-active-secondary-progressive-multiple-sclerosis-spms 2021-10-05T12:50:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-strategy-provide-innovative-medicines-more-patients-sub-saharan-africa 2021-10-05T12:50:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-presents-real-world-data-showing-effectiveness-erelzi-etanercept-szzs-rheumatic-disease-treatment 2021-10-05T12:50:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-prevent-data-show-cosentyx-delivers-early-relief-axial-spondyloarthritis 2021-10-05T12:50:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-tropifexor-ljn452-significantly-improves-several-key-biomarkers-nash-patients-moderate-severe-fibrosis 2021-10-05T12:50:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-aspens-japanese-operations-and-associated-assets-strengthening-position-worlds-third-largest-generics-market 2021-10-05T12:50:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-long-acting-oncology-supportive-care-biosimilar-ziextenzotm-pegfilgrastim-bmez 2021-10-05T12:50:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-shows-encouraging-results-versus-humira-from-first-its-kind-head-head-trial-psoriatic-arthritis 2021-10-05T12:50:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-avxs-101-intrathecal-study-update 2021-10-05T12:50:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-approval-cosentyx-label-update-europe-include-dosing-flexibility-ankylosing-spondylitis 2021-10-05T12:50:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-another-strong-quarter-double-digit-sales-growth-and-core1-margin-expansion-2019-sales-and-profit-guidance-raised-beovu-launched-us 2021-10-05T12:50:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-verzeichnet-ein-weiteres-starkes-quartal-mit-zweistelligem-umsatz-wachstum-und-hoherer-kerngewinnmarge1-umsatz-und-gewinnerwartung-fur-2019-angehoben-us-einfuhrung-von-beovu 2021-10-05T12:50:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-encore-un-fort-trimestre-croissance-deux-chiffres-des-ventes-et-expansion-de-la-marge-core1-hausse-des-previsions-de-chiffre-daffaires-et-de-resultat-en-2019-beovu-lance-aux-usa 2021-10-05T12:50:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-jakavi-ruxolitinib-meets-primary-endpoint-phase-iii-study-acute-graft-versus-host-disease 2021-10-05T12:50:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-cosentyx-treatment-results-rapid-and-sustained-resolution-signs-and-symptoms-psoriatic-arthritis-patients-and-without-enthesitis 2021-10-05T12:50:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-real-world-evidence-confirms-high-efficacy-long-term-response-and-favorable-safety-profile-cosentyx-clinical-practice 2021-10-05T12:50:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-more-patients-are-completely-symptom-free-from-chronic-spontaneous-urticaria-ligelizumab-qge031-xolair-300-mg 2021-10-05T12:50:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept 2021-10-05T12:50:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-presents-updated-strong-data-wms 2021-10-05T12:50:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-positive-52-week-prevent-data-confirm-cosentyx-efficacy-addressing-entire-axspa-spectrum 2021-10-05T12:50:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-microsoft-announce-collaboration-transform-medicine-artificial-intelligence 2021-10-05T12:50:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-palladium-study-inhaled-combination-qmf149-patients-uncontrolled-asthma 2021-10-05T12:50:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-iridium-study-inhaled-combination-qvm149-patients-uncontrolled-asthma 2021-10-05T12:50:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-delivers-consistently-superior-overall-survival-monaleesa-3-trial-demonstrates-more-life-postmenopausal-hrher2-advanced-breast-cancer-patients 2021-10-05T12:50:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-presents-new-data-epns-continuing-show-significant-therapeutic-benefit-zolgensma-prolonging-event-free-survival-now-5-years-age-patients-spinal-muscular-atrophy-sma-type-1 2021-10-05T12:50:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/positive-results-from-novartis-five-year-verify-study-type-2-diabetes-demonstrate-long-term-clinical-benefits-early-combination-treatment-galvus-and-metformin 2021-10-05T12:50:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-positive-16-week-prevent-results-advance-potential-new-indication-patients-axial-spondyloarthritis 2021-10-05T12:50:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-asclepios-trials-demonstrate-robust-efficacy-ofatumumab-patients-relapsing-multiple-sclerosis 2021-10-05T12:50:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-show-neuronal-and-glial-filaments-biomarkers-disease-activity-have-potential-support-decision-making-management-multiple-sclerosis-ms-patient 2021-10-05T12:50:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-show-mayzent-can-help-preserve-mobility-longer-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T12:50:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-ectrims-highlight-innovative-approach-reimagining-care-people-living-multiple-sclerosis-ms 2021-10-05T12:50:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-confirm-long-term-efficacy-and-safety-aimovig-majority-patients-episodic-migraine 2021-10-05T12:50:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-lung-cancer-therapy-capmatinib-inc280-granted-fda-breakthrough-therapy-designation-patients-met-mutated-advanced-non-small-cell-lung-cancer 2021-10-05T12:50:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-study-shows-migraine-support-workplace-can-improve-employee-quality-life 2021-10-05T12:50:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-global-deal-commercialize-proposed-biosimilar-natalizumab-key-multiple-sclerosis-medicine 2021-10-05T12:51:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/entresto-improved-measures-heart-structure-and-function-hfref-patients-new-novartis-study-additional-data-complement-findings 2021-10-05T12:51:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-paragon-hf-trial-suggests-entresto-benefit-hfpef-patients-narrowly-misses-primary-endpoint 2021-10-05T12:51:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-two-head-head-phase-iii-multiple-sclerosis-studies 2021-10-05T12:51:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-new-entresto-hfpef-and-hfref-data-esc-congress-2019 2021-10-05T12:51:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-will-appeal-district-court-new-jersey-ruling-biosimilar-erelzi-etanercept-szzs-us-patent-case 2021-10-05T12:51:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-stands-behind-zolgensma-onasemnogene-abeparvovec-xioi-treatment-children-less-2-years-age-spinal-muscular-atrophy 2021-10-05T12:51:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-significantly-prolongs-life-women-hrher2-advanced-breast-cancer-now-two-distinct-phase-iii-trials 2021-10-05T12:51:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-iii-paragon-hf-trial-heart-failure-patients-preserved-ejection-fraction-hfpef 2021-10-05T12:51:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-lucentis-treatment-preterm-infants-retinopathy-prematurity-rop-disease-causing-visual-impairment-and-blindness 2021-10-05T12:51:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-first-patient-enrolled-clinical-study-proposed-biosimilar-denosumab-osteoporosis 2021-10-05T12:51:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-key-multiple-sclerosis-product-gilenya-approved-china 2021-10-05T12:51:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-strong-sales-double-digit-core-operating-income-growth-and-launches-zolgensma-and-piqray-second-quarter-sales-and-profit-guidance-increased 2021-10-05T12:51:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-au-2e-trimestre-fortes-ventes-croissance-deux-chiffres-du-resultat-operationnel-core-et-lancements-de-zolgensma-et-de-piqray-prevision-des-ventes-et-du-resultat-revue-la-hausse 2021-10-05T12:51:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-starke-umsatze-eine-zweistellige-steigerung-des-operativen-kernergebnisses-und-lanciert-zolgensma-und-piqray-anhebung-der-umsatz-und-gewinnerwartung 2021-10-05T12:51:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101 2021-10-05T12:51:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-amgen-and-banner-alzheimers-institute-discontinue-clinical-program-bace-inhibitor-cnp520-alzheimers-prevention 2021-10-05T12:51:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-launches-oncology-generic-gefitinib-13-eu-countries-loss-market-exclusivity-expanding-access-essential-medicine 2021-10-05T12:51:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-cognition-data-secondary-progressive-multiple-sclerosis-spms 2021-10-05T12:51:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-xiidra-bolstering-ophthalmic-portfolio 2021-10-05T12:51:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-aimovig-cuts-acute-migraine-medication-days-half-patients-who-failed-prior-preventive-therapies 2021-10-05T12:51:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-underpin-long-term-efficacy-aimovig-where-other-treatments-have-failed 2021-10-05T12:51:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-new-publication-showing-il-17a-antibody-cosentyx-improves-inflammation-and-rapidly-suppresses-il-23-plaque-psoriasis 2021-10-05T12:51:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-2b-encore-lf-trial-nash-cirrhosis 2021-10-05T12:51:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-analysis-novartis-data-confirms-cosentyx-demonstrates-durable-comprehensive-treatment-across-psoriatic-disease 2021-10-05T12:51:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-sandoz-biosimilar-adalimumab-data-confirms-switching-from-reference-biologic-has-no-impact-safety-or-efficacy 2021-10-05T12:51:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-innovate-cml-long-term-treatment-free-remission-results-following-tasigna-use-and-promising-combination-data-investigational-compound-asciminib-abl001 2021-10-05T12:51:31+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/three-quarters-people-living-axial-spondyloarthritis-struggle-find-job-imas-survey-shows 2021-10-05T12:51:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/cosentyx-provides-long-lasting-inhibition-radiographic-progression-psoriatic-arthritis-new-novartis-data-show 2021-10-05T12:51:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-first-show-efficacy-all-key-manifestations-psoriatic-arthritis 2021-10-05T12:51:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-leader-pharmaceuticals-business-unit 2021-10-05T12:51:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-stellt-neue-leiterin-der-pharmaceuticals-business-unit-vor 2021-10-05T12:51:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/advanced-accelerator-applications-receives-positive-chmp-opinion-lysakare 2021-10-05T12:51:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-first-its-kind-histology-data-iscalimab-cfz533-suggesting-extended-survival-transplanted-organs-may-be-possible 2021-10-05T12:51:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/long-term-survival-benefit-shown-metastatic-melanoma-patients-treated-novartis-tafinlar-mekinist 2021-10-05T12:51:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shows-growing-strength-lung-cancer-innovation-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials 2021-10-05T12:51:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/xolair-omalizumab-significantly-reduced-nasal-polyps-and-congestion-symptoms-adults-chronic-rhinosinusitis-nasal-polyps-two-phase-iii-studies 2021-10-05T12:51:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-significantly-extends-life-women-hrher2-advanced-breast-cancer-monaleesa-7-trial 2021-10-05T12:51:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-quartz-study-new-investigational-inhaled-combination-treatment-qmf149-meets-primary-and-key-secondary-endpoints-patients-inadequately-controlled-asthma 2021-10-05T12:51:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only-treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer 2021-10-05T12:51:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families 2021-10-05T12:51:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma 2021-10-05T12:51:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event 2021-10-05T12:51:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-ii-data-new-inhaled-combination-treatment-qvm149-demonstrates-significant-improvements-over-current-standard-care-inhaled-treatment 2021-10-05T12:51:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-asco-and-eha-demonstrate-novel-approaches-reimagining-medicine-cancer-and-serious-blood-disorders 2021-10-05T12:51:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-aan-show-gilenya-first-and-only-disease-modifying-therapy-proven-superiority-versus-glatiramer-acetate-relapsing-remitting-ms 2021-10-05T12:51:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-demonstrates-strategic-focus-china-first-kind-generic-approval-under-quality-consistency-evaluation-system 2021-10-05T12:51:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquire-xiidra-expanding-front-eye-portfolio-and-strengthening-leadership-eye-care 2021-10-05T12:51:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-aan-show-mayzents-positive-impact-cognitive-processing-speed-core-element-cognitive-function-people-living-secondary-progressive-ms 2021-10-05T12:52:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-avexis-data-aan-showed-long-term-durability-zolgensma-patients-spinal-muscular-atrophy-sma-type-1 2021-10-05T12:52:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-first-its-kind-algorithm-based-tool-help-ms-patients-and-physicians-evaluate-and-discuss-early-signs-progression-secondary-progressive-ms 2021-10-05T12:52:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-presented-robust-data-aan-demonstrating-efficacy-zolgensma-broad-spectrum-spinal-muscular-atrophy-sma-patients 2021-10-05T12:52:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlight-extensive-long-term-safety-and-efficacy-data-aimovig-across-spectrum-migraine-aan 2021-10-05T12:52:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-aan-reinforce-novartis-commitment-transforming-lives-people-all-ages-who-live-neurological-conditions 2021-10-05T12:52:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-enters-agreement-proposed-trastuzumab-biosimilar-currently-phase-iii-development-treat-selected-her2-positive-cancer-tumors 2021-10-05T12:52:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-starts-2019-strong-sales-and-double-digit-core1-operating-income-growth-mayzent-launch-and-alcon-spin-profit-guidance-upgraded 2021-10-05T12:52:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-entame-2019-avec-une-forte-croissance-des-ventes-et-une-hausse-deux-chiffres-du-resultat-operationnel-core1-le-lancement-de-mayzent-et-le-spin-dalcon-profit-annuel-revu-la-hausse 2021-10-05T12:52:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-startet-2019-mit-starken-umsatzen-und-einer-zweistelligen-steigerung-des-operativen-kernergebnisses1-einfuhrung-von-mayzent-sowie-abspaltung-von-alcon-gewinnprognose-angehoben 2021-10-05T12:52:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-data-reinforce-effectiveness-zolgensma-treating-spinal-muscular-atrophy-sma-type-1 2021-10-05T12:52:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-brolucizumab-rth258-patients-wet-amd 2021-10-05T12:52:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-post-hoc-analysis-shows-high-dose-enerzair-breezhaler-reduces-asthma-exacerbations-versus-medium-dose-complementing-key-pivotal-iridium-study-findings 2021-10-05T14:27:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-pivotal-study-tabrectatm-patients-metex14-metastatic-non-small-cell-lung-cancer 2021-10-05T14:27:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-collaboration-between-novartis-and-africa-medical-supplies-platform-facilitate-supply-covid-19-related-medicines 2021-10-05T14:27:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-ambitious-esg-targets-increase-access-medicines-and-achieve-full-carbon-neutrality 2021-10-05T14:27:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-analysis-shows-high-consistency-lowering-ldl-c-individual-response-investigational-inclisiran 2021-10-05T14:27:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-ii-study-lnp023-patients-paroxysmal-nocturnal-hemoglobinuria-pnh 2021-10-05T14:27:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-novel-stamp-inhibitor-asciminib-abl001-meets-primary-endpoint-phase-iii-chronic-myeloid-leukemia-study 2021-10-05T14:27:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma 2021-10-05T14:27:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis 2021-10-05T14:27:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-us-district-court-district-delaware-upholds-validity-gilenya-fingolimod-dosage-regimen-patent 2021-10-05T14:27:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-ec-approval-new-xolair-indication-treat-severe-chronic-rhinosinusitis-nasal-polyps 2021-10-05T14:27:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-phase-iii-asclepios-trials-demonstrating-superior-efficacy-ofatumumab-patients-relapsing-multiple-sclerosis 2021-10-05T14:27:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-kymriah-meets-primary-endpoint-interim-analysis-pivotal-study-follicular-lymphoma 2021-10-05T14:27:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-receives-eu-approval-first-line-systemic-treatment-pediatric-psoriasis 2021-10-05T14:27:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-piqray-approval-europe-first-and-only-targeted-medicine-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T14:27:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-plans-joint-investment-help-strengthen-future-antibiotics-manufacturing-europe 2021-10-05T14:27:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-beovu-versus-aflibercept 2021-10-05T14:27:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-adakveo-receives-positive-chmp-opinion-prevention-recurrent-vaso-occlusive-crises-patients-sickle-cell-disease 2021-10-05T14:27:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-phase-iii-study-jakavi-chronic-graft-versus-host-disease-met-primary-and-key-secondary-endpoints 2021-10-05T14:27:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-h1-performance-fy-2020-guidance-confirmed-higher-end-core-operating-income-and-lower-end-sales 2021-10-05T14:27:43+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielte-im-ersten-halbjahr-eine-starke-performance-die-jahresprognose-2020-fur-das-operative-kernergebnis-bzw-den-umsatz-wurde-am-oberen-bzw-unteren-ende-fruherer-voraussagen-bestatigt 2021-10-05T14:27:45+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-une-excellente-performance-au-s1-previsions-pour-2020-confirmees-dans-le-haut-de-la-fourchette-pour-le-resultat-operationnel-core-et-dans-le-bas-pour-le-chiffre-daffaires 2021-10-05T14:27:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-launches-first-its-kind-not-profit-portfolio-medicines-symptomatic-treatment-covid-19 2021-10-05T14:27:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-iridium-data-lancet-respiratory-medicine-show-benefit-enerzair-breezhaler-qvm149-first-class-inhaled-labalamaics-combination-uncontrolled-asthma 2021-10-05T14:27:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-ec-approval-enerzair-breezhaler-including-first-digital-companion-sensor-and-app-can-be-prescribed-alongside-treatment-uncontrolled-asthma-eu 2021-10-05T14:27:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-resolves-legacy-litigation-matters-finalizing-settlement-speaker-program-litigation-government-us-and-positioning-company-future-fully-scaling-its-next-generation-digital-engagement-technologies 2021-10-05T14:27:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-reviewing-options-after-federal-circuit-upholds-lower-court-ruling-biosimilar-erelzi-case 2021-10-05T14:27:54+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-met-inhibitor-tabrectatm-approved-japan-advanced-non-small-cell-lung-cancer-metex14 2021-10-05T14:27:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-simultaneous-approval-five-new-products-from-japanese-ministry-health-labour-and-welfare-offering-japanese-patients-broad-range-novel-treatment-options 2021-10-05T14:27:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-pediatric-psoriasis-reinforcing-established-efficacy-and-safety-profile 2021-10-05T14:27:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-new-xolair-indication-treat-severe-chronic-rhinosinusitis-nasal-polyps 2021-10-05T14:27:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-resolves-legacy-fcpa-investigations 2021-10-05T14:28:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-winners-innovation-prize-assistive-tech-rewarding-new-technologies-could-improve-mobility-and-independence-people-living-multiple-sclerosis 2021-10-05T14:28:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-research-shows-technology-talent-increasingly-drawn-pharma-industry-covid-19-solve-healthcare-challenges 2021-10-05T14:28:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-discontinues-hydroxychloroquine-clinical-trial-based-slow-enrollment-remains-committed-pandemic-research-efforts 2021-10-05T14:28:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-africa-sickle-cell-disease-program-uganda-and-tanzania 2021-10-05T14:28:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-new-indication-treat-active-non-radiographic-axial-spondyloarthritis 2021-10-05T14:28:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information 2021-10-05T14:28:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iiib-argon-study-meets-primary-endpoint-comparison-enerzair-breezhaler-qvm149-versus-free-combination-two-existing-inhaled-treatments-uncontrolled-asthma 2021-10-05T14:28:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-prevent-data-show-cosentyx-helps-patients-realize-early-and-lasting-relief-axial-spondyloarthritis 2021-10-05T14:28:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-fda-review-ofatumumab-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis 2021-10-05T14:28:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-treated-tafinlar-mekinist-following-surgery 2021-10-05T14:28:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-piqray-receives-positive-chmp-opinion-treat-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T14:28:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-highlight-benefit-early-treatment-initiation-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T14:28:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-shows-overall-survival-benefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease 2021-10-05T14:28:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-late-breaking-ofatumumab-data-ean-demonstrating-robust-efficacy-and-safety-treatment-relapsing-forms-multiple-sclerosis-rms 2021-10-05T14:28:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-study-reveals-migraine-support-workspace-can-significantly-decrease-impact-disease-affected-employees 2021-10-05T14:28:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-receives-ec-approval-and-activates-day-one-access-program-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma 2021-10-05T14:28:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-bold-approaches-reimagine-cancer-and-blood-disorders-through-multiple-therapeutic-platforms 2021-10-05T14:28:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-approval-met-inhibitor-tabrectatm-metastatic-non-small-cell-lung-cancer-metex14 2021-10-05T14:28:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-chmp-positive-opinion-enerzair-breezhaler-qvm149-potential-first-class-inhaled-labalamaics-combination-uncontrolled-asthma 2021-10-05T14:28:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-gains-fourth-indication-eu-first-class-approval-axial-spondyloarthritis-spectrum 2021-10-05T14:28:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-maintains-strong-operational-performance-q1-confirms-fy-2020-guidance-time-and-advances-broad-range-efforts-support-global-response-covid-19 2021-10-05T14:28:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-setzt-im-1-quartal-die-starke-operative-performance-fort-bestatigt-derzeit-die-prognose-2020-und-fordert-verschiedenste-aktivitaten-um-globale-massnahmen-gegen-covid-19-zu-unterstutzen 2021-10-05T14:28:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-conserve-une-forte-performance-operationnelle-au-1er-trimestre-confirme-ce-stade-les-previsions-pour-2020-et-fournit-de-grands-efforts-pour-contribuer-la-reponse-mondiale-au-covid-19 2021-10-05T14:28:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-data-showing-jakavi-ruxolitinib-more-effective-best-available-therapy-acute-graft-versus-host-disease 2021-10-05T14:28:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-follicular-lymphoma 2021-10-05T14:28:40+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-mayzent-siponimod-data-show-sustained-effect-delaying-disability-five-years-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T14:28:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-sponsor-large-clinical-trial-hydroxychloroquine-hospitalized-covid-19-patients 2021-10-05T14:28:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquires-amblyotech-pursuing-novel-digital-therapy-children-and-adult-patients-lazy-eye 2021-10-05T14:28:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-data-neurology-reinforcing-real-world-and-long-term-effectiveness-and-safety-aimovig-preventive-treatment-across-full-spectrum-migraine 2021-10-05T14:28:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-plan-initiate-clinical-study-jakavi-severe-covid-19-patients-and-establish-international-compassionate-use-program 2021-10-05T14:28:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-mutual-agreement-terminate-sale-sandoz-us-generic-oral-solids-dermatology-portfolio-aurobindo 2021-10-05T14:28:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-new-analysis-further-shows-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment 2021-10-05T14:28:48+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-new-indication-axial-spondyloarthritis-spectrum 2021-10-05T14:28:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-receives-positive-chmp-opinion-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma 2021-10-05T14:28:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-life-sciences-companies-commit-expertise-and-assets-fight-against-covid-19-pandemic-alongside-bill-melinda-gates-foundation 2021-10-05T14:28:53+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/zolgensma-data-shows-rapid-significant-clinically-meaningful-benefit-sma-including-prolonged-event-free-survival-motor-milestone-achievement-and-durability-now-5-years-post-dosing 2021-10-05T14:28:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-presents-avxs-101-it-data-demonstrating-remarkable-increases-hfmse-scores-and-consistent-clinically-meaningful-response-older-patients-sma-type-2 2021-10-05T14:28:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-commits-donate-130-million-doses-hydroxychloroquine-support-global-covid-19-pandemic-response 2021-10-05T14:29:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-approval-from-japanese-ministry-health-labour-and-welfare-zolgensma-only-gene-therapy-patients-spinal-muscular-atrophy-sma 2021-10-05T14:29:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-three-pivotal-trials-showing-durable-and-potent-efficacy-inclisiran-investigational-first-class-sirna-cholesterol-lowering-therapy 2021-10-05T14:29:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic-creates-usd-20-million-global-fund-support-impacted-communities 2021-10-05T14:29:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/international-research-partnership-and-edctp-invest-eu44m-next-generation-antimalarials-combat-drug-resistant-malaria-africa 2021-10-05T14:29:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-resolves-generic-drug-antitrust-investigation-us 2021-10-05T14:29:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-2 2021-10-05T14:29:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lassemblee-generale-annuelle 2021-10-05T14:29:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-dndi-collaborate-development-new-oral-drug-treat-visceral-leishmaniasis 2021-10-05T14:29:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-ofatumumab-novel-b-cell-therapy-patients-relapsing-forms-multiple-sclerosis-rms 2021-10-05T14:29:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-ec-approval-beovu-next-generation-anti-vegf-treatment-wet-amd-leading-cause-blindness-worldwide 2021-10-05T14:29:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-met-inhibitor-capmatinib-inc280-first-potential-treatment-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review 2021-10-05T14:29:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-completes-acquisition-aspens-japanese-operations-strengthening-its-position-worlds-third-largest-market-generics-and-patent-medicines 2021-10-05T14:29:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-builds-its-axspa-leadership-us-label-update-dosing-flexibility-ankylosing-spondylitis 2021-10-05T14:29:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-margin-expansion-and-breakthrough-innovation-launching-five-nmes-2019 2021-10-05T14:29:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-2019-ein-starkes-umsatzwachstum-margen-steigerungen-und-bahnbrechende-innovationen-mit-der-markteinfuhrung-funf-neuer-wirkstoffe 2021-10-05T14:29:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-en-2019-une-forte-croissance-de-son-chiffre-daffaires-une-augmentation-de-sa-marge-et-une-percee-dans-linnovation-en-lancant-cinq-nouvelles-entites-moleculaires 2021-10-05T14:29:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-eu-approval-mayzent-siponimod-adult-patients-secondary-progressive-multiple-sclerosis-spms-active-disease 2021-10-05T14:29:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ligelizumab-qge031-more-effective-xolair-inhibiting-immunoglobulin-e-pathway-responsible-chronic-spontaneous-urticaria 2021-10-05T14:29:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-medicines-company-adding-potentially-first-class-investigational-cholesterol-lowering-therapy-inclisiran 2021-10-05T14:29:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-medicines-company 2021-10-05T14:29:27+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-luster-phase-iii-studies-patients-uncontrolled-gina-45-asthma 2021-10-05T14:29:29+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-beovu-brolucizumab-treatment-wet-amd 2021-10-05T14:29:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-data-show-superior-overall-survival-compared-fulvestrant-and-consistent-efficacy-across-advanced-breast-cancer-patient-subgroups-monaleesa-3 2021-10-05T14:29:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kymriah-demonstrates-consistent-efficacy-and-safety-outcomes-us-patients-when-used-real-world-setting 2021-10-05T14:29:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-global-survey-uncovers-profound-and-often-under-reported-effects-sickle-cell-disease-patients 2021-10-05T14:29:33+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-data-new-inhaled-dual-combination-qmf149-show-significant-improvement-across-key-asthma-outcomes-versus-monotherapy 2021-10-05T14:29:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tender-offer-medicines-company-commences 2021-10-05T14:29:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-shows-benefit-monotherapy-treatment-naive-patients-rare-and-life-threatening-blood-disorder-paroxysmal-nocturnal-hemoglobinuria 2021-10-05T14:32:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-interim-analysis-phase-ii-data-iptacopan-rare-kidney-disease-c3-glomerulopathy-c3g 2021-10-05T14:32:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-iptacopan-met-phase-ii-study-primary-endpoint-rare-kidney-disease-iga-nephropathy-igan 2021-10-05T14:32:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-tabrecta-first-published-overall-survival-and-updated-overall-response-data-patients-metex14-metastatic-nsclc 2021-10-05T14:32:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-overall-survival-pivotal-phase-iii-trial-esophageal-cancer-after-systemic-therapy 2021-10-05T14:32:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-clinically-relevant-improvement-median-overall-survival-data-final-analysis-pivotal-netter-1-study-targeted-radioligand-therapy-lutathera 2021-10-05T14:32:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-177lu-psma-617-significantly-improves-overall-survival-and-radiographic-progression-free-survival-men-metastatic-castration-resistant-prostate-cancer-phase-iii-vision-study 2021-10-05T14:32:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kymriah-pivotal-trial-demonstrates-strong-response-rates-and-remarkable-safety-profile-relapsed-or-refractory-follicular-lymphoma 2021-10-05T14:32:18+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-reports-longest-median-overall-survival-postmenopausal-hrher2-metastatic-breast-cancer-patients 2021-10-05T14:32:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-positive-phase-iii-results-from-junipera-study-supporting-cosentyx-potential-treatment-jia-population-eular-2021 2021-10-05T14:32:20+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis 2021-10-05T14:32:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program 2021-10-05T14:32:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-molecular-partners-announce-start-empathy-clinical-trial-ensovibep-treatment-covid-19 2021-10-05T14:32:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-unveil-new-data-asco-and-eha-from-its-robust-portfolio-including-overall-survival-prostate-and-breast-cancer 2021-10-05T14:32:23+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-plans-further-strengthen-its-antibiotics-manufacturing-setup-europe 2021-10-05T14:32:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reaches-milestone-delivery-1-billion-courses-antimalarial-treatment 2021-10-05T14:32:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/us-supreme-court-denies-sandoz-petition-review-biosimilar-erelzi-etanercept-szzs-case 2021-10-05T14:32:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-confirms-late-stage-clinical-development-plans-proposed-biosimilar-aflibercept-key-ophthalmology-medicine 2021-10-05T14:32:26+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-beovu-data-show-potential-fluid-resolution-more-diabetic-macular-edema-patients-fewer-injections-versus-aflibercept 2021-10-05T14:32:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-key-growth-drivers-and-launches-continue-momentum-q1-maintaining-confidence-growth-group-guidance-fy-2021-confirmed 2021-10-05T14:32:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-moteurs-cles-de-la-croissance-et-lancements-poursuivent-leur-essor-au-1er-trimestre-maintenant-la-confiance-dans-la-croissance-confirmation-des-previsions-pour-le-groupe-pour-2021 2021-10-05T14:32:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/wichtige-wachstumstreiber-und-neueinfuhrungen-von-novartis-setzen-ihre-dynamik-im-ersten-quartal-fort-und-erhalten-das-vertrauen-das-wachstum-konzernprognose-fur-2021-bestatigt 2021-10-05T14:32:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-initiate-smart-phase-3b-global-study-zolgensma-children-21-kg-building-real-world-experience 2021-10-05T14:32:34+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/kesimpta-ofatumumab-data-aan-showed-reduction-disability-progression-independent-relapse-activity-newly-diagnosed-patients-rms 2021-10-05T14:32:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-signs-initial-agreement-reserve-capacity-and-implement-technology-transfer-production-active-pharmaceutical-ingredient-roches-actemraroactemra 2021-10-05T14:32:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-adult-patients-relapsing-multiple-sclerosis 2021-10-05T14:32:37+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-targeted-radioligand-therapy-pipeline-license-compounds-targeting-fibroblast-activation-protein-fap 2021-10-05T14:32:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer 2021-10-05T14:32:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-karen-hale-chief-legal-officer 2021-10-05T14:32:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-zolgensma-data-demonstrate-age-appropriate-development-when-used-early-real-world-benefit-older-children-and-durability-5-years-post-treatment 2021-10-05T14:32:41+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-canakinumab-acz885-second-or-third-line-treatment-combination-chemotherapy-non-small-cell-lung-cancer 2021-10-05T14:32:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-change-executive-committee 2021-10-05T14:32:42+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-signs-initial-agreement-curevac-manufacture-covid-19-vaccine-candidate 2021-10-05T14:32:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-3 2021-10-05T14:32:44+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/die-aktionare-von-novartis-heissen-der-generalversammlung-alle-antrage-des-verwaltungsrats-gut 2021-10-05T14:32:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle-0 2021-10-05T14:32:46+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-strengthens-oncology-pipeline-successful-closing-tislelizumab-licensing 2021-10-05T14:32:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-gains-eu-label-update-first-its-kind-maximise-data-axial-manifestations-psoriatic-arthritis 2021-10-05T14:32:47+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-bill-melinda-gates-foundation-collaborate-discover-and-develop-accessible-vivo-gene-therapy-sickle-cell-disease 2021-10-05T14:32:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda 2021-10-05T14:32:49+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-multiple-sclerosis-patients-and-nurses-prefer-kesimpta-ofatumumab-sensoready-autoinjector-pen 2021-10-05T14:32:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-gsks-cephalosporin-antibiotics-business-reinforcing-its-leading-global-position-antibiotics 2021-10-05T14:32:50+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-breakthrough-therapy-designations-investigational-stamp-inhibitor-asciminib-abl001-chronic-myeloid-leukemia 2021-10-05T14:32:52+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kesimpta-ofatumumab-self-administered-treatment-adult-patients-relapsing-multiple-sclerosis 2021-10-05T14:32:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-signs-initial-agreement-provide-manufacturing-capacity-pfizer-biontech-covid-19-vaccine 2021-10-05T14:32:55+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-renews-who-medicine-donation-pledge-aim-ending-leprosy 2021-10-05T14:32:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-sales-growth-and-margin-expansion-continued-progress-its-next-wave-medicines-2020 2021-10-05T14:32:56+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-hat-2020-umsatz-und-margen-gesteigert-und-die-nachste-welle-von-medikamenten-weiter-vorangetrieben 2021-10-05T14:32:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/en-2020-novartis-enregistre-une-croissance-de-son-chiffre-daffaires-et-de-sa-marge-il-continue-de-faire-progresser-sa-prochaine-vague-de-medicaments 2021-10-05T14:33:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-gsk-announce-collaboration-support-scientific-research-genetic-diversity-africa 2021-10-05T14:33:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ligelizumab-qge031-receives-fda-breakthrough-therapy-designation-patients-chronic-spontaneous-urticaria-csu 2021-10-05T14:33:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-oncology-pipeline-licensing-tislelizumab-from-beigene 2021-10-05T14:33:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-complete-response-letter-from-us-fda-inclisiran 2021-10-05T14:33:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-builds-commitment-addressing-need-neuropsychiatric-disorders-cadent-therapeutics-acquisition 2021-10-05T14:33:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-pnh-and-rare-pediatric-disease-designation-c3g 2021-10-05T14:33:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-fda-advisory-committee-recommendation-use-entresto-treat-patients-hfpef 2021-10-05T14:33:09+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-positive-topline-results-from-second-phase-iii-trial-beovu-patients-diabetic-macular-edema 2021-10-05T14:33:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19 2021-10-05T14:33:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year 2021-10-05T14:33:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-data-demonstrate-superior-benefit-across-main-intrinsic-subtypes-metastatic-breast-cancer 2021-10-05T14:33:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-demonstrates-nearly-five-years-median-overall-survival-metastatic-breast-cancer 2021-10-05T14:33:15+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-bosulif-chronic-myeloid-leukemia-trial 2021-10-05T14:33:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-analyses-confirm-benefit-kymriah-clinically-meaningful-rates-complete-response-seen-patients-certain-advanced-lymphomas 2021-10-05T14:33:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-first-data-from-reach3-trial-showing-jakavi-ruxolitinib-significantly-improved-outcomes-patients-steroid-resistantdependent-chronic-gvhd 2021-10-05T14:33:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-confidence-growing-sales-margin-expansion-fueled-market-brands-and-rich-pipeline-annual-meet-management-investor-event 2021-10-05T14:33:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy 2021-10-05T14:33:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-ash-reinforce-breadth-novartis-hematology-portfolio-across-multiple-blood-cancers-and-serious-hematologic-diseases 2021-10-05T14:33:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-set-achieve-100-renewable-electricity-its-european-operations 2021-10-05T14:33:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/results-from-real-world-data-and-post-hoc-analysis-novartis-beovu-pivotal-trials-presented-aao-2020 2021-10-05T14:33:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender 2021-10-05T14:33:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-can-covid-trial-hospitalized-patients-covid-19-pneumonia-and-cytokine-release-syndrome-crs 2021-10-05T14:33:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-shows-early-synovitis-reduction-patients-psoriatic-arthritis-first-its-kind-study 2021-10-05T14:33:28+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iv-study-showing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention 2021-10-05T14:33:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-sickle-cell-medicine-adakveo-approved-europe-prevent-recurrent-vaso-occlusive-crises 2021-10-05T14:33:30+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-kymriah-manufacturing-footprint-first-ever-approved-site-commercial-car-t-cell-therapy-manufacturing-asia 2021-10-05T14:33:32+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-latest-phase-iii-data-reinforcing-cosentyx-first-line-systemic-treatment-pediatric-psoriasis 2021-10-05T14:33:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-treating-blindness 2021-10-05T14:33:35+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-collaboration-molecular-partners-develop-two-darpin-therapies-designed-potential-use-against-covid-19 2021-10-05T14:33:36+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-solid-q3-performance-11-core-operating-income-growth-net-sales-line-prior-year-strong-pipeline-progression-upgrades-full-year-core-operating-income-guidance 2021-10-05T14:33:38+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-im-3-qu-mit-solider-performance-operatives-kernergebnis-steigt-um-11-nettoumsatz-auf-vorjahresniveau-starke-pipeline-fortschritte-jahresprognose-fur-operatives-kernergebnis-angehoben 2021-10-05T14:33:39+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-au-t3-performance-solide-croissance-de-11-du-resultat-operationnel-core-chiffre-daffaires-net-proche-de-lan-dernier-pipeline-en-fort-progres-hausse-du-resultat-operationnel-core-prevu 2021-10-05T14:33:51+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-promising-interim-phase-ii-data-potential-first-class-oral-therapy-iptacopan-lnp023-rare-renal-disease-c3-glomerulopathy-c3g 2021-10-05T14:33:59+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-european-medicines-agency-ema-has-granted-orphan-drug-designation-iptacopan-lnp023-iga-nephropathy-igan 2021-10-05T14:34:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-branaplam-lmi070-huntingtons-disease-hd 2021-10-05T14:34:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-leqvio-inclisiran-potential-first-class-sirna-treatment-high-cholesterol 2021-10-05T14:34:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-received-european-medicines-agency-ema-prime-designation-iptacopan-lnp-c3-glomerulopathy-c3g 2021-10-05T14:34:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-phase-iii-analysis-demonstrates-novartis-beovu-showed-improvement-best-corrected-visual-acuity-wet-amd-patients-early-persistent-fluid 2021-10-05T14:34:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/zolgensma-data-including-patients-more-severe-sma-baseline-further-demonstrate-therapeutic-benefit-including-prolonged-event-free-survival-increased-motor-function-and-milestone-achievement 2021-10-05T14:34:06+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-avxs-101-intrathecal-clinical-development-program 2021-10-05T14:34:08+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-receives-highest-rating-any-cdk46-inhibitor-esmo-magnitude-clinical-benefit-scale 2021-10-05T14:34:10+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-piqray-data-show-survival-benefit-patients-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T14:34:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma 2021-10-05T14:34:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tafinlar-mekinist-demonstrates-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-study-published-nejm 2021-10-05T14:34:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reinforces-commitment-patient-access-pricing-eur-185-billion-sustainability-linked-bond 2021-10-05T14:34:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/european-medicines-agency-ema-approves-safety-label-update-novartis-beovu 2021-10-05T14:34:17+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-positive-topline-results-from-first-phase-iii-trial-beovu-versus-aflibercept-patients-diabetic-macular-edema-dme 2021-10-05T14:34:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-early-treatment-mayzent-siponimod-delays-disability-progression-and-show-benefits-cognitive-performance-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T14:34:21+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-data-actrims-ectrims-kesimpta-ofatumumab-newly-diagnosed-treatment-naive-adults-relapsing-multiple-sclerosis 2021-10-05T14:34:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-actrims-ectrims-highlight-strength-leading-multiple-sclerosis-ms-portfolio-life-changing-therapies-people-across-ms-spectrum 2021-10-05T14:34:24+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-community-statement-global-managed-access-program-avxs-101 2021-10-06T12:17:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-community-statement-coronavirus-disease-covid-19 2021-10-06T12:17:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-community-statement-global-managed-access-program-avxs-101-0 2021-10-06T12:17:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-statement-changes-senior-leadership-team 2021-10-06T12:17:57+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-statement-access-zolgensma-onasemnogene-abeparvovec-xioi 2021-10-06T12:17:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-reports-first-quarter-2018-financial-and-operating-results 2021-10-06T12:17:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-announces-first-patient-dosed-phase-3-trial-avxs-101-pre-symptomatic-sma-types-1-2-and-3 2021-10-06T12:17:58+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-presents-initial-data-from-pivotal-us-trial-sma-type-1-and-24-month-follow-data-from-phase-1-trial-avxs-101-sma-type-1-annual-meeting-american-academy-neurology 2021-10-06T12:18:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-present-avxs-101-data-annual-meeting-american-academy-neurology 2021-10-06T12:18:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-gene-therapy-awarded-sakigake-designation-spinal-muscular-atrophy-type-1 2021-10-06T12:18:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-enters-licensing-agreement-genethon 2021-10-06T12:18:00+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-reports-fourth-quarter-and-full-year-2017-financial-and-operating-results 2021-10-06T12:18:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-report-fourth-quarter-and-full-year-2017-financial-and-operating-results 2021-10-06T12:18:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-initiate-screening-remaining-patients-pivotal-trial-avxs-101-sma-type-1-following-review-preliminary-data-from-first-three-patients 2021-10-06T12:18:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-announces-closing-public-offering-common-stock-and-full-exercise-underwriters-option-purchase-additional-shares 2021-10-06T12:18:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-announces-pricing-public-offering-common-stock 2021-10-06T12:18:04+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-announces-proposed-public-offering-common-stock 2021-10-06T12:18:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-announces-expanded-clinical-development-program-avxs-101-spinal-muscular-atrophy 2021-10-06T12:18:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/regenxbio-and-avexis-announce-expansion-relationship-through-amended-license-agreement-development-and-commercialization-treatments-spinal-muscular-atrophy 2021-10-06T12:18:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/avexis-announces-alignment-fda-next-steps-toward-bla-submission-avxs-101-sma-type-1 2021-10-06T12:18:07+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expects-sustain-long-term-growth-robust-pipeline-25-potential-blockbusters-highlighted-rd-day 2021-10-06T17:07:25+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-broad-range-portfolio-data-ectrims-reinforcing-long-standing-commitment-people-living-multiple-sclerosis 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-resolves-legacy-federal-government-civil-investigation-us-regarding-generic-drugs 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-rapid-and-effective-disease-activity-control-remibrutinib-lou064-patients-chronic-spontaneous-urticaria 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-accelerates-efforts-toward-esg-targets-increase-access-medicines-improve-health-equity-and-achieve-net-zero-carbon-emissions 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-report-positive-results-phase-2b-study-novel-ganaplacidelumefantrine-combination-children-malaria 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-reinforce-efficacy-and-convenience-novartis-cosentyx-secukinumab-300-mg-autoinjector-adults-psoriasis 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-achieving-complete-control-chronic-spontaneous-urticaria-csu-improves-overall-quality-life-reported-patients 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-bring-gene-therapies-patients-severe-vision-loss 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquiert-arctos-medical-elargissant-ainsi-son-portefeuille-doptogenetique-afin-de-proposer-des-therapies-geniques-aux-patients-souffrant-dune-severe-perte-de-la-vision 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ubernimmt-arctos-medical-und-erweitert-damit-ihr-optogenetik-portfolio-um-patientinnen-und-patienten-mit-einem-schwerem-verlust-des-sehvermogens-gentherapien-anbieten-zu-konnen 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-collaboration-harmonia-phase-iii-head-head-trial-evaluating-kisqali-vs-ibrance-patients-hrher2-advanced-breast-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-kisqali-data-showing-longest-median-overall-survival-ever-reported-hrher2-advanced-breast-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-findings-from-real-world-study-alpelisib-demonstrating-clinical-benefit-people-pik3ca-related-overgrowth-spectrum-pros 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-positive-health-related-quality-life-data-177lu-psma-617-radioligand-therapy-patients-advanced-prostate-cancer-esmo-2021 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-first-fda-filing-acceptance-anti-pd-1-antibody-tislelizumab-people-esophageal-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-strengthens-pipeline-entering-agreement-biosimilar-bevacizumab-key-oncology-medicine 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-findings-ers-reinforcing-efficacy-enerzair-breezhaler-highlighting-its-digital-companion-well-showcasing-commitment-low-carbon-footprint-asthma-solutions 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/world-first-agreement-between-novartis-and-nhs-enables-broad-and-rapid-access-first-class-cholesterol-lowering-medicine-leqvio-vinclisiran 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-leqvio-inclisiran-analyses-show-effective-and-sustained-ldl-c-reduction-two-sub-populations-patients-ascvd 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-important-overall-survival-and-quality-life-results-across-solid-tumor-portfolio-among-other-key-data-esmo 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-belinda-study-investigating-kymriah-second-line-treatment-aggressive-b-cell-non-hodgkin-lymphoma 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-secures-new-approval-china-cosentyx-secukinumab-pediatric-psoriasis 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-trials-beovu-diabetic-macular-edema-including-dosing-intervals-16-weeks 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-lift-partial-clinical-trial-hold-and-plans-initiate-new-pivotal-phase-3-study-intrathecal-oav-101-older-patients-sma 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-strong-q2-performance-driven-momentum-key-growth-brands-fy-2021-guidance-unchanged 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-forte-performance-au-deuxieme-trimestre-soutenue-par-la-dynamique-des-marques-cles-de-croissance-previsions-pour-lexercice-2021-inchangees 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-hat-im-zweiten-quartal-dank-der-dynamik-wichtiger-wachstums-marken-eine-starke-performance-erzielt-prognose-fur-2021-unverandert 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pledges-10-year-commitment-morehouse-school-medicine-26-historically-black-colleges-universities-medical-schools-and-other-leading-organizations-co-create-effective-measurable-solutions-health-equity 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nejm-publication-positive-phase-iii-reach3-data-jakavi-chronic-gvhd 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-rob-kowalski-chief-people-organization-officer 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-eu-launch-ready-dilute-generic-pemetrexed-treat-most-prevalent-form-lung-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/positive-survival-data-novartis-investigational-radioligand-therapy-177lu-psma-617-published-new-england-journal-medicine 2021-12-02T12:33:04+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-hewlett-packard-enterprise-join-forces-advance-novartis-global-health-efforts 2021-12-02T18:33:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/kesimpta-ofatumumab-data-show-long-term-preservation-iggigm-levels-and-no-increased-risk-serious-infections-people-living-multiple-sclerosis 2021-12-03T22:33:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-zolgensma-data-demonstrate-age-appropriate-development-when-used-presymptomatically-and-rapid-clinically-meaningful-efficacy-symptomatic-children-even-those-severe-sma-baseline 2021-12-04T11:03:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-completes-acquisition-gsks-cephalosporin-business-reinforcing-leading-global-position-antibiotics 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptances-beovu-patients-diabetic-macular-edema 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/kesimpta-ofatumumab-data-ectrims-highlights-preservation-igg-levels-and-safety-experience-over-extended-exposure-35-years-people-living-relapsing-multiple-sclerosis 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/global-heart-hub-and-novartis-partner-tackle-ascvd-global-health-crisis-and-worlds-1-killer 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-signs-new-initial-agreement-biontech-support-fill-and-finish-mrna-pfizer-biontech-covid-19-vaccine 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-top-line-results-canopy-1-phase-iii-study-support-further-evaluation-canakinumab-lung-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-solid-q3-results-strong-growth-innovative-medicines-announces-strategic-review-sandoz 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-de-solides-resultats-au-3e-trimestre-avec-une-forte-croissance-dinnovative-medicines-et-annonce-un-examen-strategique-de-sandoz 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-solide-ergebnisse-mit-starkem-wachstum-bei-innovative-medicines-das-unternehmen-kundigt-eine-strategische-uberprufung-von-sandoz 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-priority-review-us-fda-and-filing-acceptance-ema-kymriah-treat-patients-relapsed-or-refractory-follicular-lymphoma 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-scemblix-asciminib-novel-mechanism-action-treatment-chronic-myeloid-leukemia 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-sell-its-roche-stake-bilateral-transaction-roche 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-verkauft-ihre-roche-beteiligung-einer-bilateralen-transaktion-roche 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-data-ash-spotlight-novartis-recently-approved-scemblix-next-generation-car-t-platform-and-expanding-hematology-portfolio 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-iptacopan-meets-primary-endpoints-phase-ii-study-rare-kidney-disease-c3-glomerulopathy-c3g 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/leqvio-inclisiran-reduced-ldl-c-people-who-are-overweight-or-obese 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-publication-cephalalgia-data-showcasing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-positive-phase-iii-results-cosentyx-children-active-enthesitis-related-arthritis-era-and-juvenile-psoriatic-arthritis-jpsa-acr-2021 2021-12-02T12:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-rd-day-spotlights-attractive-growth-profile-underpinned-strong-market-brands-20-potential-high-value-pipeline-assets-and-technology-platforms 2021-12-06T17:48:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/bilateral-transaction-between-novartis-and-roche-successfully-closed 2021-12-06T17:48:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer 2021-12-08T15:33:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-positive-results-from-year-two-phase-iii-trial-beovu-diabetic-macular-edema 2021-12-09T16:48:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-highlight-efficacy-piqray-hrher2-metastatic-breast-cancer-pik3ca-driver-mutation-immediately-post-cdk46i 2021-12-10T14:03:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kymriah-demonstrates-strong-responses-high-risk-patients-relapsed-or-refractory-follicular-lymphoma-extended-study-follow 2021-12-11T18:03:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-demonstrates-sustained-response-rate-48-week-follow-patients-chronic-myeloid-leukemia 2021-12-11T22:03:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-t-chargetm-next-generation-car-t-platform-first-human-data-ash-2021 2021-12-13T20:48:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-initiates-new-usd-15-billion-share-buyback-highlighting-confidence-growth-and-pipeline 2021-12-16T07:03:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-iii-ligelizumab-qge031-studies-chronic-spontaneous-urticaria-csu 2021-12-20T07:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-strengthens-immunotherapy-pipeline-option-collaboration-and-license-agreement-beigene-tigit-inhibitor-ociperlimab 2021-12-20T12:18:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-submits-biologics-license-application-proposed-biosimilar-trastuzumab-us-fda 2021-12-20T22:18:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-submits-marketing-authorization-application-proposed-biosimilar-trastuzumab-ema 2021-12-22T07:18:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquire-gyroscope-therapeutics-adding-one-time-gene-therapy-could-transform-care-geographic-atrophy-leading-cause-blindness 2021-12-22T08:03:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-leqvio-inclisiran-first-class-sirna-lower-cholesterol-and-keep-it-low-two-doses-year 2021-12-22T22:18:04+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis 2021-12-23T00:03:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-4 2022-03-03T13:19:05+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle-1 2022-03-03T13:19:05+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda-0 2022-03-03T13:19:05+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-peer-reviewed-research-shows-no-increased-risk-serious-covid-19-infections-kesimpta-ofatumumab-treated-adults-multiple-sclerosis 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-targets-growth-opportunities-respiratory-and-complex-generics-through-acquisition-respiratory-device-company-coalesce 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-again-demonstrate-age-appropriate-development-when-zolgensma-used-presymptomatically-and-post-hoc-data-reveal-sma-type-1-patients-could-speak-swallow-and-maintain-airway-protection 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-signs-initial-agreement-carisma-therapeutics-manufacturing-her-2-targeted-car-m-cell-therapy 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/nejm-publication-novartis-kisqali-data-shows-longest-median-overall-survival-ever-reported-hrher2-advanced-breast-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-voyager-therapeutics-reach-license-option-agreement-next-generation-gene-therapy-vectors-neurological-diseases 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-5 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut 2022-06-29T02:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-peer-reviewed-safety-and-tolerability-data-further-strengthens-kesimptas-ofatumumab-favorable-benefit-risk-profile-patients-relapsing-multiple-sclerosis 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-launches-generic-lenalidomide-19-countries-across-europe-expanding-access-essential-oncology-medicine 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-mid-single-digit-sales-growth-margin-expansion-and-advancement-robust-pipeline-2021 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enregistre-en-2021-une-croissance-du-chiffre-daffaires-net-un-chiffre-dans-le-milieu-de-la-fourchette-une-expansion-de-la-marge-et-une-avancee-du-robuste-pipeline 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-2021-ein-umsatzwachstum-im-mittleren-einstelligen-bereich-verbessert-die-margen-und-treibt-die-solide-pipeline-voran 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-molecular-partners-report-positive-topline-data-from-phase-2-study-ensovibep-mp0420-darpin-antiviral-therapeutic-covid-19 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-collaboration-alnylam-explore-targeted-therapy-restore-liver-function 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-us-court-appeals-federal-circuit-cafc-upholds-validity-gilenya-fingolimod-dosage-regimen-patent 2022-06-30T00:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-jakavi-treat-acute-and-chronic-graft-versus-host-disease 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma-europe 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-european-commission-approval-beovu-people-living-diabetic-macular-edema 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-new-organizational-structure-accelerate-growth-strengthen-pipeline-and-increase-productivity 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-gibt-neue-organisationsstruktur-bekannt-fur-schnelleres-wachstum-eine-starkere-pipeline-und-hohere-produktivitat 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-four-year-data-efficacy-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosis 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-zolgensma-manufacturing-capacity-approval-multi-product-north-carolina-facility 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-vijoice-alpelisib-first-and-only-treatment-select-patients-pik3ca-related-overgrowth-spectrum-pros 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-extends-collaboration-agreement-drive-cutting-edge-digital-solutions-global-fight-against-antimicrobial-resistance-amr 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-anti-pd-1-tislelizumab-accepted-ema-regulatory-review-esophageal-and-lung-cancers 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-early-clinical-data-unique-krasg12c-inhibitor-american-association-cancer-research-annual-meeting 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-launches-generic-brimonidine-tartratetimolol-maleate-eyedrop-us-patients-ocular-hypertension-expanding-leading-ophthalmic-portfolio 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tabrecta-patients-metex14-advanced-non-small-cell-lung-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-solid-sales-and-profit-growth-strong-performance-market-brands-supports-confidence-mid-term-growth-outlook 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-solide-croissance-du-chiffre-daffaires-et-du-benefice-la-forte-performance-des-marques-existantes-soutient-la-confiance-dans-les-previsions-de-croissance-moyen-terme 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-ein-solides-umsatz-und-gewinnwachstum-die-starke-performance-auf-dem-markt-befindlicher-marken-stutzt-das-vertrauen-die-mittelfristigen-wachstumsaussichten 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tislelizumab-plus-chemotherapy-significantly-improved-overall-survival-first-line-treatment-advanced-esophageal-cancer-phase-iii-study 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-european-commission-approval-jakavi-be-first-post-steroid-treatment-acute-and-chronic-graft-versus-host-disease 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-production-radioligand-therapy-medicines 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-latest-oncology-research-and-innovation-including-breast-and-prostate-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-appoints-new-board-representative-global-amr-industry-alliance 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-new-global-act4biosimilars-initiative-improve-patient-access-and-increase-adoption-least-30-30-countries-2030 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-partnership-american-society-hematology-fight-sickle-cell-disease-sub-saharan-africa 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-cdk46i-data-asco-reinforce-novartis-kisqali-only-drug-class-consistently-proven-overall-survival-benefit-hrher2-metastatic-breast-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-show-piqray-effectiveness-across-key-biomarkers-patients-hrher2-metastatic-breast-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tafinlar-dabrafenib-mekinist-trametinib-demonstrates-unprecedented-efficacy-pediatric-patients-braf-v600-low-grade-gliomas-phase-iiiii-study 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-novel-mechanism-action-shows-superior-long-term-efficacy-and-consistent-tolerability-96-week-follow-chronic-myeloid-leukemia-trial 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-children-and-young-adults-advanced-b-cell-all 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-research-reveals-critical-actions-needed-ensure-covid-19-driven-surge-virtual-health-and-care-drives-health-access-and-equity 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-application-proposed-biosimilar-adalimumabs-high-concentration-formulation-accepted-ema 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-nature-medicine-publication-zolgensma-data-demonstrating-age-appropriate-milestones-when-treating-children-sma-presymptomatically 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-plans-petition-us-court-appeals-federal-circuit-further-review-uphold-validity-gilenya-fingolimod-dosing-regimen-patent 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-european-commission-approval-tabrecta-treatment-metex14-skipping-advanced-non-small-cell-lung-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tafinlar-mekinist-receives-fda-approval-first-tumor-agnostic-indication-braf-v600e-solid-tumors 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-renews-commitment-neglected-tropical-disease-and-malaria-elimination-investing-usd-250-million-over-five-years-research-and-develop-new-treatments 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-scemblix-novel-treatment-adult-patients-chronic-myeloid-leukemia 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-extension-phase-data-show-nearly-80-rms-patients-treated-kesimpta-ofatumumab-had-no-evidence-disease-activity-neda-3 2022-06-30T07:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/cosentyx-secukinumab-receives-expanded-approvals-eu-use-childhood-arthritic-conditions 2022-06-28T21:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-maintains-growth-momentum-and-confirms-fy22-group-guidance 2022-12-05T17:19:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-oral-monotherapy-iptacopan-demonstrates-clinically-meaningful-superiority-over-anti-c5-treatment-phase-iii-apply-pnh-study 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-pluvicto-patients-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-unveils-new-focused-strategy-underpinned-eight-potential-multi-billion-dollar-peak-sales-brands-deep-pipeline-meet-management-event 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-plans-petition-us-supreme-court-uphold-validity-gilenya-fingolimod-dosing-regimen-patent 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-further-progress-its-biosimilar-pipeline-release-positive-results-denosumab-integrated-phase-iiii-clinical-trial 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-statement-regarding-competition-authority-investigation-assertion-patent 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-invests-early-technical-development-capabilities-next-generation-biotherapeutics 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-tislelizumab-demonstrated-efficacy-and-tolerability-first-line-advanced-liver-cancer-phase-iii-trial 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-adds-one-more-year-survival-benefit-broadest-set-patients-including-those-aggressive-hrher2-advanced-breast-cancer 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-depth-immunology-pipeline-novel-data-key-upcoming-international-congresses 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-fiona-marshall-phd-president-novartis-institutes-biomedical-research-jay-bradner-md-steps-down-from-executive-committee-novartis 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-breast-and-prostate-cancer-esmo 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-novel-mechanism-action-approved-european-commission-adult-patients-chronic-myeloid-leukemia 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-intention-separate-sandoz-business-create-standalone-company-way-100-spin 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-iii-canopy-study-evaluating-canakinumab-adjuvant-treatment-non-small-cell-lung-cancer 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/applications-proposed-first-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-us-fda-and-ema 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-supplemental-biologics-license-application-accepted-us-fda-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation-hcf 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-continued-strong-momentum-key-growth-brands-progress-strategic-initiatives-and-confirms-fy22-group-guidance 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-phase-iii-data-show-novartis-tislelizumab-significantly-extended-median-overall-survival-more-6-months-first-line-advanced-esophageal-cancer-combination-chemotherapy 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-resumes-production-and-delivery-radioligand-therapy-medicines-ahead-schedule 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-further-investment-key-manufacturing-facility-austria-support-increased-global-demand-essential-antibiotics 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-long-term-leqvio-inclisiran-data-from-novartis-show-sustained-efficacy-and-safety-over-four-years 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-scientific-advances-kisqali-iptacopan-scemblix-and-ytb323-data-sabcs-and-ash 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-decision-move-phase-3-study-novel-ganaplacidelumefantrine-sdf-combination-adults-and-children-malaria 2022-12-05T17:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-setzt-die-wachstumsdynamik-fort-und-bestatigt-die-konzernprognose-fur-das-geschaftsjahr-2022 2023-01-18T11:07:06+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-will-das-sandoz-geschaft-durch-eine-hundertprozentige-ausgliederung-als-eigenstandiges-unternehmen-abspalten 2023-01-18T11:07:09+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-eine-anhaltend-starke-dynamik-der-wichtigsten-wachstumsmarken-sowie-fortschritte-bei-strategischen-initiativen-und-bestatigt-die-konzernprognose-fur-das-geschaftsjahr-2022 2023-01-18T11:07:11+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-maintient-sa-dynamique-de-croissance-et-confirme-les-previsions-de-lexercice-2022-pour-le-groupe 2023-01-18T11:07:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continue-le-fort-elan-des-principales-marques-de-croissance-progresse-dans-ses-initiatives-strategiques-et-confirme-les-previsions-de-lexercice-2022-pour-le-groupe 2023-01-18T11:07:16+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-appointment-chairman-designate-sandoz-board-directors 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-biologics-license-application-proposed-biosimilar-denosumab-accepted-us-fda 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/patients-hidradenitis-suppurativa-experienced-sustained-efficacy-and-symptom-improvement-one-year-when-treated-novartis-cosentyx 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-grow-further-core-margin-expansion-and-achieves-important-innovation-milestones 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-poursuit-sa-croissance-avec-une-nouvelle-expansion-de-sa-marge-core-et-franchit-des-etapes-importantes-dans-linnovation 2023-06-02T01:34:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-setzt-wachstumskurs-mit-weiterer-steigerung-der-kerngewinnmarge-fort-und-erreicht-wichtige-innovations-meilensteine 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-citrate-free-high-concentration-formulation-adalimumab-biosimilar 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-leading-antifungal-agent-mycamine-from-astellas-reinforcing-hospital-offering-and-leading-anti-infectives-portfolio 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-pivotal-phase-iii-apply-pnh-data-ash-demonstrating-investigational-oral-monotherapy-iptacopan-superiority-over-anti-c5 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-hemoglobin-levels-complement-inhibitor-naive-patients-pnh 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-prolonged-pfs-benefit-pre-and-perimenopausal-patients-aggressive-hrher2-metastatic-breast-cancer-compared-chemotherapy 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pluvictotm-shows-statistically-significant-and-clinically-meaningful-radiographic-progression-free-survival-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-6 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire-0 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut-0 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-signs-memorandum-understanding-build-new-biologics-production-plant-slovenia-support-increasing-global-demand-biosimilar-medicines 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tafinlar-mekinist-approved-fda-pediatric-patients-braf-v600e-low-grade-glioma-most-common-pediatric-brain-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shares-zolgensma-long-term-data-demonstrating-sustained-durability-75-years-post-dosing-100-achievement-all-assessed-milestones-children-treated-prior-sma-symptom-onset 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-phase-iii-natalee-trial-meets-primary-endpoint-interim-analysis-demonstrating-clinically-meaningful-benefit-broad-population-patients-early-breast-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-entresto-receives-positive-chmp-opinion-pediatric-heart-failure 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-approval-european-commission-hyrimoz-adalimumab-high-concentration-formulation 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-five-year-data-disability-outcomes-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosis 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones-raises-fy-guidance 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-une-croissance-forte-de-son-chiffre-daffaires-une-expansion-robuste-de-sa-marge-des-etapes-majeures-de-linnovation-et-rehausse-ses-previsions-pour-lexercice-2023 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatzsteigerungen-eine-robuste-margenerhohung-und-wichtige-innovationsmeilensteine-erhohung-der-jahresprognose 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-appoint-pnh-trial-shows-investigational-oral-monotherapy-iptacopan-improves-hemoglobin-near-normal-levels-leading-transfusion-independence-all-treatment-naive-pnh-patients 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-new-data-across-oncology-portfolio-including-kisqali-phase-iii-natalee-trial-early-breast-cancer-asco 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-hidradenitis-suppurativa 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-exclusively-commercialize-six-products-us-reinforcing-global-leadership-position-patent-medicines 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-strengthens-pipeline-expansion-through-partnership-develop-and-manufacture-multiple-biosimilars 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-feature-new-pnh-and-cml-scientific-data-from-broad-hematology-portfolio-european-hematology-association-annual-meeting 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-sandoz-board-directors-appointed 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-marketing-authorization-applications-proposed-biosimilar-denosumab-accepted-ema 2023-06-01T07:49:05+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa 2023-12-03T09:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-plans-move-new-central-basel-headquarters-mid-2024-following-proposed-spin-standalone-company 2023-12-12T09:19:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-significantly-reduced-risk-recurrence-25-across-broad-population-patients-early-breast-cancer-clinically-meaningful-benefit-was-consistent-across-subgroups 2023-12-03T09:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-presents-compelling-investment-proposition-standalone-company-capital-markets-day 2023-12-03T09:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-unveils-results-from-global-patient-and-physician-survey-disrupting-notion-cml-solved-disease 2023-12-03T09:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-acquire-chinook-therapeutics-usd-32bn-upfront-usd-40-share 2023-12-03T09:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-introduces-act4biosimilars-action-plan-accelerate-patient-access-biosimilar-medicines 2023-12-03T09:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-signs-agreement-divest-front-eye-ophthalmology-assets-line-focused-strategy 2023-12-03T09:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-publishes-new-five-year-efficacy-data-kesimpta-ofatumumab-treatment-relapsing-multiple-sclerosis 2023-12-13T14:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-launch-hyrimoz-adalimumab-adaz-high-concentration-formulation-marking-sandoz-entrance-us-immunology-space 2023-12-02T22:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-will-appeal-us-court-appeals-uphold-validity-entresto-combination-patent-maintains-2023-guidance-and-mid-term-outlook 2023-12-02T22:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-builds-neuroscience-pipeline-and-xrna-platform-capabilities-acquisition-dtx-pharma 2023-12-02T18:49:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-raises-guidance-announces-usd-15-billion-share-buyback-and-board-endorses-sandoz-spin-off12 2023-12-02T17:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-realise-une-forte-croissance-de-son-chiffre-daffaires-et-de-sa-marge-releve-ses-previsions-et-annonce-un-rachat-dactions-dusd-15-milliards1-le-conseil-dadministration-approuve-le-spin-de-sandoz2 2023-12-02T18:49:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatz-und-margensteigerungen-und-erhoht-die-prognose-aktienruckkaufprogramm-von-usd-15-milliarden-angekundigt-der-verwaltungsrat-unterstutzt-den-spin-von-sandoz12 2023-12-02T18:49:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-plans-build-biosimilar-technical-development-center-slovenia-support-future-growth-biosimilar-pipeline 2023-12-02T17:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-multiple-sclerosis-biosimilar-natalizumab 2023-12-02T17:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-remibrutinib-phase-iii-trials-met-their-primary-endpoints-and-showed-rapid-symptom-control-chronic-spontaneous-urticaria 2023-12-02T17:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeutics 2023-12-02T17:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-positive-results-from-mylight-phase-lll-study-biosimilar-aflibercept 2023-12-02T14:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-issues-egm-invitation-and-shareholder-information-brochure-sandoz-publishes-listing-prospectus-ahead-proposed-spin-vote 2023-12-02T14:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-publiziert-einladung-und-aktionarsbroschure-zur-ausserordentlichen-generalversammlung-sandoz-veroffentlicht-den-kotierungsprospekt-im-vorfeld-der-abstimmung-zum-vorgeschlagenen-spin 2023-12-02T14:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-publie-linvitation-lage-et-la-brochure-dinformation-aux-actionnaires-sandoz-publie-le-prospectus-de-cotation-avant-le-vote-sur-la-proposition-de-scission 2023-12-02T14:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-fda-approval-tyruko-natalizumab-sztn-first-and-only-fda-approved-biosimilar-relapsing-forms-multiple-sclerosis 2023-12-02T14:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-completes-acquisition-leading-antifungal-agent-mycamine-from-astellas-reinforcing-leading-global-anti-infectives-portfolio 2023-12-02T14:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-long-term-leqvio-inclisiran-data-demonstrating-consistent-efficacy-and-safety-beyond-six-years 2023-12-02T07:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-publishes-supplement-listing-prospectus-including-sandoz-h1-2023-financial-statements 2023-12-02T06:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-publie-un-supplement-au-prospectus-de-cotation-comprenant-les-etats-financiers-de-sandoz-au-premier-semestre-2023 2023-12-02T07:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-veroffentlicht-nachtrag-zum-kotierungsprospekt-einschliesslich-finanzabschluss-von-sandoz-fur-das-1-halbjahr-2023 2023-12-02T07:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis 2023-12-01T23:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ernennt-dr-patrick-horber-zum-president-international-da-marie-france-tschudin-president-innovative-medicines-international-und-chief-commercial-officer-aus-der-geschaftsleitung-von-novartis-ausscheidet 2023-12-02T06:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-nomme-patrick-horber-docteur-en-medecine-au-poste-de-president-international-alors-que-marie-france-tschudin-president-innovative-medicines-international-et-chief-commercial-officer-quitte-le-comite-executif-de-novartis 2023-12-02T06:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-announces-exclusive-deal-commercialize-biosimilar-ustekinumab-further-reinforcing-growing-pipeline-and-immunology-patient-offering 2023-12-01T23:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-reduced-risk-cancer-recurrence-while-maintaining-quality-life-patients-diagnosed-early-breast-cancer 2023-12-01T23:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-proposed-100-spin-sandoz 2023-12-01T05:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-le-projet-de-scission-100-de-sandoz 2023-12-01T08:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-stimmen-dem-geplanten-100-igen-spin-von-sandoz-zu 2023-12-01T23:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-breast-and-gastric-cancer-biosimilar-trastuzumab 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-demonstrated-statistically-significant-and-clinically-meaningful-progression-free-survival-first-line-advanced-gastroenteropancreatic-neuroendocrine-tumors-gep-nets 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-confirms-sandoz-spin-october-4-2023 2023-12-01T10:19:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-tyruko-natalizumab-first-and-only-biosimilar-multiple-sclerosis-europe 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-divestment-front-eye-ophthalmology-assets 2023-12-01T10:19:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-new-oncology-data-esmo-2023-demonstrating-practice-changing-innovation-advanced-prostate-and-early-breast-cancer 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-natalee-analysis-reinforces-consistent-reduction-risk-recurrence-across-key-subgroups-patients-early-breast-cancer 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pluvictotm-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer-pre-taxane-setting 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-12-sales-and-21-core-operating-income-growth-from-continuing-operations-cc1-executes-sandoz-spin-achieves-important-innovation-milestones-and-raises-fy-2023-guidance 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-hausse-de-12-du-chiffre-daffaires-et-de-21-du-resultat-operationnel-core-tcc1-spin-de-sandoz-etapes-importantes-de-linnovation-hausse-des-previsions-pour-2023 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-steigert-umsatz-um-12-und-operatives-kernergebnis-um-21-fortzufuhrende-geschaftsbereiche-kwk1-sandoz-abgespalten-wichtige-innovationsmeilensteine-erreicht-und-prognose-2023-erhoht 2023-12-01T07:04:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-confirms-unconstrained-supply-pluvicto-and-continues-significantly-expand-number-treatment-centers 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-atrasentan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan 2023-12-01T10:19:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-show-potential-remibrutinib-oral-treatment-chronic-spontaneous-urticaria-providing-significant-symptom-improvement-early-week-2 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-showcases-significant-data-updates-from-kisqali-iptacopan-and-scemblix-sabcs-and-ash 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-upgrades-mid-term-sales-growth-guidance-showcases-its-differentiated-innovative-medicines-strategy-and-robust-pipeline-rd-day 2023-12-01T18:34:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-statistically-significant-proteinuria-reduction-patients-c3-glomerulopathy-c3g 2024-05-06T02:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-48-week-results-from-phase-iii-apply-pnh-trial-showing-sustained-efficacy-and-long-term-safety-fabhalta-iptacopan-adults-paroxysmal-nocturnal-hemoglobinuria-pnh 2024-05-06T02:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/latest-novartis-kisqali-natalee-analysis-reinforces-25-reduction-risk-recurrence-across-broad-population-patients-early-breast-cancer-supports-regulatory-submissions 2024-05-06T02:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh 2024-05-06T02:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-expands-production-pluvictotm-addition-its-largest-and-most-advanced-radioligand-therapy-manufacturing-facility-indianapolis 2024-05-06T02:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-shows-superior-major-molecular-response-mmr-rates-vs-standard-care-tkis-phase-iii-trial-newly-diagnosed-patients-chronic-myeloid-leukemia 2024-05-06T02:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors 2024-04-30T22:34:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-strong-full-year-performance-10-net-sales-and-18-core-operating-income-growth-cc1-margin-expansion-continuing-innovation-momentum-multiple-positive-ph3-readouts 2024-05-02T17:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-forte-performance-en-2023-hausse-de-10-du-chiffre-daffaires-net-et-de-18-du-resultat-operationnel-core-tcc1-expansion-de-la-marge-innovation-nombreux-resultats-positifs-de-phase-iii 2024-01-31T09:27:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/starkes-jahresergebnis-novartis-steigert-den-nettoumsatz-um-10-das-operative-kernergebnis-um-18-kwk1-sowie-die-margen-weitere-innovationsdynamik-mit-mehreren-positiven-phase-3-ergebnissen 2024-02-05T22:48:49+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash 2024-02-05T22:48:45+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-safety-and-efficacy-zolgensma-including-maintained-and-improved-motor-milestones-older-and-heavier-children-sma 2024-03-04T07:19:03+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-7 2024-03-05T15:34:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire-1 2024-03-05T15:34:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut-1 2024-05-02T14:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-fabhalta-iptacopan-receives-positive-chmp-opinion-first-oral-monotherapy-adult-patients-paroxysmal-nocturnal-hemoglobinuria-pnh 2024-03-22T12:34:02+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-show-early-addition-twice-yearly-leqvio-inclisiran-following-maximally-tolerated-statin-therapy-significantly-reduces-ldl-c-ascvd-patients-real-world-setting 2024-05-03T14:49:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-tender-offer-morphosys-ag-commences 2024-05-04T09:49:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-fabhalta-iptacopan-data-show-clinically-meaningful-and-statistically-significant-proteinuria-reduction-383-versus-placebo-patients-iga-nephropathy-igan 2024-05-02T20:19:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kesimpta-six-year-efficacy-data-show-substantial-benefits-recently-diagnosed-treatment-naive-people-relapsing-multiple-sclerosis 2024-04-17T14:34:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raised 2024-07-08T10:20:22+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-au-premier-trimestre-croissance-deux-chiffres-du-chiffre-daffaires-et-expansion-de-la-marge-core-hausse-des-previsions-pour-2024 2024-04-23T08:03:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-ein-zweistelliges-umsatzwachstum-und-steigert-die-kerngewinnmarge-prognose-fur-das-geschaftsjahr-2024-erhoht 2024-04-23T08:03:19+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-fda-approved-first-medicine-specifically-pediatric-patients-gastroenteropancreatic-neuroendocrine-tumors 2024-04-23T19:49:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquire-regulus-therapeutics-and-farabursen-investigational-microrna-inhibitor-treat-adpkd-most-common-genetic-cause-renal-failure 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-strong-momentum-double-digit-sales-growth-robust-margin-expansion-and-multiple-approvals-q1 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-setzt-die-starke-dynamik-fort-mit-zweistelligem-umsatzwachstum-robusten-margensteigerungen-und-mehreren-zulassungen-im-ersten-quartal 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-vanrafia-atrasentan-first-and-only-selective-endothelin-receptor-antagonist-proteinuria-reduction-primary-iga-nephropathy-igan 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-karen-hale-chief-legal-and-compliance-officer-klaus-moosmayer-chief-ethics-risk-compliance-officer-steps-down-from-executive-committee-novartis 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-radioligand-therapy-pluvicto-earlier-use-chemotherapy-psma-positive-metastatic-castration-resistant-prostate-cancer 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-present-new-data-aan-including-seven-year-disability-outcomes-and-safety-analysis-kesimpta-people-relapsing-multiple-sclerosis 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-third-fda-approval-oral-fabhalta-iptacopan-first-and-only-treatment-approved-c3-glomerulopathy-c3g 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-phase-iii-data-demonstrate-meaningful-efficacy-and-safety-results-intrathecal-onasemnogene-abeparvovec-broad-patient-population-sma 2025-11-08T05:34:12+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-2025-annual-general-meeting 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/aktionare-von-novartis-heissen-der-generalversammlung-2025-alle-antrage-des-verwaltungsrats-gut 2025-11-08T05:34:12+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-presentations-aaaai-and-aad-underscore-commitment-advancing-treatment-hidradenitis-suppurativa-hs-and-chronic-spontaneous-urticaria-csu 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-oral-fabhalta-iptacopan-receives-positive-chmp-opinion-treatment-adults-living-c3-glomerulopathy-c3g 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront 2025-11-17T11:04:16+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-strong-momentum-sales-growth-margin-expansion-reaches-key-innovation-milestones-2024 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-setzt-die-starke-umsatzdynamik-mit-margenerhohungen-fort-und-erreicht-2024-wichtige-meilensteine-bei-innovationen 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-entresto-us-patent-upheld-us-court-appeals 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-study-meets-primary-endpoint-children-and-young-adults-sma 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/longer-term-novartis-kisqali-natalee-data-show-durable-reduction-distant-recurrence-broad-population-patients-early-breast-cancer 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/longer-term-data-novartis-scemblix-reinforce-superior-efficacy-favorable-safety-and-tolerability-profile-adults-newly-diagnosed-cml 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-phase-iiib-data-shows-novartis-fabhalta-improved-hemoglobin-levels-adult-patients-paroxysmal-nocturnal-hemoglobinuria-who-switched-from-anti-c5-therapy 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-receives-european-commission-approval-broad-population-patients-hrher2-early-breast-cancer-high-risk-recurrence 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-asc4first-trial-ash-and-late-breaking-analysis-from-phase-iii-kisqali-natalee-trial-sabcs 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-upgrades-mid-term-guidance-and-highlights-deep-pipeline-core-therapeutic-areas-drive-long-term-growth 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ranks-first-2024-access-medicine-index 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-fda-approved-newly-diagnosed-cml-offering-superior-efficacy-and-favorable-safety-and-tolerability-profile 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-strong-momentum-q3-10-sales-growth-20-core-operating-income-growth-and-important-innovation-milestones-raises-fy-2024-guidance 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-setzt-die-starke-dynamik-im-dritten-quartal-fort-mit-steigerungen-beim-umsatz-10-und-operativen-kernergebnis-20-sowie-wichtigen-innovationsmeilensteinen-prognose-fur-2024-angehoben 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-oral-fabhalta-iptacopan-sustained-clinically-meaningful-results-one-year-phase-iii-c3-glomerulopathy-c3g-trial 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ribociclib-kisqali-recognized-category-1-preferred-breast-cancer-adjuvant-treatment-nccn-clinical-practice-guidelines-oncology-nccn-guidelines 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kisqali-help-reduce-risk-recurrence-people-hrher2-early-breast-cancer 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-relapsing-ms-reinforce-benefits-kesimpta-first-line-and-switch-patients 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/fda-approves-novartis-kisqali-reduce-risk-recurrence-people-hrher2-early-breast-cancer 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-shows-deepening-benefit-new-analysis-reducing-risk-recurrence-285-broad-population-patients-early-breast-cancer 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-twice-yearly-leqvio-demonstrated-clinically-meaningful-statistically-significant-ldl-c-lowering-monotherapy-patients-low-or-moderate-ascvd-risk 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-granted-fda-priority-review-treatment-adults-newly-diagnosed-cml 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-continues-deliver-strong-sales-growth-and-core-margin-expansion-q2-raises-fy-2024-bottom-line-guidance 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-poursuivi-au-t2-la-forte-croissance-de-son-chiffre-daffaires-et-lexpansion-de-sa-marge-core-hausse-des-previsions-de-son-resultat-operationnel-core-pour-2024 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-weiterhin-kraftige-umsatzsteigerungen-und-erhoht-die-kerngewinnmarge-gewinnprognose-fur-das-geschaftsjahr-2024-angehoben 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/latest-analysis-novartis-natalee-study-shows-kisqali-reduces-risk-cancer-recurrence-early-breast-cancer-patients-high-risk-node-negative-disease 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-data-confirm-sustained-efficacy-and-long-term-safety-oral-remibrutinib-chronic-spontaneous-urticaria 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-atrasentan-phase-iii-data-show-clinically-meaningful-proteinuria-reduction-further-advancing-companys-iga-nephropathy-igan-portfolio 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-latest-phase-iii-fabhalta-iptacopan-data-c3-glomerulopathy-c3g-showing-clinically-meaningful-and-statistically-significant-351-proteinuria-reduction-vs-placebo 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-meets-all-tender-offer-conditions-acquire-morphosys-ag-eur-68-share-cash 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-highlights-pioneering-innovation-cml-data-from-scemblix-phase-iii-asc4first-study-newly-diagnosed-patients-asco-and-eha 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-enters-agreement-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies 2025-05-05T13:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-asco-and-eha-showcase-momentum-pioneering-portfolio-promising-pipeline 2025-05-15T15:04:02+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-commencement-tender-offer-acquire-regulus-therapeutics 2025-05-27T14:04:03+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-reduces-risk-recurrence-younger-patients-early-breast-cancer-natalee-subgroup-analysis 2025-08-11T07:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-pluvictotm-demonstrates-statistically-significant-and-clinically-meaningful-rpfs-benefit-patients-psma-positive-metastatic-hormone-sensitive-prostate-cancer 2025-08-11T07:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-fabhalta-shows-statistically-significant-and-clinically-meaningful-improvements-hemoglobin-new-population-patients-pnh 2025-06-12T08:04:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-expiration-hsr-waiting-period-regulus-therapeutics-tender-offer 2025-06-23T07:04:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-expiration-regulus-therapeutics-tender-offer 2025-06-25T07:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-acquisition-regulus-therapeutics 2025-06-25T15:19:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-provides-update-phase-iii-gcaptain-study-cosentyx-giant-cell-arteritis-gca 2025-08-11T07:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-approval-first-malaria-medicine-newborn-babies-and-young-infants 2025-07-08T07:19:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-reports-strong-q2-double-digit-sales-growth-and-core-margin-expansion-raises-fy-2025-core-operating-income-guidance 2025-07-17T08:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-verzeichnet-ein-starkes-zweites-quartal-mit-zweistelligem-umsatzwachstum-und-erhohter-kerngewinnmarge-prognose-fur-das-operative-kernergebnis-im-geschaftsjahr-2025-angehoben 2025-07-17T08:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-appoints-mukul-mehta-chief-financial-officer-harry-kirsch-retires-after-22-years-company 2025-07-17T08:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease 2025-08-11T07:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ianalumab-phase-iii-trial-meets-primary-endpoint-itp-demonstrating-statistically-significant-improvement-time-treatment-failure 2025-08-12T07:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-esc-data-highlights-strength-cardiovascular-portfolio 2025-08-18T09:18:01+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-leqvio-shows-statistically-significant-and-clinically-meaningful-early-ldl-c-goal-achievement-less-muscle-pain 2025-08-30T17:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd 2025-09-09T07:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-further-support-benefits-kesimpta-relapsing-ms-following-switch-from-oral-disease-modifying-therapies 2025-09-24T08:34:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-showcase-transformative-data-advanced-prostate-and-early-breast-cancer-esmo-2025 2025-09-26T07:19:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-commencement-tender-offer-acquire-tourmaline-bio 2025-09-29T13:49:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-launch-direct-patient-platform-cosentyx-secukinumab-us 2025-09-29T18:49:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu 2025-09-30T22:19:11+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-fabhalta-iptacopan-meets-phase-iii-primary-endpoint-slows-kidney-function-decline-patients-iga-nephropathy-igan 2025-10-16T07:19:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-scemblix-receives-positive-chmp-opinion-treatment-adults-newly-diagnosed-cml 2025-10-17T12:49:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-kisqali-5-year-natalee-data-demonstrate-28-reduction-risk-recurrence-broadest-early-breast-cancer-patient-population 2025-10-17T14:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/psmaddition-data-show-novartis-pluvictotm-delays-progression-end-stage-prostate-cancer 2025-11-07T17:04:13+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-expiration-hart-scott-rodino-waiting-period-tourmaline-bio-tender-offer 2025-10-22T07:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-meets-primary-and-all-secondary-endpoints-phase-iii-trial-patients-polymyalgia-rheumatica-pmr 2025-10-22T07:19:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-showcases-significant-immunology-advancements-acr-congress-new-data-complex-autoimmune-diseases 2025-10-25T17:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline 2025-10-26T18:04:11+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivers-solid-sales-and-core-operating-income-growth-strong-pipeline-progress-q3-reaffirms-fy-2025-guidance 2025-10-28T15:04:13+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-verzeichnet-im-dritten-quartal-solide-steigerungen-beim-umsatz-und-operativen-kernergebnis-sowie-starke-fortschritte-der-pipeline-prognose-fur-das-geschaftsjahr-2025-bestatigt 2025-10-28T15:04:13+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-expiration-tourmaline-bio-tender-offer 2025-10-28T07:28:12+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-completes-acquisition-tourmaline-bio 2025-10-28T15:04:13+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-phase-iii-trial-next-generation-malaria-treatment-klu156-ganlum-meets-primary-endpoint-potential-combat-antimalarial-resistance 2026-03-25T16:19:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-opens-new-radioligand-therapy-manufacturing-facility-california-part-23b-us-expansion-plan 2026-03-25T09:49:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-novartis-data-asn-kidney-week-and-aha-scientific-sessions-demonstrate-momentum-broad-crm-portfolio-and-pipeline 2026-03-28T20:34:12+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ianalumab-first-drug-reduce-disease-activity-and-patient-burden-sjogrens-disease-phase-iii-trials 2026-03-31T22:49:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-announces-plans-build-flagship-manufacturing-hub-north-carolina 2026-03-25T05:49:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-projects-5-6-cc-sales-cagr-2025-2030-long-term-growth-backed-30-potential-high-value-pipeline-assets 2026-03-25T18:04:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-fda-approval-itvisma-only-gene-replacement-therapy-children-two-years-and-older-teens-and-adults-spinal-muscular-atrophy-sma 2026-03-25T15:19:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-data-underscore-pioneering-scientific-innovation-hematology-and-oncology-ash-and-sabcs 2026-04-02T17:22:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/1-4-metastatic-breast-cancer-patients-treated-novartis-kisqali-remain-progression-free-beyond-4-years 2026-03-30T15:19:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ianalumab-significantly-extends-disease-control-patients-immune-thrombocytopenia-only-four-once-monthly-doses 2026-04-01T08:34:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-and-us-government-reach-agreement-lowering-drug-prices-us 2026-04-02T17:22:16+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-add-radioligand-therapy-manufacturing-facility-winter-park-florida-fourth-us-serve-patients-and-advance-23-billion-investment 2026-03-25T16:04:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-sjogrens-disease 2026-03-25T19:34:13+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-pipeline-2025 2026-04-01T17:19:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-erzielte-im-jahr-2025-eine-umsatzsteigerung-im-hohen-einstelligen-prozentbereich-eine-kerngewinnmarge-von-40-sowie-weitere-fortschritte-der-pipeline 2026-03-25T23:34:13+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-breaks-ground-new-global-biomedical-research-center-san-diego-accelerate-drug-discovery 2026-04-01T10:34:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-vanrafia-phase-iii-data-support-slowing-kidney-function-decline-patients-iga-nephropathy 2026-03-19T22:04:15+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-remibrutinib-first-therapy-achieve-phase-iii-primary-endpoint-chronic-inducible-urticaria-cindu 2026-04-02T08:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-rhapsido-remibrutinib-data-aaaai-showing-potential-beyond-chronic-spontaneous-urticaria-csu 2026-04-02T17:04:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/new-real-world-data-reinforce-earlier-use-pluvictotm-chemotherapy-metastatic-castration-resistant-prostate-cancer 2026-03-25T17:19:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-build-new-radioligand-therapy-site-denton-texas-delivering-more-next-generation-treatments-patients 2026-04-02T07:49:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-remibrutinib-chronic-spontaneous-urticaria-csu 2026-04-02T07:49:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy 2026-03-24T22:05:00+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-2026-annual-general-meeting 2026-04-01T21:49:13+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/aktionare-von-novartis-heissen-der-generalversammlung-2026-alle-antrage-des-verwaltungsrats-gut 2026-03-25T16:49:14+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa 2026-03-30T15:19:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-agrees-acquire-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline 2026-04-02T07:49:14+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-presents-new-data-early-symptom-relief-and-long-term-control-complex-skin-diseases-aad-2026 2026-03-28T21:50:57+01:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-agrees-acquire-excellergy-inc-building-allergy-leadership-next-generation-anti-ige-innovation 2026-04-01T04:04:12+02:00 daily 0.5 https://stg1.novartis.com/news/media-releases/novartis-igan-data-new-england-journal-medicine-show-fabhalta-slowed-kidney-function-decline-493 2026-03-29T07:19:14+02:00 daily 0.5 https://stg1.novartis.com/news/novartis-inaugurates-innovative-watershed-project-india-increase-water-availability 2024-06-07T12:57:01+02:00 daily 1.0 https://stg1.novartis.com/news/world-cancer-day-2021 2025-05-21T11:20:38+02:00 daily 1.0 https://stg1.novartis.com/news/global-health-corporate-responsibility 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/achieving-100-renewable-electricity 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-appoints-marc-boutin-global-head-patient-engagement-advocacy 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-provides-update-use-and-safety-beovu-patients-wet-amd 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/avexis-data-integrity-updates 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/epis-explores-how-covid-19-shaping-future-digital-engagement-within-healthcare 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-ranks-second-2021-access-medicine-index 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/news/highlights-from-co-creating-impact-summit-2020 2025-05-21T13:10:02+02:00 daily 1.0 https://stg1.novartis.com/news/world-chagas-disease-day-2021 2025-05-21T13:13:09+02:00 daily 1.0 https://stg1.novartis.com/news/bold-advocates-blood-cancers-and-blood-disorders 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/blood-cancer-awareness-month-cutting-edge-innovation-hematology 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/solar-1-nejm-publication 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/mission-transform-planetary-health 2025-05-21T13:16:31+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-flexible-return-office-and-site-field-activities-starting-may-11-2020 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-completes-safety-review-and-initiates-update-beovu-prescribing-information-worldwide 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-first-european-donation-hydroxychloroquine-switzerland 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-coronavirus-update-supply-chain-response-measures-efpia-rd-call 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/expanding-car-t-manufacturing-australia 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-ash 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/why-healthcares-digital-moment-now 2025-05-27T07:42:24+02:00 daily 1.0 https://stg1.novartis.com/news/avexis-renamed-novartis-gene-therapies-signifying-growing-importance-gene-therapy-novartis-corporate-strategy 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/ruxcovid-clinical-trial 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/study-suggests-there-may-be-two-stages-fatal-lung-disease-covid-19 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/choice-responsibility-reimagining-how-we-work 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/international-womens-day-2020 2025-05-21T13:24:55+02:00 daily 1.0 https://stg1.novartis.com/news/world-sight-day-2020 2025-05-21T13:27:33+02:00 daily 1.0 https://stg1.novartis.com/news/standing-racial-equity-and-justice-one-novartis 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-update-following-who-solidarity-trial-announcement 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-plan-initiate-clinical-trial-canakinumab-patients-covid-19-pneumonia 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/leading-performance-sustainability 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/news/world-heart-day-2020-from-our-heart-yours 2025-05-27T07:14:33+02:00 daily 1.0 https://stg1.novartis.com/news/50-climate-leaders 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/new-report-shows-how-ai-health-critical-covid-19-response-and-recovery 2025-05-27T07:38:31+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-coronavirus-update-remote-working-business-travel-restrictions 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/expanding-car-t-manufacturing-europe-serve-more-patients 2025-05-21T13:30:22+02:00 daily 1.0 https://stg1.novartis.com/news/committed-increasing-access 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/pride-novartis-2020-inspired-make-difference 2025-05-21T13:32:21+02:00 daily 1.0 https://stg1.novartis.com/news/world-sickle-cell-day-2020 2025-05-21T13:38:47+02:00 daily 1.0 https://stg1.novartis.com/news/pride-novartis-2019 2025-05-21T14:26:06+02:00 daily 1.0 https://stg1.novartis.com/news/world-chagas-disease-day-2020 2025-05-21T14:29:27+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-covid-19-response-fund-provides-support-healthcare-workers-and-communities 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-esmo 2022-07-28T12:22:49+02:00 daily 1.0 https://stg1.novartis.com/news/day-african-child-2020 2025-05-21T14:38:57+02:00 daily 1.0 https://stg1.novartis.com/news/world-cancer-day-2020 2025-05-21T14:41:23+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-world-economic-forum-annual-meeting-davos-2020 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/sustaining-momentum-toward-universal-health-coverage-africa 2025-05-22T15:05:40+02:00 daily 1.0 https://stg1.novartis.com/news/discussing-innovative-solutions-address-unmet-healthcare-needs-asia 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-joins-accelerating-covid-19-therapeutic-interventions-and-vaccines-activ-initiative 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-further-steps-protect-and-support-its-associates-during-covid-19-pandemic 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-ranks-4-patientviews-2019-corporate-reputation-survey-patient-organizations 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/news/behind-research-driving-our-data-medical-conferences 2025-05-27T07:25:26+02:00 daily 1.0 https://stg1.novartis.com/news/uncovering-profound-and-under-reported-effects-people-living-sickle-cell-disease 2025-05-22T15:08:49+02:00 daily 1.0 https://stg1.novartis.com/news/amazon-web-services-aws-announces-strategic-collaboration-novartis-accelerate-digital-transformation-its-business-operations 2025-05-27T07:04:41+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-opens-facility-innovative-cell-and-gene-therapies-switzerland 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/world-sight-day-2019 2025-05-22T15:20:36+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-and-microsoft-announce-collaboration-transform-medicine-artificial-intelligence 2025-05-27T06:57:39+02:00 daily 1.0 https://stg1.novartis.com/news/health-experts-explore-response-chronic-illness-poor-countries 2025-05-22T15:39:48+02:00 daily 1.0 https://stg1.novartis.com/news/world-malaria-day-2019 2025-05-22T16:16:57+02:00 daily 1.0 https://stg1.novartis.com/news/global-equal-parental-leave-policy-all-novartis-parents 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-moves-address-superbug-threat 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/celebrating-community-partnership-day 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-recognized-global-leader-sustainable-water-and-climate-management 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/biosimilar-drugs-have-potential-save-more-usd-54-billion 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-foundation-joins-global-partnership-zero-leprosy 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/news/world-sickle-cell-day-2019 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/exploring-future-access-healthcare-lower-income-countries 2025-05-22T16:36:17+02:00 daily 1.0 https://stg1.novartis.com/news/alcon-survey-reveals-people-are-happier-and-more-satisfied-their-lives-after-cataract-surgery 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/car-t-therapies-are-manufactured-each-individual-patient 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/asthma-and-exercise-why-patients-can-and-should-stay-active 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/beyond-pill-precision-medicine-practice 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/improving-diabetes-awareness-and-treatment-adherence-india 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/how-digital-technologies-are-creating-new-normal-people-living-copd 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/when-innovation-draws-new-future-patient-treatments 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/taking-action-psoriasis-patients-who-psoriasis-resolution 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-medikidz-and-copd-foundation-partnership-superhero-proportions 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/innovation-practice-how-we-form-partnerships-pharma 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-evolving-business-practices-better-educate-medical-community 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/medical-researchers-using-new-tools-turn-science-fiction-science-fact 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/students-take-challenges-digital-medicine 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/news/fighting-high-blood-pressure-vietnam 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/world-asthma-day-2021 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/nurturing-next-generation-scientists 2025-05-23T07:57:55+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-and-red-cross-partner-tackle-chronic-diseases-refugee-populations 2025-05-23T08:03:56+02:00 daily 1.0 https://stg1.novartis.com/news/essential-consultants-updates 2021-10-14T09:40:24+02:00 daily 1.0 https://stg1.novartis.com/news/avxs-101-managed-access-program 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/news/world-malaria-day-2021 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-dialogue-explore-solutions-rise-chronic-diseases-developing-world 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-host-stakeholder-dialogue-ways-improve-access-healthcare-lower-income-countries 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/european-patient-innovation-summit-recommends-increasing-impact-digital-technologies 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/alcon-becomes-separately-traded-standalone-company 2025-05-27T06:33:02+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-rd-day 2025-05-27T09:30:45+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-jp-morgan-2020 2025-07-02T18:47:13+02:00 daily 1.0 https://stg1.novartis.com/news/co-creating-impact-summit-society-and-planet 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/life-science-companies-and-bill-melinda-gates-foundation-joint-communique 2025-05-23T08:37:48+02:00 daily 1.0 https://stg1.novartis.com/news/european-patient-innovation-summit-publishes-call-action-ensure-greater-patient-involvement-digital-health-solution-development 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-research-shows-technology-talent-increasingly-drawn-pharma-industry-covid-19 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/world-malaria-day-2020 2025-05-23T08:36:20+02:00 daily 1.0 https://stg1.novartis.com/news/impact-measurement-and-valuation 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/news/ai-nurse-set-transform-standards-care-heart-failure-patients-china 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/meet-novartis-management-2020 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-discontinuation-cirrus-1-study-cfz533-iscalimab-kidney-transplant-patients 2021-10-04T08:25:52+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-receives-fda-fast-track-designation-lna043-osteoarthritis-knee 2021-10-04T08:28:19+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-sabatolimab-receives-orphan-drug-designation-from-european-commission-myelodysplastic-syndromes 2021-10-14T13:31:54+02:00 daily 1.0 https://stg1.novartis.com/news/fda-accelerates-review-novartis-stamp-inhibitor-asciminib-abl001-patients-chronic-myeloid-leukemia-cml 2021-10-04T08:26:24+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-receives-fda-orphan-drug-designation-nis793-pancreatic-cancer 2021-10-04T08:28:06+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-complete-response-resubmission-inclisiran-new-drug-application 2021-10-04T08:26:03+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-investigational-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc 2023-04-11T16:10:26+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-entresto-indicated-treatment-hypertension-china 2021-10-04T08:25:43+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-receives-fda-fast-track-designation-sabatolimab-mbg453-myelodysplastic-syndromes 2021-10-04T08:28:13+02:00 daily 1.0 https://stg1.novartis.com/news/industry-and-academia-collaborating-innovate-patients 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/fda-grants-priority-review-investigational-targeted-radioligand-therapy-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc 2021-10-14T10:02:25+02:00 daily 1.0 https://stg1.novartis.com/news/one-billion-antimalarial-treatments-delivered-extraordinary-partnership-journey 2025-05-23T08:30:26+02:00 daily 1.0 https://stg1.novartis.com/news/asia-pacific-patient-innovation-summit-examines-capability-building-gaps-patient-organizations 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/enabling-our-associates-work-safely-our-sites 2021-10-07T13:13:01+02:00 daily 1.0 https://stg1.novartis.com/news/beacon-hope-addressing-health-disparities-through-holistic-community-based-collective-action 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-hematology-relentless-pursuit-cure 2025-05-23T08:23:44+02:00 daily 1.0 https://stg1.novartis.com/news/two-decades-pioneering-innovation-cml-and-beyond 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/news/covid-19-news-archive 2023-07-03T16:14:31+02:00 daily 1.0 https://stg1.novartis.com/news/world-sight-day-2021 2025-05-23T08:20:51+02:00 daily 1.0 https://stg1.novartis.com/news/sound-up 2025-05-22T15:52:06+02:00 daily 1.0 https://stg1.novartis.com/news/raising-awareness-prostate-cancer-during-movember 2025-05-22T15:45:50+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-receives-fda-fast-track-designation-branaplam-lmi070-treatment-huntingtons-disease 2021-12-16T10:00:12+01:00 daily 1.0 https://stg1.novartis.com/news/2021-global-managed-access-program-community-update 2022-01-31T14:36:51+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-co-creating-impact-summit-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-european-patent-office-orders-grant-european-gilenya-fingolimod-05mg-daily-dose-patent 2022-02-15T10:02:38+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-condemns-war-ukraine-and-commits-supporting-humanitarian-efforts 2022-03-15T08:49:19+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-expands-humanitarian-efforts-ukraine-through-donation-essential-medicines 2022-03-08T16:49:12+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-condemns-war-ukraine-update-march-22 2022-03-22T08:11:41+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-provides-more-usd-25-million-medical-aid-patients-ukraine-and-bordering-countries 2022-04-19T14:32:46+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-resumes-business-ukraine 2022-07-28T12:22:49+02:00 daily 1.0 https://stg1.novartis.com/news/from-the-heart 2025-05-22T15:07:30+02:00 daily 1.0 https://stg1.novartis.com/news/zolgensma-acute-liver-failure-update 2022-08-16T17:30:22+02:00 daily 1.0 https://stg1.novartis.com/news/branaplam-vibrant-hd-study-update 2022-08-25T16:01:23+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-hematology-working-help-ensure-patients-are-getting-access-they-need 2025-05-22T14:56:34+02:00 daily 1.0 https://stg1.novartis.com/news/world-sight-day-2022 2025-05-22T14:53:44+02:00 daily 1.0 https://stg1.novartis.com/news/creating-positive-social-change-through-volunteering 2025-05-22T14:49:26+02:00 daily 1.0 https://stg1.novartis.com/news/zolgensma-global-managed-access-program-2023 2023-01-09T08:36:49+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-shares-strategy-insights-and-highlights-key-pipeline-catalysts-jp-morgan-healthcare-conference-2023 2023-01-09T17:18:36+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-provides-update-phase-iii-stand-trial-assessing-crizanlizumab 2023-02-01T12:36:05+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-announces-support-people-affected-earthquake-turkey-and-syria 2023-02-07T19:10:01+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-releases-emergency-funding-usd-1-million-people-turkey-and-syria-and-launches-employee-donation-and-volunteering-programs 2023-02-09T16:14:57+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-unwavering-support-one-year-from-start-war-ukraine 2023-02-28T17:30:32+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-completes-fda-filing-approval-millburn-facility-support-pluvicto-launch 2023-03-03T08:56:35+01:00 daily 1.0 https://stg1.novartis.com/news/fda-approves-novartis-millburn-facility-us-commercial-production-pluvicto 2023-04-21T17:17:29+02:00 daily 1.0 https://stg1.novartis.com/news/chmp-recommends-revoking-conditional-marketing-authorization-adakveo-crizanlizumab 2023-05-26T14:28:49+02:00 daily 1.0 https://stg1.novartis.com/news/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab 2023-08-04T14:29:20+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-statement-about-entresto-sacubitrilvalsartan-selection-medicare-drug-price-negotiation-program 2023-08-29T14:51:15+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-statement-filing-inflation-reduction-act-lawsuit 2023-09-01T20:47:26+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-giving-volunteering-wins-accps-2023-corporate-social-impact-team-year-award 2023-10-11T14:26:30+02:00 daily 1.0 https://stg1.novartis.com/news/gt005-ppy988-development-program-geographic-atrophy 2023-09-11T16:14:11+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-provides-support-moroccan-earthquake-victims 2023-09-13T15:52:00+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-statement-collaboration-and-license-agreement-tislelizumab-beigene-ltd 2023-09-19T14:36:00+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-condemns-terrorist-actions-against-people-israel-and-loss-innocent-lives 2023-10-13T13:31:56+02:00 daily 1.0 https://stg1.novartis.com/news/violence-against-innocent-people-runs-counter-our-work-improve-human-health 2023-10-19T07:57:08+02:00 daily 1.0 https://stg1.novartis.com/news/our-next-era 2024-10-28T09:23:26+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-shares-strategy-and-growth-update-jp-morgan-healthcare-conference-2024 2024-01-08T17:33:04+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-appoints-sloan-simpson-global-head-investor-relations 2024-02-29T08:59:50+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-confirms-plans-file-pluvicto-pre-taxane-label-expansion-h2-2024-based-latest-data-from-phase-iii-psmafore-study 2024-04-04T15:27:08+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2 2024-04-09T22:26:46+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-scemblix-1l-cml 2024-12-02T14:42:01+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-statement-maximum-fair-price-entresto 2024-08-15T14:50:34+02:00 daily 1.0 https://stg1.novartis.com/news/novartis-employs-creative-deal-structure-establish-borealis-biosciences-divests-legacy-chinook-site-invests-form-new-company-and-engages-rd-collaboration 2024-08-22T13:53:42+02:00 daily 1.0 https://stg1.novartis.com/news/official-partner-eurovision-song-contest-2025 2024-10-31T11:19:44+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-bolsters-neuroscience-pipeline-licensing-ptc518-huntingtons-disease 2024-12-02T12:59:50+01:00 daily 1.0 https://stg1.novartis.com/news/novartis-presentation-jp-morgan-healthcare-conference-2025 2025-01-14T09:56:21+01:00 daily 1.0 https://stg1.novartis.com/news/europe-talks-health-sovereignty-now-it-must-deliver 2025-04-24T20:25:12+02:00 daily 1.0 https://stg1.novartis.com/news/vas-narasimhan-named-2025-time100-health-list 2025-05-08T16:06:09+02:00 daily 1.0 https://stg1.novartis.com/news/bringing-breakthroughs-more-patients 2025-09-29T20:17:52+02:00 daily 1.0 https://stg1.novartis.com/stories/artificial-intelligence-decodes-cancer-pathology-images 2025-05-19T15:46:57+02:00 daily 1.0 https://stg1.novartis.com/stories/african-experts-call-renewed-global-drive-beat-malaria 2025-05-19T15:57:02+02:00 daily 1.0 https://stg1.novartis.com/stories/10-big-questions-dissect-science-papers 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/abcdes-melanoma-prevention-and-detection 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/challenging-young-scientist-focus-patients 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/biological-battle-bulge 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/building-boot-camps-immune-cells-near-tumors 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/bringing-gene-therapy-focus 2025-05-27T08:24:27+02:00 daily 1.0 https://stg1.novartis.com/stories/can-we-unlock-bodys-ability-regenerate-lost-hearing 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/stories/building-collaborations-fight-pandemic 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/breaking-vicious-cycle-inflammation 2025-05-19T16:10:07+02:00 daily 1.0 https://stg1.novartis.com/stories/bringing-real-change-people 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/cancer-cocktails-abl001-hitting-one-target-twice 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/cancer-cocktails-come-age 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/bringing-science-and-medicine-together-help-patients-cancer 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/stories/cancer-cocktails-lee011-popular-combination-partner 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/cancer-cocktails-ljm716-closing-common-release-valve 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/cancer-researchers-ready-aim-cures 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/chan-zuckerberg-initiative-friends-novartis-scientist-mission-conquer-disease 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/clinical-trial-comes-together-weeks-address-coronavirus 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/cellular-drama-heart-researchers-family 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/clinical-trials-make-move-toward-mice 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/close-look-cryo-electron-microscopy 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/collaborating-explore-new-gene-regulation-therapies 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/collaborating-unlock-secrets-microbiome 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/compound-designed-fight-alzheimers-disease-shows-promise-lab 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/compounds-spur-insulin-producing-cells-replicate-lab 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/combination-therapies-seeking-block-cancers-pathways-growth 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/counting-combos-complex-liver-diseases 2025-05-27T07:19:42+02:00 daily 1.0 https://stg1.novartis.com/stories/confidence-led-researcher-swim-against-current 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/covid-19-answering-your-top-questions 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/data42-program-shows-novartis-intent-go-big-data-and-digital 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/could-umbilical-cords-yield-more-stem-cells-life-saving-transplants 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/digital-health-ecosystem-gets-boost-novartis-biome 2025-05-21T11:43:52+02:00 daily 1.0 https://stg1.novartis.com/stories/embracing-big-data-understand-complex-diseases 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/decades-long-journey-blood-cancer-research 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/drug-development-gets-big-data-analytics-boost 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/evolution-scientist 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/experimental-gene-therapy-discovered-house-enters-clinical-testing 2025-05-21T11:47:16+02:00 daily 1.0 https://stg1.novartis.com/stories/experimental-treatment-clears-malaria-infections-small-clinical-study 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/exploring-longstanding-questions-about-heart-disease 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/eye-fastest-muscle-human-body 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/dna-encoded-molecules-provide-new-edge-cancer-drug-hunts 2025-05-21T13:43:07+02:00 daily 1.0 https://stg1.novartis.com/stories/factory-foreman-keeps-livers-line-workers-task 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/eyewitness-healer-pursues-new-treatments-patients 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/fresh-look-fighting-glaucoma 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/from-patient-patient-advocate-how-cancer-diagnosis-fueled-new-career-path 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/getting-down-roots-alzheimers-disease 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/going-global-meet-local-needs-china 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/how-love-sport-led-scientific-breakthrough 2025-05-21T13:49:07+02:00 daily 1.0 https://stg1.novartis.com/stories/heart-failure-leading-cause-hospitalizations-it-doesnt-have-be 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/eye-patients-mind-innovation 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/helping-clinical-trial-patients-during-lockdown 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/how-scientists-aim-expand-immunotherapy-options-cancer-patients 2025-05-21T13:52:49+02:00 daily 1.0 https://stg1.novartis.com/stories/immuno-oncology-researchers-seek-build-smart-drug-combos 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/innovating-trusted-class-antibiotics-attack-superbugs 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/investigating-myopia-mystery 2025-05-21T13:58:47+02:00 daily 1.0 https://stg1.novartis.com/stories/it-takes-rd-village-fight-pandemic 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/intractable-tumor-cells-crippled 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/keeping-heart-patients-heart-everything-we-do 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/let-there-be-sight 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/loss-friend-liver-cancer-sharpens-focus-experimental-therapy 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/killing-three-diseases-one-stone-lab 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/leveraging-livers-ability-heal-scarred-tissue 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/making-possible-stepping-toward-future-cell-and-gene-therapy 2025-05-21T14:07:59+02:00 daily 1.0 https://stg1.novartis.com/stories/meet-achim-leading-data42-program 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/mutant-protein-spreads-through-neural-circuit-huntingtons-disease 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/moving-from-speculation-science-during-pandemic 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/not-your-grandparents-nuclear-medicine 2025-05-21T14:11:51+02:00 daily 1.0 https://stg1.novartis.com/stories/machine-learning-poised-accelerate-drug-discovery 2025-05-21T14:39:40+02:00 daily 1.0 https://stg1.novartis.com/stories/neuroscientists-restore-cell-cell-signaling-and-sociability-autism-models 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/new-drug-manufacturing-tools-change-pharma-chemistry 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/new-recruit-has-big-dreams-cancer-immunotherapy 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/new-hope-treating-inflammatory-diseases-kidney 2025-05-21T14:59:46+02:00 daily 1.0 https://stg1.novartis.com/stories/novartis-and-pfizer-join-forces-upend-oncology-dogma 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-cancer-researchers-advance-precision-medicine 2025-05-21T15:05:39+02:00 daily 1.0 https://stg1.novartis.com/stories/novartis-researches-smas-genetic-roots 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/open-science-demystified 2025-03-26T06:05:38+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-scientists-target-resistance-threat-malaria 2025-05-21T15:24:26+02:00 daily 1.0 https://stg1.novartis.com/stories/organic-dealmaker-drug-discovery 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/open-resources-novartis-help-drive-innovation 2025-05-21T15:26:47+02:00 daily 1.0 https://stg1.novartis.com/stories/physician-scientist-donald-ganem-takes-reins-infectious-disease 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/potential-weight-loss-treatment-takes-shape-help-from-patients 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/predictive-analytics-could-bring-medicines-patients-faster 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/reaping-cancer-clues-from-blood 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/rare-speed-rare-disease 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/researchers-overcome-hurdles-test-experimental-malaria-drug 2025-03-26T06:05:38+01:00 daily 1.0 https://stg1.novartis.com/stories/researchers-aim-beat-trick-play-tumors-drug-combo 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/quest-new-measure-mental-health 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/researcher-races-find-new-treatment-his-progressive-disease 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/researchers-phd-leads-medical-breakthrough-rare-skin-disease 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/researcher-seeks-roots-plants-healing-power 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/respiratory-clinical-trials-putting-patients-heart-research 2025-05-21T15:33:27+02:00 daily 1.0 https://stg1.novartis.com/stories/rewriting-playbook-clinical-testing-rare-disease 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/saving-tumor-suppressors-from-shredder 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/shaping-future-sickle-cell-disease 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/search-differences-make-difference 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/specter-malaria-resists-treatment 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/stepping-toward-regenerative-medicine-diabetes 2025-05-22T07:06:24+02:00 daily 1.0 https://stg1.novartis.com/stories/small-viruses-could-accelerate-cell-and-gene-therapy-research 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/stopping-alzheimers-disease-it-starts 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/stifling-danger-signals-rheumatoid-arthritis 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/tackling-common-denominator-liver-disease 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/systematically-exposing-vulnerabilities-cancer-cells 2025-05-22T07:09:56+02:00 daily 1.0 https://stg1.novartis.com/stories/taking-clinical-trials-next-level-through-technology 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/taking-obesity 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/tracking-patients-progress-radio-signals-and-machine-learning 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/talking-bruno-strigini-why-were-entering-transformative-time-cancer-care 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/teaming-academia-discover-medicines 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/turning-research-advances-innovative-medicines 2025-05-22T07:12:32+02:00 daily 1.0 https://stg1.novartis.com/stories/women-science-cathryn-clary 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/visualizing-immuno-oncology-research 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-kristen-harrington-smith 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-annie-martin 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-mimi-huizinga 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-hannah-mosca 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-lauren-abrey 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-sandrine-piret-gerard 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-renee-rodgers 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-lilli-petruzzelli 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-shilpa-shah-mehta 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-shannon-campbell 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-susanne-schaffert 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-medy-attalla 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/word-street-what-cell-and-gene-therapy 2025-05-22T07:29:06+02:00 daily 1.0 https://stg1.novartis.com/stories/women-science-tania-small 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/3-d-printing-scientists-reinvent-research-tools 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-virginia-lazala 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/bringing-virtual-reality-lab 2025-05-22T07:35:37+02:00 daily 1.0 https://stg1.novartis.com/stories/brain-dish-researchers-take-neurological-disorders 2025-05-27T09:25:06+02:00 daily 1.0 https://stg1.novartis.com/stories/5-tips-making-smart-decisions-research-projects 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/building-brain-organoids-shed-light-disease 2025-05-22T07:39:40+02:00 daily 1.0 https://stg1.novartis.com/stories/cancer-spies-find-drug-beating-covert-cells 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/can-we-edit-our-genes-fight-disease 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/chemical-genetics-sleuthing-behind-modern-drug-discovery 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/could-digital-technology-drive-clinical-research-africa 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/disease-pathways-key-new-drug-discovery 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/electrical-brainstorms-traced-genetic-mutations 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/crispr-genome-editing-fuels-cancer-drug-discovery 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/countering-genome-reprogramming-cancer-cells 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/eye-disease-tracked-glitch-starburst-cells 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/five-things-look-scientific-mentor 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/hooked-science-jay-bradner-becomes-top-researcher-novartis 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/hardwiring-future 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/giraffes-have-high-blood-pressure-why-dont-they-drop-dead 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/fixing-whats-lost-translation 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/how-address-culture-gap-between-academia-and-industry-biomedicine 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/improving-science-communication-3-easy-steps 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/mhealth-revolution-healthcare 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/how-i-built-mini-gut-next-no-biology-training 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/how-zika-infects-growing-brain 2025-05-22T08:37:49+02:00 daily 1.0 https://stg1.novartis.com/stories/minion-challenges-assumptions-about-genome 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/molecular-glue-kills-cancer-cells-mice 2025-05-22T09:14:26+02:00 daily 1.0 https://stg1.novartis.com/stories/letters-my-younger-self-female-scientists-share-their-wisdom 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/neuroscientists-target-alzheimers-silent-stage 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/nurturing-life-science-ecosystem 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/opening-chemistry-education-world 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/rebuilding-blood 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/rediscovering-power-natures-exquisite-complexity 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/reigniting-passion-science 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/reimagining-protein-sequencing 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/robots-speed-pace-modern-drug-discovery 2025-05-22T09:56:58+02:00 daily 1.0 https://stg1.novartis.com/stories/stopping-free-radicals-their-source 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-antibody-increases-muscle-growth-mice-and-human-cell-cultures 2025-05-22T09:59:37+02:00 daily 1.0 https://stg1.novartis.com/stories/surfing-wave-big-data-analytics 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/three-lessons-ive-learned-industry-postdoc 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/turning-heat-tumors 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/visual-tour-scientific-strategies-combating-coronavirus 2025-05-22T10:06:34+02:00 daily 1.0 https://stg1.novartis.com/stories/vision-hacker 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/tuning-drugs-succeed-cells-surface 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-alexandra-bach-weidmuller 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/what-goes-wrong-window-soul-glaucoma 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/when-tiny-brains-are-best-brain-research 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-jean-silveri 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-cyndy-grosskreutz 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/turning-power-nuclear-technology-medical-force 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-jennifer-allport-anderson 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/young-talent-emerging-technologies-come-together-biocamp 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/2-million-kids-receive-malaria-medicine 2025-05-22T10:11:21+02:00 daily 1.0 https://stg1.novartis.com/stories/women-science-wendy-winckler 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-marjorie-eiref 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/ai-changing-face-healthcare 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/asian-health-experts-call-final-push-wipe-out-deadliest-form-malaria 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/bringing-chagas-disease-peoples-attention 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/bringing-modern-medicine-rural-vietnam 2025-05-22T10:14:12+02:00 daily 1.0 https://stg1.novartis.com/stories/cancer-didnt-stop-covid-19 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/collaboration-strengthening-care-chronic-illness-ethiopia 2025-05-22T10:17:03+02:00 daily 1.0 https://stg1.novartis.com/stories/chagas-disease-breaking-silence 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/confronting-global-spread-chronic-disease 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/tackling-rare-disease-working-toward-treatment-sma 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/sleuths-use-hi-tech-sensors-fight-pharmaceutical-crime 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/dealing-spread-chronic-disease-africa 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/fighting-malaria-africa 2025-05-22T10:23:55+02:00 daily 1.0 https://stg1.novartis.com/stories/ensuring-medicine-supply-patients-during-covid-19 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/fighting-respiratory-disease-source 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/delivering-access-first-launch-kenya 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/health-collaboration-russia-helped-reduce-blood-pressure-deaths 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/fighting-pneumonia-biggest-killer-young-children 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/kenya-confronts-chronic-diseases-building-progress-against-aids 2025-03-26T05:12:29+01:00 daily 1.0 https://stg1.novartis.com/stories/helping-people-sickle-cell-disease-painful-and-life-threatening-blood-disorder 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/helping-syrian-refugees-manage-chronic-diseases 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/improving-lives-through-community-based-care 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/sight-savers-jet-rescue 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/streamlining-systems-respond-covid-19 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/tailoring-tactics-tackle-chronic-disease-low-income-countries 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/talking-ann-aerts-head-novartis-foundation 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/life-dedicated-fighting-malaria 2025-05-22T10:28:53+02:00 daily 1.0 https://stg1.novartis.com/stories/living-breast-cancer-uganda 2021-10-13T11:00:21+02:00 daily 1.0 https://stg1.novartis.com/stories/living-hypertension-cameroon-few-dollars-day 2021-09-28T14:41:19+02:00 daily 1.0 https://stg1.novartis.com/stories/malaria-fighter-rides-bicycle-battle-disease 2025-05-22T10:31:06+02:00 daily 1.0 https://stg1.novartis.com/stories/malaria-still-disrupting-lives-despite-progress 2021-10-13T13:19:02+02:00 daily 1.0 https://stg1.novartis.com/stories/talking-juergen-brokatzky-geiger-global-head-corporate-responsibility-novartis 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/talking-patrice-matchaba-global-head-corporate-responsibility-novartis 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/telemedicine-taking-health-care-worlds-far-corners 2025-05-22T10:33:14+02:00 daily 1.0 https://stg1.novartis.com/stories/text-messages-africa-help-fight-malaria 2025-05-22T10:36:27+02:00 daily 1.0 https://stg1.novartis.com/stories/treating-cataracts-leading-cause-preventable-blindness-worldwide 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/women-science-fionnuala-doyle 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/fighting-ms-through-innovation 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/from-melanoma-survivor-front-line-nurse 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/ai-nurse-evolving-heart-failure-patients-china 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/body-painter-captures-anguish-those-who-suffer-from-psoriasis 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/changing-landscape-cancer-treatment 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/caring-someone-heart-failure 2025-05-27T07:16:45+02:00 daily 1.0 https://stg1.novartis.com/stories/choosing-right-care 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/conversations-patient-advocates-ron-hollander-president-inca 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/coping-eye-disease-and-fading-vision-late-life 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/meet-manuel-cobos-transplant-surgeon-and-researcher 2021-10-13T14:51:37+02:00 daily 1.0 https://stg1.novartis.com/stories/creative-ways-help-kids-understand-rare-diseases 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/dealing-psoriasis 2025-05-22T10:39:43+02:00 daily 1.0 https://stg1.novartis.com/stories/debunking-myths-about-multiple-sclerosis 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/digital-innovation-looks-set-dominate-2021-healthcare-agenda 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/digital-health-providing-opportunities-advocacy-groups-and-community-patients 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/meet-martin-grobusch-malaria-fighter 2021-10-13T15:53:46+02:00 daily 1.0 https://stg1.novartis.com/stories/experts-call-new-approach-patient-and-physician-management-type-2-diabetes 2025-05-22T10:51:05+02:00 daily 1.0 https://stg1.novartis.com/stories/giving-small-community-big-voice 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/fitness-trainer-strives-keep-his-mothers-mind-limber 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/from-nurse-patient-facing-aggressive-blood-cancer 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/glaucoma-silently-steals-sight 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/meet-visionary-who-beat-odds-realize-his-vision-inclusive-eye-care 2025-05-22T11:30:42+02:00 daily 1.0 https://stg1.novartis.com/stories/groundskeeper-tackles-cancer-several-ways 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/heart-failure-coping-one-worlds-biggest-killers 2025-05-22T11:33:44+02:00 daily 1.0 https://stg1.novartis.com/stories/importance-caregivers 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/inside-cancer-diagnosis 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/patients-perspective-biomarker-testing 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/led-steven-taylor-sjogrens-syndrome-foundation-raising-awareness-little-known-autoimmune-disease 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/lessons-from-blind-chef 2025-05-22T11:36:11+02:00 daily 1.0 https://stg1.novartis.com/stories/living-heart-failure 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/living-hfpef-patients-story 2025-05-22T11:47:30+02:00 daily 1.0 https://stg1.novartis.com/stories/longevity-vitality-japanese-elders-provide-examples-healthy-aging 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/lung-cancer-test-or-not-test 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/meet-tj-sharpe 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/most-europeans-have-limited-awareness-about-heart-failure 2025-05-22T12:07:56+02:00 daily 1.0 https://stg1.novartis.com/stories/migraine-one-worlds-most-common-diseases 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/new-years-resolution-copd 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/no-longer-living-fear 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/one-boys-quest-battle-cancer 2025-05-22T12:10:28+02:00 daily 1.0 https://stg1.novartis.com/stories/parenting-child-rare-disease 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/patient-advocacy-work-one-mans-contributions-copd-community 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/psoriasis-story-hidden-condition 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/putting-patients-first 2025-05-22T12:12:41+02:00 daily 1.0 https://stg1.novartis.com/stories/rare-every-day-experiences-challenges-and-victories-rare-disease-community 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/protecting-our-tomorrows-portraits-meningococcal-disease 2025-05-22T13:06:29+02:00 daily 1.0 https://stg1.novartis.com/stories/realities-living-premenopausal-metastatic-breast-cancer 2025-05-22T12:54:26+02:00 daily 1.0 https://stg1.novartis.com/stories/reimagining-asthma-care-how-data-and-digital-could-bring-asthma-management-goals-within-reach 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/surviving-heart-failure 2025-05-22T12:48:35+02:00 daily 1.0 https://stg1.novartis.com/stories/speaking-cml 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/targeting-roots-sjogrens-syndrome 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/tj-sharpe-why-clinical-trials-matter 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/visionary-silke-mader-has-vision-care-premature-infants-and-their-parents 2025-05-22T12:41:09+02:00 daily 1.0 https://stg1.novartis.com/stories/why-research-rare-diseases-matters 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/turning-sound-patient-voices-lung-cancer-research-and-development 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/flexibility-novartis-ana-graf 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/enabling-130000-employees-grow-organization-committed-continuous-learning 2021-09-29T10:38:57+02:00 daily 1.0 https://stg1.novartis.com/stories/your-genes-your-melanoma 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/flexibility-novartis-deepti-mittal 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/flexibility-novartis-christine-sturchler-and-aileen-wrynn 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/flexibility-novartis-janneke-van-der-kamp 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/flexibility-novartis-peter-canavan 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/flexibility-novartis-linda-karpiak 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/flexibility-novartis-robert-gschwentner-and-stefan-lackner 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/going-extra-mile-keep-clinical-trials-track-during-covid-19-pandemic 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-social-business-careers-improving-health-lower-income-countries 2025-05-22T15:01:59+02:00 daily 1.0 https://stg1.novartis.com/stories/oncology-careers-life-changing-purpose 2025-05-22T14:10:01+02:00 daily 1.0 https://stg1.novartis.com/stories/parental-leave-novartis-alfreds-story 2025-05-22T10:46:51+02:00 daily 1.0 https://stg1.novartis.com/stories/parental-leave-novartis-michaels-story 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/nudging-bias-out-organization 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/qa-new-nibr-cio-dimitris-agrafiotis 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/reimagining-cancer-workplace 2025-05-27T09:28:18+02:00 daily 1.0 https://stg1.novartis.com/stories/teaching-daughter-power-purpose 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/two-decades-volunteering-novartis 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/making-healthcare-sustainable-developing-world 2025-05-22T10:35:52+02:00 daily 1.0 https://stg1.novartis.com/stories/positive-gains-are-needed-accelerate-change-women-lung-disease 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/new-drugs-could-offer-hope-malaria-patients 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/partnering-improved-cancer-care-around-globe 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/pioneering-business-approach-expands-healthcare-indian-villages 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-joins-pharma-wide-effort-meet-global-demand-covid-19-vaccines 2025-05-22T10:26:33+02:00 daily 1.0 https://stg1.novartis.com/stories/new-orbis-flying-eye-hospital-helps-fight-blindness-china 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-access-impact-evaluation-progress-update-our-work-boston-university 2025-03-26T05:04:55+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-invites-scrutiny-effort-improve-access-medicine 2025-05-22T10:01:39+02:00 daily 1.0 https://stg1.novartis.com/stories/artificial-intelligence-decodes-cancer-pathology-images-without-image-gallery 2025-05-27T06:21:49+02:00 daily 1.0 https://stg1.novartis.com/stories/can-data-from-heart-disease-trial-lead-potential-cancer-treatment 2025-05-22T09:10:45+02:00 daily 1.0 https://stg1.novartis.com/stories/cancer-research-drives-breast-cancer-treatment-forward 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/discovery-gives-cystic-fibrosis-researchers-new-direction 2025-10-28T06:36:47+01:00 daily 1.0 https://stg1.novartis.com/stories/guidance-system-lights-path-drug-discovery 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/need-new-heart-disease-medicines-drives-wave-potential-therapies 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/researchers-boost-understanding-t-cell-therapy-blood-cancer 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/novartis-and-uc-berkeley-take-undruggable-proteins-new-collaboration 2025-05-22T09:03:34+02:00 daily 1.0 https://stg1.novartis.com/stories/striving-vanquish-leukemia 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/sourcing-innovation-strategically 2025-03-26T05:03:44+01:00 daily 1.0 https://stg1.novartis.com/stories/take-visual-tour-medicines-target-rna 2025-05-21T15:12:48+02:00 daily 1.0 https://stg1.novartis.com/stories/toward-improving-health-and-longevity-transplanted-organs 2025-05-21T14:29:38+02:00 daily 1.0 https://stg1.novartis.com/stories/using-super-resolution-microscopy-see-neurodegeneration 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/visualizing-molecular-glues 2025-05-21T14:18:17+02:00 daily 1.0 https://stg1.novartis.com/stories/advancing-medicine-through-collaboration 2025-10-28T06:35:49+01:00 daily 1.0 https://stg1.novartis.com/stories/how-19th-century-technology-speeding-drug-discovery 2025-05-21T14:13:56+02:00 daily 1.0 https://stg1.novartis.com/stories/seeing-through-knees-quest-alleviate-osteoarthritis 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/why-novartis-scouts-disruptive-technology 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/future-chronic-myeloid-leukemia-evolving 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/inspiring-daughter-make-her-own-path 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/being-and-becoming-data-science-company 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/doing-right-thing-good-business 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/discover-how-inflammation-could-fan-flames-cancer 2025-03-26T05:41:06+01:00 daily 1.0 https://stg1.novartis.com/stories/your-neighborhood-community-based-approach-health-equity-us 2025-03-26T05:35:18+01:00 daily 1.0 https://stg1.novartis.com/stories/search-new-options-patients-lung-cancer 2025-03-26T05:50:56+01:00 daily 1.0 https://stg1.novartis.com/stories/toward-regrowing-cartilage 2025-05-21T13:42:24+02:00 daily 1.0 https://stg1.novartis.com/stories/blood-cancer-patients-long-road-diagnosis 2025-05-21T13:21:24+02:00 daily 1.0 https://stg1.novartis.com/stories/photographer-captures-patients-around-world-persevering-itp 2025-05-21T13:07:31+02:00 daily 1.0 https://stg1.novartis.com/stories/expanding-new-digital-healthcare-solution-across-chronic-heart-disease-management 2021-10-11T08:39:32+02:00 daily 1.0 https://stg1.novartis.com/stories/restoring-vision-and-hope-thousands-southeast-asia 2023-02-06T10:13:26+01:00 daily 1.0 https://stg1.novartis.com/stories/demystifying-science-myelodysplastic-syndromes 2025-05-21T12:59:31+02:00 daily 1.0 https://stg1.novartis.com/stories/breaking-down-barriers-patients-sickle-cell-disease 2025-05-21T12:49:41+02:00 daily 1.0 https://stg1.novartis.com/stories/make-difference-start-patients 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/solving-puzzle-immunotherapy 2025-05-21T12:42:13+02:00 daily 1.0 https://stg1.novartis.com/stories/stopping-coronavirus-and-next-one 2025-05-21T11:23:10+02:00 daily 1.0 https://stg1.novartis.com/stories/art-drug-design-technological-age 2025-05-21T11:16:33+02:00 daily 1.0 https://stg1.novartis.com/stories/when-it-comes-cancer-theres-power-good-partner 2025-05-21T11:07:01+02:00 daily 1.0 https://stg1.novartis.com/stories/prioritizing-needs-patients 2023-02-06T10:10:30+01:00 daily 1.0 https://stg1.novartis.com/stories/understanding-hidradenitis-suppurativa-through-jasmines-eyes 2025-05-21T10:48:58+02:00 daily 1.0 https://stg1.novartis.com/stories/tackling-health-toll-climate-change 2025-05-21T10:43:27+02:00 daily 1.0 https://stg1.novartis.com/stories/staying-one-step-ahead-malaria-parasite 2025-05-21T09:50:31+02:00 daily 1.0 https://stg1.novartis.com/stories/boosting-access-cancer-care-where-its-needed-most 2022-06-13T09:30:28+02:00 daily 1.0 https://stg1.novartis.com/stories/how-emilys-act-bravery-inspired-wave-continued-innovation 2025-05-21T08:23:27+02:00 daily 1.0 https://stg1.novartis.com/stories/prostate-cancer-collective-commitment-serving-underserved-communities 2022-06-13T09:12:51+02:00 daily 1.0 https://stg1.novartis.com/stories/shared-mission-take-impossible-cancer-research 2025-01-30T15:41:42+01:00 daily 1.0 https://stg1.novartis.com/stories/sickle-cell-screening-urged-newborns-africa 2023-02-06T09:22:58+01:00 daily 1.0 https://stg1.novartis.com/stories/renewing-our-commitment-neglected-tropical-disease-and-malaria-elimination 2022-06-23T07:30:04+02:00 daily 1.0 https://stg1.novartis.com/stories/lets-talk-about-c-word-navigating-cancer-diagnosis-and-life-beyond-it-leanne-pero 2022-10-12T16:02:31+02:00 daily 1.0 https://stg1.novartis.com/stories/neuroscience-inflection-point-knowledge-and-technology 2025-05-21T08:15:30+02:00 daily 1.0 https://stg1.novartis.com/stories/scientist-from-start-qa-nibr-president-fiona-marshall 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/prostate-cancer-and-support-care-partner-carl-and-arlenes-story 2025-05-21T08:09:35+02:00 daily 1.0 https://stg1.novartis.com/stories/compassionate-use-providing-access-much-needed-treatments 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/when-you-think-word-cancer-what-are-first-words-spring-mind 2023-04-24T15:44:38+02:00 daily 1.0 https://stg1.novartis.com/stories/qa-addressing-unmet-needs-people-living-pnh-rare-and-chronic-blood-disorder 2023-08-29T14:32:50+02:00 daily 1.0 https://stg1.novartis.com/stories/future-medicine-here 2023-05-30T09:55:27+02:00 daily 1.0 https://stg1.novartis.com/stories/treatments-blood-cancers-and-serious-blood-disorders-are-advancing-rapidly-novartis-helping-lead-way 2023-09-08T15:13:36+02:00 daily 1.0 https://stg1.novartis.com/stories/belonging-here-how-novartis-helped-me-come-out-transgender-woman 2025-03-26T05:15:15+01:00 daily 1.0 https://stg1.novartis.com/stories/mentoring-matters-how-we-grow-together-novartis 2025-03-26T05:15:15+01:00 daily 1.0 https://stg1.novartis.com/stories/beacon-hope-lights-way-more-equitable-future 2023-11-30T18:38:42+01:00 daily 1.0 https://stg1.novartis.com/stories/shoulder-to-shoulder 2023-12-08T17:10:45+01:00 daily 1.0 https://stg1.novartis.com/stories/innovation-fueled-compassion 2023-12-14T09:16:07+01:00 daily 1.0 https://stg1.novartis.com/stories/balancing-family-life-legal-career 2024-02-07T13:56:41+01:00 daily 1.0 https://stg1.novartis.com/stories/facing-fear-breast-cancer-recurrence 2024-02-05T10:04:04+01:00 daily 1.0 https://stg1.novartis.com/stories/partnership-against-epilepsy 2024-02-05T10:10:58+01:00 daily 1.0 https://stg1.novartis.com/stories/water-project-revives-rural-community-india 2024-02-05T09:59:30+01:00 daily 1.0 https://stg1.novartis.com/stories/giving-voice-people-misunderstood-disease 2024-02-05T10:08:14+01:00 daily 1.0 https://stg1.novartis.com/stories/cancer-patient-gets-new-lease-life 2024-01-29T15:21:43+01:00 daily 1.0 https://stg1.novartis.com/stories/empowering-next-generation-healthcare-leaders 2024-01-29T15:23:04+01:00 daily 1.0 https://stg1.novartis.com/stories/going-upstream-improve-heart-health-philadelphia 2024-01-26T11:32:14+01:00 daily 1.0 https://stg1.novartis.com/stories/colombia-researcher-works-against-devastating-disease 2024-01-26T11:32:56+01:00 daily 1.0 https://stg1.novartis.com/stories/listening-cml-patient-community 2024-02-14T08:13:45+01:00 daily 1.0 https://stg1.novartis.com/stories/drug-delivery-service-delivery-and-future-cancer-care 2025-03-26T06:06:16+01:00 daily 1.0 https://stg1.novartis.com/stories/personal-journey-full-circle-from-curiosity-about-life-earth-transformative-therapies-novartis 2024-10-07T14:35:31+02:00 daily 1.0 https://stg1.novartis.com/stories/legacy-blood-cancer-innovation 2024-09-13T13:22:35+02:00 daily 1.0 https://stg1.novartis.com/stories/workplace-inclusion-really-important 2025-09-01T16:39:21+02:00 daily 1.0 https://stg1.novartis.com/stories/every-number-has-story-my-journey-novartis-refugee 2024-10-07T14:42:17+02:00 daily 1.0 https://stg1.novartis.com/stories/negative-impact-ira-patient-access-innovative-treatments 2024-10-07T14:38:11+02:00 daily 1.0 https://stg1.novartis.com/stories/addressing-unmet-needs-inherited-neuromuscular-diseases 2024-11-21T12:58:31+01:00 daily 1.0 https://stg1.novartis.com/stories/biologist-head-hunter 2025-02-05T17:28:48+01:00 daily 1.0 https://stg1.novartis.com/stories/parental-leave-leadership-opportunity 2025-02-28T15:51:39+01:00 daily 1.0 https://stg1.novartis.com/stories/marcs-story-raising-awareness-elevated-lpa-cardiovascular-disease 2025-03-24T09:35:58+01:00 daily 1.0 https://stg1.novartis.com/stories/science-motion-autumn-and-sabrinas-noteworthy-novartis-adventure 2025-04-22T07:34:05+02:00 daily 1.0 https://stg1.novartis.com/stories/why-advocating-your-ms-so-important 2025-05-22T13:24:47+02:00 daily 1.0 https://stg1.novartis.com/stories/how-novartis-helping-eliminate-leprosy 2026-02-04T09:06:40+01:00 daily 1.0 https://stg1.novartis.com/stories/whats-next-neuroscience-drug-discovery 2026-02-16T07:15:11+01:00 daily 1.0 https://stg1.novartis.com/stories/victor-bulto-and-thierry-diagana-named-2026-time100-health-list 2026-02-11T15:38:13+01:00 daily 1.0 https://stg1.novartis.com/stories/breaking-ground-global-health 2026-02-25T15:55:48+01:00 daily 1.0 https://stg1.novartis.com/stories/turning-personal-experience-purpose-driven-careers 2026-03-10T13:34:39+01:00 daily 1.0 https://stg1.novartis.com/stories/supercharging-rd-how-ai-helps-us-bring-medicines-patients-faster 2026-03-10T13:27:55+01:00 daily 1.0 https://stg1.novartis.com/stories/bringing-proteins-together-take-cancer-apart 2026-03-12T10:09:20+01:00 daily 1.0 https://stg1.novartis.com/stories/building-future-novartis-innovation-lab-ai-game-studio-xr-emerging-tech 2026-03-19T15:02:04+01:00 daily 1.0 https://stg1.novartis.com/careers/career-search/job/details/req-10022538-it-strategic-business-partner-usi-salesforce 2024-10-01T15:30:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10042198-qc-analyst 2025-11-25T12:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10029164-rechtsreferendar-mwd-der-rechtsanwaltsstation-oder-im-pflichtwahlpraktikum 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/393466br-patient-access-lead-0 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10049721-japan-program-head-immunology 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10047858-product-manager-hf-en-alternance 2026-01-21T07:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10048763-analyst-marketing-services 2025-12-03T01:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10053326-maintenance-technician 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10054151-intern-it 2025-11-01T08:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10054210-intern-finance 2025-11-01T08:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10013454-therapeutic-data-strategy-director 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10056628-ed-evidence-generation-ta-head-oncology 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10054444-principal-clinical-data-scientist 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10058488-data-steward 2025-12-03T01:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10051889-senior-principal-clinical-data-scientist 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059603-risk-surveillance-lead 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059647-veeva-development-lead 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059989-sales-executive 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10050524-senior-clinical-data-scientist 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10060203-snr-specialists-data-science-ai-data-digital-it 2025-12-03T01:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10060184-senior-specialist-it-solution-delivery-data-digital-it 2025-11-01T08:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10060406-snr-specialist-platform-services-data-digital-it 2025-11-01T08:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10020584-produktionsmitarbeiter-mwd-schaftenau-tirol-austria 2026-03-23T09:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10060710-isotope-project-lead 2026-03-24T15:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059402-ldc-data-business-manager-operations 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061532-produktionsmitarbeiter-mwd-befristet 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10060795-director-decision-science-portfolio-2-openings 2026-02-24T13:32:58+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10040602-senior-sap-security-identity-management 2025-11-13T08:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10062599-process-expert 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061530-tehnik-v-proizvodnji-farmacevtskih-ucinkovin-mzd 2026-03-18T08:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10021772-lehre-mechatronik-mfd 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10021773-lehre-elektrotechnik-mfd 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10021766-lehre-labortechnik-mfd 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064230-lehre-metalltechnik-mfd 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064317-reliability-engineer-maintenance-planning-wmd-50-einstellung 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10062668-genai-solution-architect 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064031-clinical-data-engineering-lead 2025-12-03T01:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10063581-head-erc-china 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065677-facilities-mechanic 2026-02-24T21:33:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10060374-specialist-laboratorijske-opreme-v-kontroli-kakovosti-mzd-ljubljana-menges 2026-03-12T13:31:04+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064325-production-technician 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10063514-director-evidence-generation 2025-11-12T11:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065561-early-talents 2025-11-13T13:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10056080-associate-rlt-lab-technician 2025-11-18T10:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066972-japan-program-head-oncology 2025-11-17T16:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067189-executive-assistant-coordinator 2025-11-18T13:31:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066857-vodja-inzeniringa-lokacije-mzd-site-engineering-head-mfd 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066912-ai-search-seo-manager 2026-02-24T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067259-executive-director-crm-innovation-labs 2026-01-07T22:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067285-vice-president-crm-product-management-lead 2026-04-02T21:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066861-senior-manager-field-capability-development-spanish-speaker 2026-02-13T08:32:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067260-executive-director-crm-product-strategy 2025-11-21T16:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066049-senior-business-analyst-veeva-clinical-vault 2025-11-21T17:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066772-engineering-specialist 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067456-head-legal-investigations-china 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067523-snr-specialist-itot-business-services-solutions-delivery 2025-12-19T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061108-patient-safety-group-manager 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067249-site-quality-head-mfd-vodja-kakovosti-mzd 2026-04-01T11:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067455-senior-manager-cgt-itotautomation 2026-03-04T17:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064030-senior-engineer-automation 2026-01-08T16:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067824-data-steward-en-alternance 2026-01-21T07:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067823-po-outils-canaux-digitaux-data-en-alternance 2026-01-21T07:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067826-stage-ingenieur-data 2026-01-21T07:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068192-production-lead 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067047-manufacturing-science-technology-experts 2025-12-05T14:31:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067046-engineering-experts 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067049-supply-chain-experts 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067048-manufacturing-experts 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061972-business-workstream-lead-ldc-lean-digital-core-gmt 2026-01-26T10:32:57+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10021760-lehre-chemieverfahrenstechnik-mfd-de-de 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065531-technical-steward-mwd-de-de 2025-12-09T13:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10051988-banco-de-talentos-para-consultores-tecnicos-es-es 2025-12-09T13:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059703-banco-de-talentos-para-pessoas-com-deficiencia-pcd-es-es 2025-12-09T13:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061501-associate-qa-officer-operations-ja-jp 2025-12-09T13:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067469-qa-manager-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068233-director-genetic-toxicology-expert 2025-12-10T12:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068156-chef-de-produit-rlt 2026-03-27T11:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068652-senior-project-engineermanager-level 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068341-odgovorna-oseba-za-sproscanje-zdravil-na-trg-mzd-qp-mfd 2026-03-18T12:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067629-senior-expert-science-technology-iii-prd 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10049041-onderhoudstechnieker-filling-bio 2025-12-15T12:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068410-senior-expert-human-factors-engineering 2025-12-22T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066763-validation-lead 2025-12-15T22:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066741-senior-principal-statistical-programmer 2025-12-16T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068643-area-sales-manager 2025-12-17T08:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068590-senior-technical-steward-medical-devices 2025-12-19T20:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068862-quality-experts 2025-12-18T15:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068836-senior-global-gcppv-auditor 2025-12-19T11:31:32+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069041-vodja-upravljanja-kakovosti-operacije-mzd-qa-operations-lead-mfd 2026-03-20T12:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068816-vodja-tehnoloskih-prenosov-mzd-technical-transfer-lead-mfd 2026-02-04T12:32:51+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10062245-director-integrated-field-insights-analytics 2026-01-20T05:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069097-qa-operations-supervisor 2025-12-26T16:31:03+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068777-project-qa-lead 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069203-sales-representative-oncology-taipei 2026-03-26T09:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068209-head-trade 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069078-private-marketout-pocket-product-manager 2026-01-05T14:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10063537-info-specialist-literature-intelligence 2026-01-05T05:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065347-global-monitoring-functional-excellence-lead 2026-01-12T11:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10047028-director-business-applications-ai-products 2026-03-24T18:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069223-principal-senior-principal-biostatistician 2026-01-06T21:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069222-associate-director-biostatistics 2026-01-07T01:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068829-production-lead-weekend-days 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068697-production-technician-weekend-nights 2026-01-07T06:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069051-head-corporate-comms 2026-01-07T08:31:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069282-material-coordinator 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069345-associate-director-statistical-programming 2026-01-09T17:31:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069343-senior-principal-statistical-programmer 2026-01-09T17:31:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067871-engineering-evergreen 2026-01-12T10:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069404-enterprise-security-architect-digital-workspace 2026-01-15T09:30:57+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069499-senior-principal-biostatistician 2026-01-13T16:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069438-kierownik-ds-kluczowych-klientow-kardiologia-wojewodztwo-lubelskie 2026-01-13T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068041-market-brands-manager 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066742-assoc-director-statistical-programming 2026-02-12T13:31:59+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065710-kierownik-ds-kluczowych-klientow-kardiologia-rybnik-czestochowa-kedzierzyn-kozle 2026-01-16T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066986-legal-intern 2026-01-23T10:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068064-portfolio-account-specialist-oncology-vic-part-time 2026-01-18T13:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069735-qc-manager 2026-01-19T17:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069927-senior-statistical-programmer 2026-01-20T02:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069927-senior-statistical-programmer-ja-jp 2026-01-20T02:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069822-administrative-assistant 2026-01-20T14:31:42+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067812-customer-engagement-specialist-ru-ru 2026-01-20T13:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-de-de 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-es-es 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-it-it 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-ja-jp 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-nl-nl 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-ru-ru 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-tr-tr 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069973-packaging-specialist-weekends-night-shift 2026-01-21T16:33:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067194-manager-scientific-writing 2026-01-22T12:33:31+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069743-head-portfolio-strategy-operations-neuroscience-gene-therapy 2026-01-26T21:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065124-director-policy-ja-jp 2026-01-23T03:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069390-expert-science-technology-ii 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065793-communications-governance-support-web-digital-optimization 2026-01-26T15:31:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059264-manager-implementation-planning-experience-design 2026-01-26T15:31:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070032-learning-delivery-manager 2026-02-25T15:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070332-mechaniker-fur-abfullung-und-visuelle-inspektion-mfd 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070063-buyer-mandarin-speaker-zh-cn 2026-01-29T02:34:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070223-allergy-territory-account-specialist-sacramentofresno 2026-01-29T15:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070070-country-promotion-manager-cardiology 2026-02-03T16:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070180-maintenance-technician 2026-01-30T02:32:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067898-site-it-specialist 2026-01-30T02:32:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068813-manager-scientific-writing 2026-01-30T10:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070390-principal-statistical-programmer 2026-01-30T13:33:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070657-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070571-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070661-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070651-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070663-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070553-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070731-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070856-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-de-de 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-es-es 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-it-it 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-ja-jp 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-nl-nl 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-ru-ru 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-tr-tr 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-zh-cn 2026-02-02T11:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070666-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070932-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065292-scientist-drug-product-development-senior-expert-science-technologymfd 2026-02-02T17:33:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070107-neuroscience-territory-account-specialist-grand-rapids-mi 2026-02-02T19:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070743-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070735-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070744-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070747-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070764-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070745-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070637-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070654-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070035-ekspert-tehnologije-izdelkov-mzd-product-steward-mfd 2026-02-03T08:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-de-de 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-es-es 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-it-it 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-ja-jp 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-nl-nl 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-ru-ru 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-tr-tr 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070297-ekspert-upravljanja-kakovosti-operacije-mzd 2026-02-03T11:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070999-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071127-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-de-de 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-es-es 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-it-it 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070486-associate-or-manager-phad-japan-ja-jp 2026-02-03T11:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-ja-jp 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-nl-nl 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-ru-ru 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-tr-tr 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070616-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070419-country-promotion-manager-immunology 2026-02-12T20:33:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069506-director-crm-product-owner-3-positions 2026-02-11T17:31:57+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-de-de 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-es-es 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-it-it 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-ja-jp 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-nl-nl 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-ru-ru 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-tr-tr 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071101-brand-manager-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-zh-cn 2026-02-04T03:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070902-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-de-de 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-es-es 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-it-it 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-ja-jp 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-nl-nl 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-ru-ru 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-tr-tr 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-zh-cn 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071230-logistics-manager 2026-02-04T10:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071266-senior-project-managerlocal-platform-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070283-production-support-engineer-mfd 2026-02-11T06:32:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071264-medical-advisor 2026-02-05T03:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071317-engineer-automation 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070943-qa-compliance-expert-sampling-and-manufacturing-mfd 2026-02-05T13:32:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071446-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-de-de 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-de-de 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-es-es 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-es-es 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-it-it 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-it-it 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-ja-jp 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-ja-jp 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-nl-nl 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-nl-nl 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-ru-ru 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-ru-ru 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-tr-tr 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-tr-tr 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-zh-cn 2026-02-05T12:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070343-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-zh-cn 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071213-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071049-kierownik-ds-kluczowych-klientow-kardiologia-wojewodztwo-mazowieckie 2026-02-05T17:32:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071371-key-account-manager-rlt-mazowieckie-podlaskie-lubelskie-swietokrzyskie-podkarpackie 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070791-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071435-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070929-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071460-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071479-brand-manager-ipa 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071184-strategy-manager 2026-02-06T11:31:39+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071397-process-improvement-manager-operational-excelence 2026-02-06T19:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059749-clinical-development-director-renal 2026-02-09T10:31:50+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070092-global-head-ai-and-data-privacy-legal 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10052215-senior-clinical-development-medical-director-renal 2026-02-09T15:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071199-medical-representative-disease-area-specialist 2026-02-10T09:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-de-de 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-es-es 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-it-it 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-ja-jp 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-nl-nl 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-ru-ru 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-tr-tr 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-zh-cn 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065816-associate-director-web-analytics 2026-02-10T12:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071511-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-10T14:31:31+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065811-associate-director-ai-innovation-lab-martech 2026-02-10T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071387-director-marketing-strategy-multiple-sclerosis 2026-02-11T02:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071611-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-11T02:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071710-content-operation-supervisor 2026-03-26T10:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-11T09:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-de-de 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-es-es 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-it-it 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-ja-jp 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-nl-nl 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-ru-ru 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-tr-tr 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-zh-cn 2026-02-11T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-11T12:34:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070090-data-analytics-and-tool-manager 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071842-gaojiquyushichangjingli 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-11T13:32:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071298-skrbnik-osnovnih-podatkov-materialov-mzd-site-master-data-expert-mfd 2026-02-11T16:32:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071843-quyushichangjingli 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-de-de 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-de-de 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-es-es 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-es-es 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-it-it 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-it-it 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-ja-jp 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-ja-jp 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-ja-jp 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071654-cluster-category-manager-general-ja-jp 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-nl-nl 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-nl-nl 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-ru-ru 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-ru-ru 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-tr-tr 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-tr-tr 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-zh-cn 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-zh-cn 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070904-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-12T10:31:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070330-supply-chain-dispatch-shipping-expert 2026-02-12T11:33:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070328-supply-chain-customer-service-agent 2026-02-12T11:33:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070255-senior-hse-expert 2026-02-12T12:32:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-de-de 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071852-senior-manager-field-capability-development-german-speaker 2026-02-13T08:32:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-es-es 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-it-it 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-ja-jp 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-nl-nl 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-ru-ru 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-tr-tr 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-zh-cn 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071532-priloznosti-za-iskalce-prve-zaposlitve-v-novartisu-v-sloveniji 2026-02-13T11:33:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072076-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-lingshou-zh-cn 2026-02-13T11:33:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071791-clinical-operations-country-head-france 2026-02-16T18:31:31+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072141-medical-safety-physician 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071828-qc-analyst-ii-labortechniker-mwd 2026-02-16T09:31:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071384-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-16T09:31:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071977-expert-science-technology-radiochemistry 2026-02-16T12:31:31+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072078-senior-expert-science-technology-radiochemistry 2026-02-16T12:31:31+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070121-senior-clinical-development-director-cardiovascularmetabolic 2026-02-17T16:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071948-qc-specialist-ii 2026-02-17T10:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071895-site-hse-head 2026-02-17T15:31:59+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070456-record-report-sr-specialist-es-es 2026-02-17T15:31:59+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069563-customer-engagement-associate-oncologia 2026-02-17T16:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072219-director-market-access-strategy-ta-onc 2026-02-18T22:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069001-operater-vizualne-kontrole-mdz-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-sl-si 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-sl-si 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-13T03:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-sl-si 2026-02-28T03:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069141-tehnik-v-proizvodnji-bioloskih-ucinkovin-mzd-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071882-specialist-upravljanja-kakovosti-za-podrocje-skladnosti-racunalniskih-sistemov-qa-ecompliance-specialist-mfd-sl-si 2026-03-12T10:31:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-sl-si 2026-02-24T03:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067472-operater-na-pripravisterilizaciji-ali-polnjenju-mzd-sl-si 2026-02-19T07:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072237-senior-manager-international-finance 2026-02-19T14:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066032-manager-integrated-field-insights-analytics 2026-03-04T17:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072463-sr-people-partner-er-lead 2026-02-23T07:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072578-technical-transfer-lead-wmd 2026-02-23T12:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071967-qc-analyst 2026-03-17T14:31:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072335-trial-vendor-senior-manager 2026-02-23T17:31:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072464-trial-vendor-senior-manager 2026-03-02T16:33:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071466-head-neuromuscular-diseases-translational-medicine 2026-02-23T20:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072397-dermatology-area-business-leader-san-francisco-ca 2026-02-23T23:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072494-qc-manager 2026-02-23T23:31:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066910-ai-search-seo-analyst 2026-02-24T11:32:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071085-senior-supply-chain-specialist-mfd 2026-02-24T12:32:50+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10063697-global-medical-director-cell-gene-therapy 2026-02-24T12:32:50+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072473-ekspert-upravljanja-kakovosti-i-mzd-qa-senior-manager-mfd 2026-03-06T11:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072629-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-25T04:33:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071663-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-25T04:33:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072563-senior-product-specialist 2026-03-30T06:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072758-senior-study-leader 2026-02-25T10:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070086-technisch-operator-packaging-visco-elastics 2026-02-25T22:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-de-de 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072787-validation-lead-gongyiyanzhengjingli 2026-03-09T06:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-es-es 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-it-it 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-ja-jp 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-nl-nl 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-ru-ru 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-tr-tr 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-zh-cn 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069230-sr-procurement-ai-analytics-lead 2026-02-26T06:31:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10050992-betriebswerker-maschinenbediener-bereich-herstellung-3-schichten-mwd-wehr-deutschland 2026-02-26T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072568-global-it-category-ai-transformation-manager 2026-02-26T10:31:39+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072292-site-quality-head-texas-ad-level 2026-02-26T23:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072294-site-quality-head-florida-ad-level 2026-02-26T23:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072492-senior-patent-attorney 2026-02-27T02:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-de-de 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-de-de 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-es-es 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-es-es 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-it-it 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-it-it 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-ja-jp 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-ja-jp 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-nl-nl 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-nl-nl 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-ru-ru 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-ru-ru 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-sl-si 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-sl-si 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-tr-tr 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-tr-tr 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-zh-cn 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-zh-cn 2026-02-27T06:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072773-assoc-director-sap-cloud-platform-integration 2026-02-27T09:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072898-medical-director-neuroscience-global-medical-affairs 2026-02-27T13:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072896-executive-medical-director-global-medical-affairs-neuroscience 2026-02-27T13:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065476-ad-engineering-design-construction 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065729-senior-expert-container-closure-integrity-mfd 2026-02-27T15:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072695-associate-director-field-insights-analytics-xportfolio 2026-03-23T21:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072691-associate-director-field-capability-development-innovation 2026-02-27T21:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072688-associate-director-field-portfolio-early-assets-gtm-analytics 2026-03-02T22:33:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072908-procurement-intern-wd-zh-cn 2026-02-28T04:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072912-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-02-28T06:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061762-field-product-specialist-cardiovascular-and-metabolism-nam-dinh-thai-binh 2026-03-02T05:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-02T07:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070275-associate-director-field-medical-execution-neuroscience 2026-03-02T10:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070270-associate-director-field-medical-execution-crm 2026-03-19T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072418-payroll-services-senior-expert 2026-03-02T10:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-de-de 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-de-de 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-es-es 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-es-es 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-it-it 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-it-it 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-ja-jp 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-ja-jp 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-nl-nl 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-nl-nl 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-ru-ru 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-ru-ru 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-sl-si 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-sl-si 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-tr-tr 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-tr-tr 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-zh-cn 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-zh-cn 2026-03-02T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065466-associate-director-biomedical-research-clinical-quality 2026-03-02T18:33:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068062-portfolio-account-specialist-oncology-qld-part-time 2026-03-03T00:33:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068789-head-public-affairs-taiwan 2026-03-03T02:33:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10037580-sr-manager-executive-communications 2026-03-03T06:32:58+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-de-de 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-es-es 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-it-it 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-ja-jp 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-nl-nl 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-ru-ru 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-sl-si 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-tr-tr 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070985-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-zh-cn 2026-03-03T07:32:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072957-business-analyst-marketing-platform-ops-manager-senior-manager 2026-03-03T09:32:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073057-field-product-specialist-oncology-immunology-hai-phong 2026-03-03T10:32:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072986-medical-affairs-head 2026-03-03T12:33:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073051-patient-journey-specialist-hcm 2026-03-03T11:32:55+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073059-regional-martech-operations-engagement-lead 2026-03-16T05:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073137-hse-specialist 2026-03-03T12:33:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072874-principal-scientist-compound-hub-lab-leader-compound-management 2026-03-03T17:33:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071377-scientist-analytical-science-and-technology 2026-03-06T16:31:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071377-scientist-analytical-science-and-technology 2026-03-06T16:31:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10058909-ed-head-analytics-engineering 2026-03-03T19:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072931-production-process-support-associate 2026-03-03T19:31:40+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072800-ed-decision-science-renal-ta-and-us-portfolio-product-strategy 2026-03-03T22:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072817-manager-nabave-tretjih-dobaviteljev-mzd-supply-operations-manager-mfd 2026-03-04T08:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071116-head-new-product-international-china 2026-03-04T08:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072827-specialist-mbr-designer 2026-03-04T10:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073021-senior-medical-science-liaison-oncology 2026-03-05T10:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073238-career-opportunities-engineering 2026-03-04T14:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064204-senior-patent-litigation-paralegal 2026-03-04T16:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073076-refs-managerfacility-manager 2026-03-04T18:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073147-early-clinical-development-physician-immunology 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-de-de 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-es-es 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-it-it 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-ja-jp 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-nl-nl 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-ru-ru 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-sl-si 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-tr-tr 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071783-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-05T06:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-de-de 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-de-de 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-es-es 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-es-es 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-it-it 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-it-it 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-ja-jp 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-ja-jp 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-nl-nl 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-nl-nl 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-ru-ru 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-ru-ru 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-sl-si 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-sl-si 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-tr-tr 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-tr-tr 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073218-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-zh-cn 2026-03-05T08:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070340-ekspert-tehnologije-izdelkov-mzd-product-steward-mfd 2026-03-05T13:31:45+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071553-medical-lead-rhumatology-en-stage 2026-03-05T14:31:39+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073410-vzorcevalec-mzd-sampling-operator-mfd 2026-03-05T15:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072530-value-access-head 2026-03-10T15:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071094-medical-science-liaison-msl-onc-prostate-radioligand-therapies-south-texas-remote 2026-03-05T23:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072860-executive-director-functional-ai-process-excellence-market-access 2026-03-05T23:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073074-senior-pipeline-manager 2026-03-24T09:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071170-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073375-field-product-specialist-cardiovascular-and-metabolism-hn 2026-03-06T04:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065078-team-head-clinical-label-management 2026-03-06T05:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073374-product-specialist-dermatology-sabah-and-sarawak 2026-03-06T09:31:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061610-payroll-expert 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073054-senior-legal-counsel-business-operations-launch-and-activation 2026-03-06T11:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069900-manager-ai-innovation 2026-03-06T13:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073131-manager-project-management-web-experience 2026-03-06T15:31:38+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072441-head-clinical-development-business-solutions 2026-03-09T10:31:31+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073208-regional-sales-manager 2026-03-09T06:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073630-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-de-de 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-es-es 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-it-it 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-ja-jp 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-nl-nl 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-ru-ru 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-sl-si 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-tr-tr 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-zh-cn 2026-03-09T08:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073402-process-unit-operator-temporary 2026-03-09T09:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071311-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071379-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073486-senior-expert-science-technology 2026-03-10T06:31:36+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073694-msl-lead-oncology 2026-03-09T22:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073695-msl-lead-crm-neuroscience 2026-03-09T22:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073498-director-phad-india 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067210-senior-product-specialist-oncology-hyderabad 2026-03-24T07:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-de-de 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-es-es 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-it-it 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-ja-jp 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-nl-nl 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-ru-ru 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-sl-si 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-tr-tr 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-zh-cn 2026-04-03T00:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073058-agentic-ai-engineer-ai-ds-bsi 2026-03-12T05:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065812-manager-innovation-lab-ai 2026-03-10T13:31:39+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073187-trial-vendor-associate-director 2026-03-10T17:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073178-trial-vendor-senior-manager 2026-03-10T17:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10063125-associate-director-change-delivery-and-operations 2026-03-10T19:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073365-senior-market-access-manager 2026-03-11T05:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-de-de 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-es-es 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-it-it 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-ja-jp 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-nl-nl 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073788-lab-equipment-senior-qc-specialist-ru-ru 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-ru-ru 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-sl-si 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-tr-tr 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-zh-cn 2026-03-11T11:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073233-tehnolog-proizvodnega-inzeniringa-lokacije-mzd 2026-03-11T12:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073880-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-11T14:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064353-director-oncology-data-science-lmw 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069704-recruitment-experience-partner-rep-lead-region-europe 2026-03-11T17:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073690-technology-product-associate-director 2026-03-13T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073693-logistics-planning-specialist-temporal-8-months 2026-03-11T19:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073333-associate-director-marketing-program-governance 2026-03-12T03:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070715-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073852-sr-business-excellence-insights-mgr 2026-03-12T06:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073036-associate-director-reporting-transformation-ai-enablement 2026-03-12T07:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073675-vodja-itot-proizvodne-lokacije-mzd-itot-site-head-mfd 2026-03-12T14:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069998-country-president-levant 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10047115-director-data-science 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073464-executive-director-marketing-strategy-car-t-immunology 2026-03-20T15:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073796-specialist-quality-control-raw-materials 2026-03-12T21:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073795-analyst-quality-control-raw-materials 2026-03-12T21:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073797-analyst-quality-control-physical-chemistry 2026-03-12T22:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073458-director-future-field-engagement-strategy-metrics-incentives 2026-03-13T18:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073451-director-future-field-engagement-strategy-engagement-methodology 2026-03-13T18:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073801-specialist-quality-control-physical-chemistry 2026-03-12T22:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073457-director-future-field-engagement-strategy-capabilities 2026-03-13T18:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073454-director-future-field-engagement-strategy-role-design 2026-03-13T18:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073450-director-future-field-engagement-strategy-customer-archetypes 2026-03-13T18:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073978-senior-manager-market-engagement-governance 2026-03-13T11:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074008-ad-market-engagement-governance 2026-03-13T09:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073731-assistant-strategy-manager 2026-03-30T09:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064533-manager-martech-product-analytics 2026-03-13T11:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074049-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066842-po-hr-business-partner 2026-03-13T14:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073812-cardiovascular-territory-account-specialist-flemington-nj 2026-03-30T16:33:46+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073874-global-gmp-senior-quality-auditor 2026-03-13T15:31:04+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073920-trial-vendor-associate-director-community-lead 2026-03-13T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074087-ai-enterprise-security-architect 2026-03-13T17:31:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073697-director-channel-pricing-strategy-advanced-platforms-multiple-positions 2026-03-13T18:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073713-oncology-sales-specialist-breast-womens-cancer-san-bernardino-ca 2026-03-13T18:31:43+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073919-maintenance-technician 2026-03-13T19:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073609-renal-rare-territory-account-specialist-fort-lauderdale-fl 2026-03-13T19:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074091-director-financial-controls-compliance-us 2026-03-13T20:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072288-dermatology-territory-account-specialist-burbank-san-luis-obispo-bakersfield 2026-03-26T20:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074016-allergy-territory-account-specialist-san-jose-ca 2026-03-13T23:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073597-renal-rare-regional-director-west 2026-03-15T23:31:03+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074046-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073130-data-analyst-marketing-automation-platforms 2026-03-16T05:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074128-equipment-engineer-i-zh-cn 2026-03-16T06:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073988-study-analyst 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072747-senior-rd-counsel 2026-03-16T09:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074038-expert-science-technology-oral-solid-dosage 2026-03-16T09:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072836-principal-scientist-bmd-study-coordinator-and-bmd-study-expert-bscbse-biomarkers 2026-03-16T09:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073629-principal-scientist-ii-biomarker-sample-management-bsm-biomarkers-development-bmd 2026-03-16T10:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074138-senior-technical-manager-mst-eso 2026-03-17T09:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072824-quality-team-leader-qc-mfd-de-de 2026-03-18T14:32:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074137-technical-manager-mst-eso 2026-03-17T09:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071373-associate-qa-compliance-expert-qms 2026-03-18T09:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073483-visji-ast-specialist-mzd 2026-03-16T16:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073481-ast-analitik-ii-mzd 2026-03-16T14:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074164-neuroscience-ms-area-business-leader-californianevada 2026-03-16T15:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073871-global-head-qa-operations-aseptics 2026-03-16T16:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073482-ast-specialist-iii-mzd 2026-03-16T16:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074182-elektro-messtechniker-calibration-supervisor-fur-prufmittelverwaltung-mwd-schaftenau-tirol-de-de 2026-03-16T17:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074182-elektro-messtechniker-calibration-supervisor-fur-prufmittelverwaltung-mwd-schaftenau-tirol 2026-03-16T17:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072704-enterprise-nhp-strategy-and-governance-lead 2026-03-16T17:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073811-time-service-delivery-expert 2026-03-25T12:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072862-manager-data-science 2026-03-17T06:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072861-manager-data-science 2026-03-17T06:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072863-associate-director-data-science 2026-03-17T06:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071217-senior-expert-medical-device-analytical-representative-mfd 2026-04-01T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074180-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-17T07:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074136-sales-and-marketing-manager-oncology-radioligand-therapy-area-gulf-cluster 2026-03-17T08:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074210-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-sl-si 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073136-senioradvanced-medicalsales-representative-zh-cn 2026-03-17T08:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074212-field-product-specialist-cardiovascular-and-metabolism-hcm 2026-03-17T09:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064222-director-regulatory-affairs-digital-medical-devices 2026-03-17T10:31:46+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074216-process-expert-mfd-halle-saale-sachsen-anhalt-de-de 2026-03-17T11:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073842-manager-vendor-business-office 2026-03-17T13:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074234-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071158-senior-manager-regulatory-affairs-cmc 2026-03-17T15:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073448-process-expert-aseptic-drug-products-adp-process-support 2026-03-17T16:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065854-director-launch-excellence-strategy-1-2 2026-03-19T19:31:46+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073583-ultra-rare-disease-territory-account-specialist-phoenix-az 2026-03-17T18:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073577-ultra-rare-disease-territory-account-specialist-denver-co 2026-03-26T23:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074201-director-psl-car-t-immunology 2026-03-17T21:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069505-ed-crm-product-owner-data-ai 2026-03-17T21:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074294-statutory-lead 2026-03-18T02:31:24+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069909-manager-medical-data-enablement 2026-03-18T08:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10066592-validation-expert-fmd-kurtkoy-istanbul 2026-03-18T10:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071421-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072628-sourcing-manager-network-services 2026-03-18T12:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073843-business-operations-manager-bom-tactical 2026-03-18T13:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074263-expert-engineering-device-development-mfd 2026-03-18T13:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073841-document-quality-management-associate-director 2026-03-18T13:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074097-qa-operations-manager-qp 2026-03-18T14:32:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072906-manager-data-governance 2026-03-18T14:32:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074165-mekanik-teknisyeni-kurtkoy-istanbul 2026-03-18T14:32:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067825-support-applicatif-outils-canaux-digitaux-en-alternance 2026-03-18T15:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073809-clinical-program-leader-senior-clinical-program-leader-translational-clinical-oncology-dual-posting 2026-03-18T15:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067673-senior-medical-information-manager-i 2026-03-24T09:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074070-gfmd-junior-fi-co-specialist 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073513-director-nps-field-engagement-strategy-remote-multiple-positions 2026-03-18T17:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074022-director-oncology-translational-research 2026-03-18T16:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073556-ultra-rare-disease-territory-account-specialist-long-island-ny 2026-03-18T17:31:35+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10043997-ed-personalized-precision-medicine 2026-03-18T18:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074009-associate-director-analytics-automation-reusability 2026-03-18T20:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074281-ed-decision-science-product-lead-hematology 2026-03-18T21:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073806-quality-control-specialist 2026-03-18T22:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073938-senior-principal-scientistassociate-director-pk-sciences-dual-level-posting 2026-03-18T22:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073939-principal-scientist-i-or-ii-pk-sciences-therapeutic-areas-dual-level-posting 2026-03-18T22:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-sl-si 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074324-h2r-services-manager-china 2026-03-19T05:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-de-de 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073545-study-start-senior-lead 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-es-es 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-it-it 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-ja-jp 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-nl-nl 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-ru-ru 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-sl-si 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-sl-si 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-tr-tr 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-zh-cn 2026-03-19T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-sl-si 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073923-director-translational-medicine-expert-clinical-pharmacology 2026-03-19T15:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073643-vodja-projektne-pisarne-razvoja-bioloskih-ucinkovin-mzd-associate-director-drug-substance-development-dsd-project-management-si-mfd 2026-03-19T16:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074096-associate-director-portfolio-strategy-operations 2026-03-19T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074172-senior-manager-operational-excellence 2026-03-20T07:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073940-director-nonclinical-safety-assessment-expert-multiple-therapeutic-areas 2026-03-24T19:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074082-renal-rare-territory-account-specialist-knoxvillenashville 2026-03-19T19:31:46+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073537-ra-submission-production-capability-lead 2026-03-19T22:31:37+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073478-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067105-senior-expert-science-technology 2026-03-20T04:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-ru-ru 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-sl-si 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-tr-tr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074463-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-20T10:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072482-global-talent-acquisition-business-partner-mexico-us-lacan 2026-03-20T11:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072943-sr-analyst-payor-access-reimbursement-ia 2026-03-20T12:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074285-process-expert 2026-03-20T12:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074183-country-head-customs-trade-compliance 2026-03-20T12:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074083-therapeutic-area-biomarker-leadbiomarker-strategy-cardiovascular-and-metabolism 2026-03-20T13:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074286-manufacturing-systems-expert 2026-03-20T13:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074162-qa-compliance-specialist-i-specialist-upravljanja-kakovosti-skladnost-i 2026-03-20T13:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074221-senior-expert-engineering-device-development 2026-03-20T13:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074084-therapeutic-area-biomarker-leadbiomarker-strategy-cardiovascular-and-metabolism 2026-03-20T14:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073546-associate-director-it-business-analyst 2026-03-23T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074507-sr-spec-maintenance-planner-scheduler 2026-03-20T15:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074088-portfolio-pathologist-anatomic 2026-03-20T15:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074114-investor-relations-executive-director 2026-03-20T15:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074219-itot-specialist-mfd-itot-spezialist-mwd 2026-03-26T15:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074532-clinical-development-postgraduate-fellow-ireland 2026-03-23T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074200-specialist-supplier-quality 2026-03-20T16:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074534-clinical-development-postgraduate-fellow-uk 2026-03-20T16:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069509-cardiovascular-territory-account-specialist-columbus 2026-03-20T16:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074350-clinical-development-postgraduate-fellow-ch 2026-03-20T16:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073724-ldc-operations-business-cutover-lead 2026-03-20T19:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074025-oncology-sales-specialist-breastwomens-cancer-seattle 2026-03-20T19:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074026-oncology-sales-specialist-breast-womens-cancer-portland-or 2026-03-20T19:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068170-campaign-delivery-manager 2026-03-20T20:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065908-senior-expert-dsp-development-mfd 2026-03-20T21:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074105-medical-science-liaison-msl-onc-prostate-radioligand-therapies-ky-tn-and-wv-remote 2026-03-21T03:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10007713-alternant-controle-de-gestion-bpa-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067679-head-ddit-china-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070974-senior-brand-manager-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071152-gaojiquyushichangjingli-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070852-gaojidequjingli-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071263-senior-sales-executive-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071284-senior-brand-manager-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070869-guangkuoshichangjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071274-e-commerce-manager-o2o-fr-fr 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071249-marketing-director-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071255-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070868-guangkuoshichangjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071400-senior-sales-executive-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071166-gaojiquyushichangjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071826-senior-brand-manager-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071742-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071847-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071846-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071267-guangkuoshichangjingli-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071509-guangkuoshichangjingli-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071946-senior-marketing-manager-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072759-gaojiquyushichangjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072825-medical-science-liaison-immu-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072826-medical-science-liaison-immu-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071636-sr-manager-retail-marketing-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071439-sr-business-insight-strategy-manager-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073034-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073042-medical-advisor-manager-immu-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073043-msl-manager-immu-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073120-medical-advisor-immu-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073009-quyushichangjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071441-gaojidequjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073362-medical-advisor-neuroscience-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073628-brand-manager-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073626-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073719-gaojidequjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073501-app-market-access-expert-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073849-sales-manager-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073444-stg-medical-lead-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073668-app-market-access-expert-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073524-technicien-de-production-cdd-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071468-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073753-app-alternant-affaires-publiques-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074139-field-support-specialist-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074151-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-27T06:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072984-qc-analyst-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074315-project-expert-development-china-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072954-site-maintenance-technician-l-specialist-compounding-fr-fr 2026-03-21T13:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074378-early-clinical-development-physician-cvm-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072808-senior-regulatory-affairs-manager-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074460-quyushichangjingli-fr-fr 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072687-head-drug-substance-project-leadership 2026-03-22T23:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073928-engineering-lead-trd-rlt 2026-03-22T23:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-de-de 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-es-es 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-fr-fr 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-it-it 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-ja-jp 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-nl-nl 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-ru-ru 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-sl-si 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-tr-tr 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074509-senior-brand-manager-zh-cn 2026-03-23T02:31:22+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074429-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074427-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070772-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073743-manager-brand-medical-and-finance-data-enablement 2026-04-02T04:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073844-director-productivity-m365-platforms-infrastructure-services 2026-03-23T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074565-qc-analyst-iii 2026-03-23T06:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074568-japan-program-manager-development-ja-jp 2026-03-23T06:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073757-gcp-compliance-manager-program-study 2026-03-23T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074584-clinical-development-fellow 2026-03-23T09:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074146-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-23T08:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064681-global-regulatory-affairs-associate-director-cardio-metabolic 2026-03-23T09:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10065090-drug-product-project-leader-mfd-associate-director-science-technology 2026-03-23T10:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073999-manager-bsi-consulting-program-management-pmo-focus 2026-03-23T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074389-instructional-designer-learning-bsi-consulting-program-management 2026-03-23T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074335-nitrosamines-specialist-mfd-kurtkoy-istanbul 2026-03-23T11:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074605-value-access-head 2026-03-23T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073386-laboratorijski-analitik-v-bioanalitskem-laboratoriju-mzd 2026-03-23T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073982-quality-control-analyst-mfd-kurtkoy-istanbul 2026-03-23T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074218-projektni-vodja-zivljenskega-cikla-izdelka-ekspert-mzd-product-lifecycle-project-manager-expert-mfd-sl-si 2026-03-24T08:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073857-manager-oskrbovalne-verige-eso-mzd-manager-eso-supply-chain-mfd-sl-si 2026-03-24T08:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073917-director-translational-medicine-expert-clinical-pharmacology 2026-03-23T14:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074636-recruitment-experience-partner-flex 2026-03-23T14:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073878-expert-qualification-and-automation-ao-mfd 2026-03-23T14:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070065-s2p-business-partner-lead 2026-03-23T15:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072287-site-quality-head-mwd 2026-03-23T15:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074282-clinical-biospecimen-senior-scientist 2026-03-23T15:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074121-associate-director-ai-analytics-customer-engagement 2026-03-23T15:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074626-assoc-director-ddit-dev-clinical-enablement-it-business-analyst 2026-03-23T16:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074412-global-program-clinical-head-neuroscience 2026-03-23T16:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074639-recruitment-experience-partner-flex 2026-03-23T16:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072387-manager-innovation-lab-xr-solutionist-extended-reality 2026-03-23T16:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072987-associate-director-innovation-lab-content-assets-delivery 2026-03-23T16:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072169-qa-officer 2026-03-23T17:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073550-data-analytics-platform-head 2026-03-23T17:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071009-clinical-development-medical-director-cdmd-neuroscience 2026-03-23T18:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073704-director-data-strategy-value-delivery 2026-03-23T19:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074354-medical-science-liaison-csu-ontario 2026-03-23T19:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074653-production-technician-ii-shengchanjishuyuan 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073472-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-24T03:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068234-director-genetic-toxicology-expert 2026-03-24T04:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10059478-executive-director-analytics-aide-insights-decisions 2026-03-24T06:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074466-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-24T06:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068839-global-process-owner-manufacturing-execution-serialization-product-tracking 2026-03-24T07:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068398-strategic-account-manager-rlt 2026-03-24T07:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073248-associate-director-medical-information 2026-03-24T08:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070501-central-monitor 2026-03-24T08:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071638-digital-finance-manager-analytics-operations 2026-03-24T08:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073634-quality-operations-process-specialist 2026-03-24T08:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074322-seniorprincipal-scientist-ii-bmd 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073414-laboratorijski-analitik-mzd 2026-03-24T09:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074332-sales-representative-neuroscience-kaohsiung 2026-03-24T10:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074327-sales-representative-neuroscience-taipei 2026-03-24T10:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074587-znanstveni-svetovalec-v-tehnicnem-razvoju-mzd-senior-expert-science-technology-mfd 2026-04-02T07:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074053-process-expert-mfd-de-de 2026-03-30T10:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073133-qc-analyst-ii 2026-03-24T11:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073588-ultra-rare-disease-territory-account-specialist-beverly-hills-ca 2026-03-24T13:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069978-global-medical-affairs-director-autoimmune-diseases 2026-03-30T15:33:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073589-ultra-rare-disease-territory-account-specialist-sacramento-ca 2026-03-24T13:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073584-ultra-rare-disease-territory-account-specialist-salt-lake-city-ut 2026-03-24T13:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072955-qualified-person 2026-03-24T13:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074585-ast-laboratorijski-analitik-v-bioloskih-ucinkovinah-menges-mzd 2026-03-24T14:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071962-project-manager-mfd 2026-03-24T14:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071367-central-monitor 2026-03-24T14:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071483-head-qa-ops-and-compliance 2026-03-24T14:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074675-medical-crm-neuroscience-head 2026-03-24T14:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074530-maintenance-technician-es-es 2026-03-24T14:31:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073566-ultra-rare-disease-territory-account-specialist-miami-fl 2026-03-24T15:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074492-portfolio-strategy-director-neuroscience 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073893-raziskovalec-mst-mzd-scientist-mst-mfd-downstream-process 2026-03-24T15:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073564-ultra-rare-disease-territory-account-specialist-jacksonville-fl 2026-03-24T15:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073902-raziskovalec-mst-mzd-scientist-mst-mfd-upstream-process 2026-03-24T15:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074289-ldc-business-lead 2026-03-24T16:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073574-ultra-rare-disease-territory-account-specialist-chicago 2026-03-24T16:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073572-ultra-rare-disease-territory-account-specialist-indianapolis 2026-03-24T16:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073569-ultra-rare-disease-territory-account-specialist-cincinnati 2026-03-24T16:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073570-ultra-rare-disease-territory-account-specialist-richmond 2026-03-24T16:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-de-de 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073557-ultra-rare-disease-territory-account-specialist-jersey-city-nj 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073554-ultra-rare-disease-territory-account-specialist-hartford-ct 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-es-es 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-fr-fr 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-it-it 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-ja-jp 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-ja-jp 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-nl-nl 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-ru-ru 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-sl-si 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-tr-tr 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074725-brand-manager-zh-cn 2026-03-24T17:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067275-renal-rare-disease-territory-account-specialist-st-louis-mo 2026-03-24T18:31:29+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074569-congress-and-digital-channel-partner 2026-03-25T01:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074632-gene-therapies-regional-director-east 2026-03-24T20:32:46+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074002-director-marketing-strategy-radioligand-therapy 2026-03-24T22:31:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074363-director-product-strategy-value-realization 2026-03-24T23:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074371-director-platform-enablement-4-positions 2026-03-25T00:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074365-director-product-strategy-2-positions 2026-03-25T00:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074376-director-product-design-2-positions 2026-03-25T00:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074538-renal-rare-territory-account-specialist-san-jose-ca 2026-03-25T01:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074503-maintenance-lead 2026-03-25T02:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074505-technical-services-lead 2026-03-25T02:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074689-sso-feasibility-manager 2026-03-25T02:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-de-de 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-es-es 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-fr-fr 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-it-it 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-ja-jp 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-nl-nl 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-ru-ru 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-sl-si 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-tr-tr 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071941-medical-science-liaison-csu-zh-cn 2026-03-25T03:31:23+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-de-de 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-de-de 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-de-de 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-es-es 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-es-es 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-es-es 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-fr-fr 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-fr-fr 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-fr-fr 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-it-it 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-it-it 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-it-it 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-ja-jp 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-ja-jp 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-ja-jp 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-nl-nl 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-nl-nl 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-nl-nl 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-ru-ru 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-ru-ru 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-ru-ru 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-sl-si 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-sl-si 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-sl-si 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-tr-tr 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-tr-tr 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-tr-tr 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-zh-cn 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-zh-cn 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-zh-cn 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068854-regulatory-affairs-head-vietnam 2026-03-25T07:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073726-associate-manager-scientific-writing 2026-03-25T07:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074791-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T03:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074696-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-25T08:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071691-technischer-produktionmitarbeiter-mwd-halle-saale-sachsen-anhalt 2026-03-25T09:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10062736-director-provider-master-data-management 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061065-associate-director-provider-master-data-management 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070830-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074495-facilities-engineer 2026-03-25T12:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074716-legal-trainee-novartis-corporate-functions-de-de 2026-03-25T13:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072893-senior-administrative-assistant 2026-03-25T13:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072500-global-quality-controlanalytical-science-and-technology-head 2026-03-25T14:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072337-materials-operator 2026-03-25T14:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-de-de 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074325-sr-business-analyst-ddit-dev-ra 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-ru-ru 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-ru-ru 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-ru-ru 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-sl-si 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-sl-si 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-sl-si 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-tr-tr 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-tr-tr 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-tr-tr 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074692-key-account-executive-zh-cn 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074691-key-account-executive-zh-cn 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074129-brand-manager-zh-cn 2026-03-25T06:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074577-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068854-regulatory-affairs-head-vietnam 2026-03-25T07:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073726-associate-manager-scientific-writing 2026-03-25T07:31:18+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074791-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074696-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-25T08:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074686-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071691-technischer-produktionmitarbeiter-mwd-halle-saale-sachsen-anhalt 2026-03-25T09:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10062736-director-provider-master-data-management 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061065-associate-director-provider-master-data-management 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074806-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070830-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-25T10:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074495-facilities-engineer 2026-03-25T12:31:27+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074716-legal-trainee-novartis-corporate-functions-de-de 2026-03-25T13:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072893-senior-administrative-assistant 2026-03-25T13:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072500-global-quality-controlanalytical-science-and-technology-head 2026-03-25T14:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072337-materials-operator 2026-03-25T14:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-de-de 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074325-sr-business-analyst-ddit-dev-ra 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-es-es 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-fr-fr 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-it-it 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-ja-jp 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-nl-nl 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-ru-ru 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-sl-si 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-tr-tr 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073737-qa-officer-operations-zh-cn 2026-03-25T15:31:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074750-principal-scientist-adpkd-biology-lead-renal-research 2026-03-25T16:31:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074555-senior-scientist-assay-development-screening 2026-03-25T21:31:03+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074735-qc-analyst-microbiology 2026-03-25T21:31:03+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074734-qc-analyst-microbiology 2026-03-25T21:31:03+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074421-allergy-territory-account-specialist-syracusebuffalo-ny 2026-03-25T23:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072607-portfolio-account-specialist-vic-west-oncology 2026-03-25T23:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073433-medical-director-rheumatology-remote 2026-03-26T00:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074780-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074143-supplier-governance-specialist 2026-03-26T06:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074685-people-partner-team-lead 2026-03-26T06:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072789-tehnolog-proizvodnih-procesov-ii-mzd-process-expert-ii-mfd 2026-03-26T07:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074869-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074873-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-de-de 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073839-time-services-specialist 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074787-clinical-operations-manager 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-es-es 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-fr-fr 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-it-it 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-ja-jp 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-nl-nl 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-ru-ru 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-sl-si 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-tr-tr 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074890-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-26T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074886-global-clinical-operations-study-start-manager-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074784-clinical-sciences-associate-director 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074786-clinical-sciences-trial-leader 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074785-senior-clinical-sciences-trial-leader 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074831-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-26T09:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073946-gaojidequjingli-de-de 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073946-gaojidequjingli 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073946-gaojidequjingli-es-es 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073946-gaojidequjingli-fr-fr 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073946-gaojidequjingli-it-it 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074925-marketing-associate-nl-nl 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074925-marketing-associate-ru-ru 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074925-marketing-associate-sl-si 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074925-marketing-associate-tr-tr 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074925-marketing-associate-zh-cn 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074793-automation-sr-manager 2026-03-26T22:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073581-ultra-rare-disease-territory-account-specialist-dallas-tx 2026-03-26T23:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074926-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074904-global-clinical-operations-portfolio-team-lead 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074951-field-product-specialist-cardiovascular-ha-noi 2026-03-27T04:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071163-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-27T04:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071514-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-27T04:31:20+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072914-dam-librarian 2026-03-27T07:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074351-trial-vendor-associate-director 2026-03-27T07:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070068-senior-manager-refs-finance 2026-03-27T09:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071102-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-27T09:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10064113-computational-biologistexpert-i-data-science-80-100-junior-position 2026-04-01T00:32:00+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069127-therapy-area-head-cardiovascular 2026-03-27T11:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074092-senior-technical-manager-drug-substance 2026-03-27T11:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061176-technical-project-manager-clinical-enablement-team 2026-03-27T11:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074600-vodja-izmene-mzd 2026-03-27T12:31:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074843-executive-medical-director-rlt 2026-03-27T13:33:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074933-senior-clinical-trial-leader-translational-medicine 2026-03-27T14:33:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074934-associate-director-clinical-sciences-translational-medicine 2026-03-27T14:33:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074614-clinical-pharmacology-trial-leader-trial-leadership-translational-medicine 2026-03-27T14:33:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074777-fixed-asset-sr-specialist-es-es 2026-03-27T14:33:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074393-head-data-privacy-and-ai-europe-legal 2026-03-27T15:33:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071503-representante-de-ventas-inmunologia 2026-03-27T15:33:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074804-operater-mzd 2026-03-27T15:33:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074779-finance-control-and-compliance-manager-es-es 2026-03-27T15:33:48+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074849-ed-functional-ai-process-excellence-ids 2026-03-27T16:33:59+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074447-basel-campus-development-coordinator 2026-03-27T16:33:59+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074448-facilities-management-lead 2026-03-27T16:33:59+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074770-senior-clinical-research-associate-remote-position 2026-03-27T19:33:51+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074989-game-studio-solutionist 2026-03-27T17:33:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074990-manager-innovation-lab-emerging-marketing-solutions-ems 2026-03-27T18:33:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073118-head-customer-excellence 2026-03-27T20:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073601-sales-rep-sr-oncologia-rio-de-janeiro-pt-br 2026-03-27T20:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074558-rheumatology-territory-account-specialist-springfield-mo 2026-03-27T21:33:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074769-cardiovascular-territory-account-specialist-boise 2026-03-27T21:33:34+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074861-process-engineer-iii 2026-03-27T23:33:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074860-senior-manager-asset-lifecycle-management 2026-03-27T23:33:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074303-director-science-technology-scientific-office-ds 2026-03-29T22:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074192-associate-director-web-operations-remote 2026-03-30T17:33:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074976-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074964-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-30T04:31:14+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074969-global-clinical-operations-clinical-project-manager 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10058282-japan-program-clinical-head-crm 2026-03-30T05:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10060492-mst-technical-manager 2026-03-30T06:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074970-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074980-director-technical-project-portfolio-management-mfd 2026-03-30T07:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074346-ekspert-mednarodne-trgovine-mzd 2026-03-30T08:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074910-associate-manager-pe-governance-office 2026-03-30T09:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074991-associate-director-innovation-lab-innovation-practice 2026-03-30T10:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074982-senior-scientific-engagement-program-manager 2026-03-31T08:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074170-global-category-manager-marketing-agencies 2026-03-30T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074907-senior-manager-engagement-services-operations-hcp 2026-03-30T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074406-project-engineer 2026-04-02T12:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074906-manager-engagement-services-operations-hcp 2026-03-30T12:31:19+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072295-quality-assurance-officer-operations-mwd 2026-03-30T13:33:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074914-hr-specialist-operations-turkish-speaker 2026-03-30T13:33:30+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-de-de 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074450-head-design-construction-management 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-es-es 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-fr-fr 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-it-it 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-ja-jp 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-nl-nl 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-ru-ru 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-sl-si 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-tr-tr 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074360-global-program-safety-lead-zh-cn 2026-03-30T14:33:53+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072605-gcp-compliance-manager-program-study 2026-03-30T15:33:26+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073688-visji-specialist-kontrole-kakovosti-v-bioanalitskem-laboratoriju-mzd 2026-03-30T16:33:46+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10051977-salesforce-marketing-cloud-engagement-platform-expert 2026-03-30T17:33:52+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074553-expertsenior-expert-data-science 2026-04-01T15:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069388-director-product-strategy-lead-radioligand-therapy 2026-03-30T18:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074654-tender-associate-es-es 2026-03-30T18:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-de-de 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074853-material-buyerplanner 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-es-es 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075144-sales-representative-oncology-cdmx-es-es 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-fr-fr 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-it-it 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-ja-jp 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-nl-nl 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-ru-ru 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-sl-si 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-tr-tr 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074108-access-strategy-manager-zh-cn 2026-03-30T19:33:44+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070448-operations-specialist 2026-03-30T20:31:49+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072479-sales-value-manager 2026-03-30T21:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070451-regional-director-msls-onc-radioligand-therapies-south-east-region-atl-remote 2026-03-30T23:31:17+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074909-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-03-31T03:31:41+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074795-associate-director-tppm 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074792-senior-expert-ii-tppm 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074708-clinical-trial-supply-manager 2026-03-31T05:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067389-market-research-manager 2026-03-31T05:31:15+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074833-specialist-quality-operations 2026-03-31T07:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074829-specialist-quality-operations 2026-03-31T07:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074835-assoc-dir-ddit-ies-hpc-infrastructure-sr-engineer 2026-03-31T08:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070975-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075173-biomarker-lead 2026-04-03T06:30:54+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073745-product-expert-it-it 2026-03-31T09:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075037-senior-scientific-writer-ii 2026-03-31T10:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072414-gcp-compliance-manager-emea-hub 2026-03-31T10:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-de-de 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073741-tehnik-v-proizvodnji-bioloskih-ucinkovin-mzd 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074446-manager-nabave-tretjih-dobaviteljev-mzd-supply-operations-manager-mfd 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-es-es 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-fr-fr 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-it-it 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-ja-jp 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-nl-nl 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-ru-ru 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-sl-si 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-tr-tr 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-zh-cn 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072571-junior-manufacturing-technician 2026-03-31T12:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073822-oncology-specialist-rlt-prostate-atlanta-south 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061182-global-program-associate-director 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074913-process-engineer-iii 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074919-clinical-development-medical-director 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073918-project-engineer-capex-lead-es-es 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074455-director-international-value-access-ns 2026-04-01T17:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074752-pricing-director-ns 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072425-recruitment-experience-partner-rep-dutch-or-spanish 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074459-international-heor-hta-director-ns 2026-04-01T17:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072003-recruitment-experience-partner-rep-dach 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068634-medical-information-agent 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072026-recruitment-experience-partner-rep-dach 2026-03-31T18:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075119-senior-clinical-research-associate-remote-position 2026-03-31T21:31:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074977-associate-director-risk-assurance-uk-spain 2026-03-31T22:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075115-project-manager-implementation-electronic-billing-temporary 2026-03-31T22:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071626-field-product-specialist-cardiovascular-hcm 2026-04-01T04:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067449-field-product-specialist-oncology-hcm 2026-04-01T04:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071404-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075200-senior-international-trade-analyst 2026-04-01T06:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075179-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075239-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-01T06:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072932-manager-payor-access-reimbursement-ia 2026-04-01T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074226-senior-analyst-content-analytics 2026-04-01T10:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074965-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-01T10:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073046-therapy-area-partner-cardiovascular-riyadh 2026-04-01T11:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073251-key-account-manager-riyadh 2026-04-01T11:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075254-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-03T05:30:56+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070148-manager-ai-innovation 2026-04-01T12:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074481-early-talent-program-automation-engineer 2026-04-01T12:31:16+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-de-de 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075170-gxp-training-learning-business-partner 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075252-head-data-digital-it-enterprise-architecture 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-es-es 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-fr-fr 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-it-it 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-ja-jp 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-nl-nl 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-ru-ru 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-sl-si 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-tr-tr 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/global-category-manager-it-software-zh-cn 2026-04-01T13:31:11+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069575-cardiovascular-territory-account-specialist-hollywood-fl 2026-04-01T15:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072547-allergy-area-business-leader-pacific-northwest 2026-04-01T17:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074542-senior-expert-bioinformatics 2026-04-01T19:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074370-director-crm-product-operations 2026-04-01T19:31:21+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069858-manager-master-data-management 2026-04-01T20:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074367-director-crm-portfolio-management 2026-04-01T21:31:01+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-de-de 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10069901-manager-payer-mdm 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073741-tehnik-v-proizvodnji-bioloskih-ucinkovin-mzd 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074446-manager-nabave-tretjih-dobaviteljev-mzd-supply-operations-manager-mfd 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-es-es 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-fr-fr 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-it-it 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-ja-jp 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-nl-nl 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-ru-ru 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-sl-si 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-tr-tr 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074742-production-technician-temporary-zh-cn 2026-03-31T11:31:05+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072571-junior-manufacturing-technician 2026-03-31T12:31:33+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-de-de 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-de-de 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073822-oncology-specialist-rlt-prostate-atlanta-south 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10061182-global-program-associate-director 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074913-process-engineer-iii 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-es-es 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-es-es 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-fr-fr 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-fr-fr 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-it-it 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-it-it 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-ja-jp 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-ja-jp 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-nl-nl 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-nl-nl 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-ru-ru 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-ru-ru 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-sl-si 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-sl-si 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-tr-tr 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-tr-tr 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072837-associate-clinical-database-developer-zh-cn 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072840-associate-clinical-database-developer-zh-cn 2026-03-31T15:31:25+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-de-de 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-de-de 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-de-de 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074919-clinical-development-medical-director 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-es-es 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-es-es 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-es-es 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073918-project-engineer-capex-lead-es-es 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-fr-fr 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-fr-fr 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-fr-fr 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-it-it 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-it-it 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-it-it 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-ja-jp 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-ja-jp 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-ja-jp 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-nl-nl 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-nl-nl 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-nl-nl 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-ru-ru 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-ru-ru 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-ru-ru 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-sl-si 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-sl-si 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-sl-si 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-tr-tr 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-tr-tr 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-tr-tr 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072835-associate-clinical-database-developer-zh-cn 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072838-associate-clinical-database-developer-zh-cn 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072834-associate-clinical-database-developer-zh-cn 2026-03-31T16:31:06+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074455-director-international-value-access-ns 2026-04-01T17:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074752-pricing-director-ns 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072425-recruitment-experience-partner-rep-dutch-or-spanish 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074459-international-heor-hta-director-ns 2026-04-01T17:31:28+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072003-recruitment-experience-partner-rep-dach 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10068634-medical-information-agent 2026-03-31T17:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072026-recruitment-experience-partner-rep-dach 2026-03-31T18:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075119-senior-clinical-research-associate-remote-position 2026-03-31T21:31:08+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074977-associate-director-risk-assurance-uk-spain 2026-03-31T22:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075115-project-manager-implementation-electronic-billing-temporary 2026-03-31T22:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071626-field-product-specialist-cardiovascular-hcm 2026-04-01T04:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10067449-field-product-specialist-oncology-hcm 2026-04-01T04:31:12+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10071404-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075200-senior-international-trade-analyst 2026-04-01T06:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075179-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075239-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-01T06:31:02+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10070122-sr-specialist-csoc-onboarding-and-tools 2026-04-01T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10072932-manager-payor-access-reimbursement-ia 2026-04-01T07:31:09+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073981-jr-quality-control-specialist-mfd-kurtkoy-istanbul-temporary 2026-04-01T09:31:07+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074226-senior-analyst-content-analytics 2026-04-01T10:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10074965-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-01T10:31:10+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073670-group-head-bdl-finance-apma 2026-04-01T11:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073046-therapy-area-partner-cardiovascular-riyadh 2026-04-01T11:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10073251-key-account-manager-riyadh 2026-04-01T11:31:13+00:00 daily 0.5 https://stg1.novartis.com/careers/career-search/job/details/req-10075254-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2026-04-02T08:31:47+00:00 daily 0.5